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 RESUMO 
 
A soja e seus derivados têm sido associados a diversos efeitos benéficos à saúde humana. 
Dentre os seus compostos bioativos destacam-se as isoflavonas, conhecidas por suas 
potenciais atividades anti-inflamatória, antilipogênica, estrogênica e neuroprotetora. No 
entanto, a atividade biológica das isoflavonas difere entre as suas formas químicas, sendo as 
agliconas e seus metabólitos, como o equol, considerados mais bioativos. Este estudo teve 
como objetivo aprimorar as condições do processo para a biotransformação de polifenóis do 
extrato hidrossolúvel de soja (EHS) pela enzima tanase, obtida a partir do Paecilomyces 
variotii por fermentação sólida, e pela enzima β-glicosidase comercial, e verificar o efeito dos 
novos extratos gerados em modelos de inflamação, obesidade, estrogenicidade e 
neuroproteção. O EHS foi obtido a partir de grãos de soja da variedade IAC Foscarin 31 e 
biotransformado pelas enzimas tanase e β-glicosidase, nas formas livre e imobilizada em 
alginato de sódio. Estudos in vitro foram realizados para determinar a atividade antioxidante, 
anti-inflamatória e antilipogênica, assim como o potencial estrogênico e neuroprotetor. A 
biotransformação enzimática com a tanase livre e imobilizada foi responsável por um 
aumento de 36−46 vezes no teor das agliconas daidzeína e genisteína. Para o EHS 
biotransformado com a β-glicosidase imobilizada (EHSBI), o aumento foi correspondente a 
35−38 vezes. Além disso, o metabólito equol foi identificado no EHS biotransformado com 
tanase livre (EHSTL), correspondendo a 0,26 ± 0,03 µg/mL da amostra. Aumento de 2,3 e 
1,25 vezes foi observado na atividade antioxidante pelos ensaios ORAC e FRAP, 
respectivamente, para o EHSTL; para o EHS biotransformado com tanase imobilizada 
(EHSTI) e EHSBI não houve aumento significativo no poder antioxidante. Na avaliação do 
potencial estrogênico, o EHSTL foi responsável pela maior ação estrogênica nas células 
MCF-7 BUS. Embora o efeito antilipogênico no ensaio com os adipócitos 3T3-L1 não tenha 
sido significante neste estudo, as respostas anti-inflamatórias foram bastante expressivas. A 
adição dos EHS biotransformados com as enzimas livre e imobilizadas em macrófagos RAW 
264.7 estimulados por lipopolissacarídeo (LPS) causou uma redução no perfil inflamatório. 
Para o EHSTL, na maior concentração testada, foi observada uma diminuição de 37 vezes na 
expressão de TNF-α e IL-6 não foi detectada. Óxido nítrico não foi detectado quando as 
células foram tratadas com EHSTI e EHSBI na concentração intermediária testada. A 
avaliação do potencial neuroprotetor do EHSTL também mostrou um perfil menos pró-
inflamatório nas células de micróglia N9 estimuladas pelo LPS, com redução de 3,1 e 2,8 
vezes na expressão de TNF-α e IL-1β. Entretanto, os tratamentos com o meio condicionado 
 da micróglia não afetaram a expressão neuronal de sinapsina I nas células SH-SY5Y. A 
biotransformação do EHS com as enzimas tanase e β-glicosidase mostrou-se uma eficiente 
estratégia para melhorar o seu potencial bioativo. O uso de tanase livre provou que é possível 
produzir equol a partir do EHS usando apenas bioprocesso enzimático in vitro, sem 
intervenção microbiana intestinal, o que confirma o grande potencial desta enzima. Além 
disso, o EHSTL apresentou os melhores resultados nos ensaios antioxidante, anti-
inflamatório, estrogênico e neuroprotetor, podendo atuar como nutracêutico e conferir efeitos 
benéficos à saúde humana. 
 
Palavras-chave: isoflavonas, biotransformação, enzimas, inflamação, neuroproteção 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ABSTRACT 
 
Soy and its derivative have been associated with several beneficial effects on human health. 
Among their bioactive compounds there are the isoflavones, known for their potential anti-
inflammatory, anti-lipogenic, estrogenic and neuroprotective activities. However, the 
biological activity of isoflavones differs among their chemical forms, being aglycones and 
their metabolites, such as equol, considered more bioactive. This study aimed to improve the 
process conditions for the biotransformation of soymilk polyphenols by tannase enzyme, 
obtained from Paecilomyces variotii by solid fermentation, and by commercial β-glycosidase 
enzyme, and to verify the effect of the new extracts generated in models of inflammation, 
obesity, estrogenicity, and neuroprotection. Soymilk was obtained from soybean of IAC 
Foscarin 31 variety and biotransformed by tannase and β-glycosidase enzymes, in free and 
immobilized by sodium alginate forms. In vitro studies were performed to determine the 
antioxidant, anti-inflammatory and anti-lipogenic activities, as well as the estrogenic and 
neuroprotective potential. The enzymatic biotransformation with free and immobilized 
tannase was responsible for the increase of 36−46 times in the content of aglycones daidzein 
and genistein. For biotransformed soymilk with immobilized β-glycosidase (SIB), the 
increase was corresponding to 35−38 fold. In addition, the equol metabolite was identified in 
the biotransformed soymilk with free tannase (SFT), corresponding to 0.26 ± 0.03 µg/mL of 
sample. Increase of 2.3 and 1.25 times was observed in antioxidant activity by ORAC and 
FRAP assays, respectively, for SFT; for biotransformed soymilk with immobilized tannase 
(SIT) and SIB there was not significant increase in the antioxidant power. In the estrogenic 
potential evaluation, SFT was responsible for the highest estrogenic action in MCF-7 BUS 
cells. Although the anti-lipogenic effect in 3T3-L1 adipocyte assay was not significant in this 
study, anti-inflammatory responses were very expressive. The addition of biotransformed 
soymilk with free and immobilized enzymes in RAW 264.7 macrophages stimulated by 
lipopolysaccharide (LPS) has caused decrease in the inflammatory profile. For SFT, at the 
highest tested concentration, a 37-fold decrease in TNF-α expression was observed and IL-6 
was not detected. Nitric oxide was not detected when cells were treated by SIT and SIB at 
intermediate tested concentration. The neuroprotective potential evaluation of SFT also 
showed a less pro-inflammatory profile in N9 microglia cells LPS-stimulated, with reduction 
of 3.1 and 2.8 times in the expressions of TNF-α and IL-1β. However, microglia condition 
media treatments did not affect the neuronal expression of synapsin I in SH-SY5Y cells. The 
soymilk biotransformation with tannase and β-glycosidase enzymes revealed to be an efficient 
 strategy to improve its bioactive potential. The use of free tannase proved that it is possible to 
produce equol from soymilk using only in vitro enzymatic bioprocess, without intestinal 
microbial intervention, which confirms the great potential of this enzyme. Moreover, SFT 
presented the best results in the antioxidant, anti-inflammatory, estrogenic and 
neuroprotective assays, and may act as nutraceutical and confer beneficial effects on human 
health. 
 
Keywords: isoflavones, biotransformation, enzymes, inflammation, neuroprotection 
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GENERAL INTRODUCTION 
 
Soybean seeds, an important dietary source of polyphenols, have attracted great 
attention due to their potential benefits on human health. These benefits are mainly attributed 
to isoflavones, a class of phytoestrogens present in high concentration in soybeans and soy-
based products.  
Isoflavones contain four distinct chemical structures known as aglycone 
(genistein, daidzein, and glycitein), glycoside (genistin, daidzin, and glycitin), acetyl 
glycoside (acetyl genistin, acetyl daidzin, and acetyl glycitin), and malonyl glycoside 
(malonyl genistin, malonyl daidzin, and malonyl glycitin) (KUDOU et al., 1991; NAIM et al., 
1973; OHTA et al., 1979, 1980; WALTER, 1941; WALTZ, 1931). They exist predominantly 
in glycoside forms in soybeans. However, the isoflavones bioavailability differs among their 
chemical forms, and studies have associated that aglycones and their metabolites, such as 
equol, are considered to exert higher health benefits compared to other forms (IZUMI et al., 
2000; NIELSEN; WILLIAMSON, 2007; SHAO et al., 2011).  
Equol [7-hydroxy-3-(4-hydroxyphenyl)-chroman] is a daidzein metabolite and, 
according to literature, is formed exclusively by intestinal bacteria (SETCHELL; BROWN; 
LYDEKING-OLSEN, 2002; YUAN; WANG; LIU, 2007). This metabolite is related to higher 
bioavailability in the human body and is directly associated with the clinical efficacy of 
isoflavones (ROWLAND et al., 2003). For this reason, the enrichment of soy-based products 
with isoflavone aglycones and bioactive metabolite, like equol, has attracted growing 
attention. 
Studies indicate that different processing can promote chemical modifications in 
isoflavones, altering their absorption and metabolism rates independently of each individual’s 
microbiota, and enzymatic biotransformation is an interesting option already explored in 
studies aimed at the deglycosylation of these compounds for greater absorption (PARK et al., 
2001; YANG et al., 2009; CHEN et al., 2013). In this sense, the tannase appears as an 
alternative to improve the bioactive potential of soymilk. Is known that the enzyme acts in 
phenolic complex and exhibits deglycosylation activity (FERREIRA et al., 2013). Besides, 
our research group previously demonstrated the potential of aglycones production and equol 
metabolite generation by tannase in soymilk bioprocessing (DE QUEIRÓS; MACEDO; 
MACEDO, 2016). 
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In view of the broad range of action of tannase on phenolics in foods, it was 
important to further evaluate the capacity of the enzyme to biotransform soy isoflavones, 
since the tannase has presented a more extensive action on phenolics than β-glycosidase, as 
well as higher bioactive potential on the generated extracts. Thus, the application of the 
biotransformed soy extracts in the evaluation of biological potential should be investigate. 
Several studies have reported the beneficial effects of soy isoflavones, including 
the antioxidant potential (DE QUEIRÓS; MACEDO; MACEDO, 2016; MA et al., 2013; 
RODRÍGUEZ-ROQUE et al., 2013; SZYMCZAK et al., 2017), inhibition capacity of lipid 
accumulation in adipocytes (HE et al., 2016; HWANG et al., 2015; TAXVIG et al., 2013), 
anti-inflammatory properties (DHARMAPPA et al., 2010; KAWAHARA et al., 2015; 
VALLES et al., 2010), estrogenic action (IMHOF; MOLZER; IMHOF, 2008; PONS et al., 
2014; SUNITA; PATTANAYAK, 2011), and neuroprotective effects (CHEN et al., 2008; 
CHINTA et al., 2013; MIRAHMADI et al., 2018; PARK et al., 2007; QIAN et al., 2012). 
In this context, this study aimed to improve the process conditions for 
biotransformation of soymilk polyphenols by tannase to obtain a soy product with higher 
biological potential. The traditional enzymatic biotransformation of soy isoflavones with β-
glycosidase was performed altogether to compare the results with an established process. In 
order to verify the benefits of the new extracts generated by biotransformation, in vitro 
models of inflammation, obesity, estrogenicity, and neuroprotection were proposed.  
The thesis is organized in four chapters: the first is based on a review article, 
entitled “Bioconversion of isoflavones into bioactive equol: state of the art”, published by 
Recent Patents on Food, Nutrition & Agriculture (Appendix 1); the second, based on the 
research article “Enhanced estrogenic effects of biotransformed soy extracts” (Appendix 2), 
published by Journal of Functional Foods, which evaluated the improvement of the process 
conditions for enzymatic biotransformation of soymilk polyphenols and the estrogenic 
potential of the samples; the third, based on the research article “Effect of biotransformed soy 
extracts on anti-inflammatory, antioxidant, and anti-lipogenic potential”, submitted to The 
Journal of Nutritional Biochemistry, which contains the results of antioxidant, anti-
inflammatory, and anti-lipogenic potential of the studied extracts; and the fourth, based on the 
research article “Biotransformed soy isoflavones modulating microglia inflammation”, 
submitted to Food & Function, which evaluated the neuroprotective potential of 
biotransformed soymilk. Appendix 3 contains the results that were not included in the 
research articles (centesimal composition and enzymatic activity of tannase and β-
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glycosidase); Appendix 4 contains the book chapter written by the research group entitled 
“The importance of microbial and enzymatic bioconversions of isoflavones in bioactive 
compounds”, published in the Food Bioconversion book; and Appendix 5 contains the 
statement about register to be realized on the SisGen Platform. 
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CHAPTER 1. BIOCONVERSION OF ISOFLAVONES INTO BIOACTIVE 
EQUOL: STATE OF THE ART 
(REVIEW PAPER PUBLISHED BY RECENT PATENTS ON FOOD, NUTRITION & 
AGRICULTURE) 
Danielle Branta Lopes, Amanda Rejane Alves de Ávila, Lívia Dias de Queirós, 
Juliana Alves Macedo, Gabriela Alves Macedo 
 
Abstract 
Soy isoflavones, an important class of phytoestrogens, are suggested to be 
responsible for a number of biological activities associated with health benefits, including 
defense against various chronic diseases, including breast and prostate cancer, cardiovascular 
disorders, and osteoporosis, and they may alleviate the symptoms of menopause. However, 
current researches have shown that the clinical efficacy of these phenolic compounds is 
related to the ability of an individual to biotransform isoflavones into equol, which is a 
metabolite of daidzein formed exclusively by the intestinal microbiota. This biologically 
active metabolite presents greater effects than other isoflavones; however, only about 30−50% 
of people have a microbiota that is able to produce equol from dietary daidzein. Concern has 
recently grown about applications to improve the production of this metabolite. This paper 
summarizes the metabolism of equol, its production, and clinical implications. 
Keywords: bioavailability, daidzein, daidzin, equol, fecal microbiota, isoflavones, 
phytoestrogens, soy 
 
1. Introduction 
Isoflavones are phenolic compounds from the secondary metabolism of plants and 
belong to the class of flavonoids acting as phytoestrogens due to their structural similarity 
with 17β-estradiol hormone. They have a restricted distribution in nature but are found in 
relatively high concentrations in leguminous plants, especially soybeans (MESSINA, 2007). 
In plants, isoflavones most often are conjugated to sugar residues and are bound as β-
glycosides as in daidzin, glycitin, and genistin, or as aglycones: daidzein, glycitein, and 
genistein. There are also acetylglucoside forms: 6˝-O-acetyldaidzin, 6˝-O-acetylglicitin, and 
6˝-O-acetylgenistin; and malonylglucoside forms: 6˝-O-malonyldaidzin, 6˝-O-malonylglicitin, 
and 6˝-O-malonylgenistin (KUDOU et al., 1991; NAIM et al., 1973; OHTA et al., 1979, 
1980; WALTER, 1941; WALTZ, 1931). 
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Isoflavones are predominantly present as glycosides in foods. The bioactivity and 
bioavailability of glycosidic isoflavones are relatively low due to their high molecular weight 
and hydrophilicity (CROZIER; JAGANATH; CLIFFORD, 2009; DE CREMOUX et al., 
2010; GUADAMURO et al., 2015; LIU; HU, 2002). However, after ingestion, isoflavone 
glycosides can be partially hydrolyzed in the small intestine, thus releasing their aglycone 
counterparts, including daidzein, genistein and, to a less extent, glycitein (DAY et al., 1998; 
DE PASCUAL-TERESA et al., 2006; RICHELLE et al., 2002; ZUBIK; MEYDANI, 2003).  
It has been demonstrated that aglycones are absorbed more rapidly and in higher 
concentrations than their glycosides and acetyl and malonyl-glucoside forms in human 
intestines (BARNES et al., 2011). The transformations required, as described below, are 
mostly performed by the enzymes of the gut microbiota that are responsible for the 
hydrolysis of the conjugated isoflavones. However, our knowledge about gut microbes, their 
enzymes, and the pathways involved in the metabolism of isoflavones is still limited 
(ATKINSON; FRANKENFELD; LAMPE, 2005; CLAVEL; MAPESA, 2013; 
KEMPERMAN et al., 2010; YUAN; WANG; LIU, 2007). It is known that transformation of 
a conjugated isoflavone to its aglycone occurs in sequential steps involving several enzymes 
produced by a number of microbial types (CLAVEL; MAPESA, 2013; SÁNCHEZ-CALVO 
et al., 2013). Usually, the first step in polyphenol degradation involves the release of 
aglycones and oligomers via the action of gastric acid pH, esterases, and microbial glycosyl 
hydrolases (members of the β-glucosidase family). All these three actions can carry out the 
hydrolysis of the sugar moiety, facilitating and enhancing their absorption, which happens in 
the upper small intestine by passive diffusion (CANTAREL et al., 2009; CLAVEL et al., 
2006; KEMPERMAN et al., 2010). After conversion to the aglycone form, approximately 
one-third is absorbed through the gut epithelium as free isoflavone. The remainder proceeds 
in a second step, known as intestinal and hepatic phase, in which microbial glucuronidases 
(UDP-glucuronyl transferases) and sulfatases (PAPS-sulfotransferases) achieve the 
corresponding conjugation with glucuronic acid and sulfate. These conjugated compounds 
can be then excreted by both renal and biliary pathways; the later suffering enterohepatic 
recirculation, which leads to deconjugation, reabsorption, and further metabolism (YUAN; 
WANG; LIU, 2007). Finally, in the third step, some microbial transformations of the 
polyphenolic core, like ring fission by Eubacterium ramulus (CLAVEL et al., 2006), 
produce metabolites that may have changed bioactivities with respect to human health, 
originating from compounds either of greater biological activity, such as equol [7-hydroxy-3-
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(4hydroxyphenyl)-chroman] and 5-hydroxy equol, or inactive molecules, such as O-
demethylangolensin (O-DMA) and pethylphenol, which will be absorbed in the intestinal 
lumen (CLAVEL; MAPESA, 2013; SETCHELL et al., 2002). 
In the specific case of daidzein, the unabsorbed portion is hydrogenated, which 
leads to dihydrodaidzein (DHD), and this is converted into O-DMA or equol (BOWEY; 
ADLERCREUTZ; ROWLAND, 2003; CHANG; NAIR, 1995; YUAN; WANG; LIU, 2007). 
For the equol production, the three steps occur in this way: daidzin is first hydrolyzed to 
remove the glycoside residue and release the bioavailable form daidzein. The hydrolysis is 
extremely efficient and is performed by the action of the membrane bound enzyme, found in 
the brush-border of the small intestine, and by the action of intestinal bacterial β-
glucosidases (DAY et al., 1998). The isoflavone aglycones are, then, directly absorbed 
through the intestinal epithelium or are subjected to a new metabolism by the action of 
colonic microbiota (DECROOS et al., 2005; ZUBIK; MEYDANI, 2003). After hydrolysis, 
under the reducing conditions of the colon, unabsorbed aglycones will be hydrogenated by 
intestinal bacteria, resulting in DHD, which will be transformed in O-DMA or equol, as 
already mentioned (ARAI et al., 2000; DECROOS et al., 2005; LUND et al., 2004). The 
equol, a metabolite of daidzein biotransformation, is produced exclusively by the intestinal 
bacteria (BOWEY; ADLERCREUTZ; ROWLAND, 2003; DECROOS et al., 2005), and 
probably, by the joint action of a variety of bacteria (ATKINSON et al., 2008; SETCHELL 
et al., 2005; SETCHELL; BROWN; LYDEKING-OLSEN, 2002). The composition of the 
microbiota is a determinant factor for the nature of the metabolites formed, and varies among 
individuals (ATKINSON et al., 2004; RAFII et al., 2003). Only approximately one third of 
humans harbor an intestinal microbiota that is able to transform daidzein into equol, who are 
named equol producers; O-DMA production is spread more widely and is not directly related 
to equol (LAMPE et al., 2001; ROWLAND et al., 2000; SETCHELL; BROWN; 
LYDEKING-OLSEN, 2002).   
Numerous studies have demonstrated that equol (C15H14O3) is the most important 
product of the soy isoflavone daidzein (ATKINSON; FRANKENFELD; LAMPE, 2005; 
SETCHELL; BROWN; LYDEKING-OLSEN, 2002; SETCHELL; CLERICI, 2010; 
TAGHIZADEH et al., 2013; TOUSEN et al., 2015), and can also be converted into six other 
metabolites, mainly 3'-hydroxy-equol, and 6-hydroxy-equol (RÜFER; GLATT; KULLING, 
2006). They have attracted great interest due to their high affinity for estrogen receptors, 
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greater absorption efficiency, antioxidant properties, and anticarcinogenic effects 
(MITCHELL et al., 1998; SETCHELL; BROWN; LYDEKING-OLSEN, 2002).  
Equol has a heterocyclic structure with a chiral carbon atom in C3 position and 
may occur in two distinct enantiomeric forms, (R)-(+)-equol and (S)-(−)-equol, with different 
biological activities. Both forms show very different performance in terms of their binding 
affinities with estrogen receptor α (ERα) and estrogen receptor β (ERβ). In humans, 
metabolism of daidzein only produces (S)-(−)-equol (LAMBERTON; SUARES; WATSON, 
1978; SETCHELL et al., 2005). This form has a higher affinity for binding to ERβ, whereas 
the (R)-(+)-equol shows preference for binding to ERα. (S)(−)-equol also binds ERβ better 
than daidzein (MUTHYALA et al., 2004). 
Many studies have documented the fundamental role of intestinal microbiota in 
the equol formation (BOLCA; VAN DE WIELE; POSSEMIERS, 2013; POSSEMIERS et al., 
2011; SÁNCHEZ-CALVO et al., 2013; VAN HYLCKAMA VLIEG et al., 2011). Several of 
them have isolated and identified bacteria of animal and human origins that can convert 
daidzein into equol. ELGHALI et al. (2012) incubated Bifidobacteria species with daidzein 
and the equol production started during the first 6 h of fermentation using Bifidobacterium 
longum BB536 and Bifidobacterium breve ATCC 15700. Levels of equol increased during the 
incubation period, indicating that equol was stable in the medium and was not converted to 
other metabolites. A high concentration of equol was obtained after 96 h of fermentation, 
achieving 314 µmol L-1 using B. longum and 291 µmol L-1 with B. breve. TAMURA; HORI; 
NAKAGAWA (2011) studied the production of equol by Lactobacillus rhamnosus JCM 
2771. They detected, in a fecal microbiota suspension from a male equol producer with 
daidzein, the equol production achieved 95 µmol L-1. A supplementation with a high 
concentration of L. rhamnosus was made in this fecal microbiota suspension, and the equol 
production increased, obtaining around 150 µmol L-1. RAIMONDI et al. (2009) screened 
twenty-two strains of Bifidobacterium for their ability to transform the isoflavones daidzin 
and daidzein. Most of the strains released the aglycone from daidzin and 12 gave yields 
higher than 90%. However, all the strains failed to transform daidzein into reduced 
metabolites, like S-equol. Results suggested that selected probiotic strains, all species of 
human origin, can be used to speed up the release of daidzein, which improves its 
bioavailability for absorption by colonic mucosa and/or biotransformation to S-equol by other 
intestinal microorganisms.  
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It is clear that the intestinal bacteria perform an important role in daidzein 
metabolism, and in equol production (ATKINSON; FRANKENFELD; LAMPE, 2005). 
Nevertheless, dietary compounds, such as prebiotics and fibers, influence intestinal microbial 
populations, and their activities also contribute to the production of equol, acting on its 
absorption and bioavailability (GIBSON et al., 2004; SETCHELL et al., 2013). ZHENG et al. 
(2014) studied the effect of lactulose as a potential equol-promoting prebiotic in vitro. The 
effect of lactulose on transformation of daidzein into equol by sows’ fecal microbiota was 
investigated, and results showed that lactulose treatment improved bacteria growth 
parameters, changing the kinetics of fermentation in vitro. Lactulose combined with daidzein 
altered the microbiota profile, increased equol production, reduced methanogen producing 
bacteria, and increased sulfate-reducing bacteria within 24 h. TOUSEN et al. (2011) 
investigated the combined effects of daidzein and resistant starch (RS) intake on equol 
production and on intestinal microbiota in ovariectomized (OVX) mice. The resistant starch is 
not absorbed in the proximal intestine and acts as a dietary fiber in the colon. After six weeks, 
urinary equol concentration was significantly higher in the OVX mice treated with 0.1% 
daidzein and 12% RS-supplemented diet. The occupation ratios of Bifidobacterium spp. in the 
cecal microbiota in groups fed just with 12% RS were significantly higher than those in the 
other groups. The study showed that a diet supplemented with daidzein and RS significantly 
altered the intestinal microbiota and increased equol production. OHTA et al. (2002) tested 
the effect of the combination of isoflavones and fructooligosaccharides (FOS) on the equol 
production of OVX and surgical control rats. FOS stimulates the growth of bifidobacteria, 
which cleave isoflavone conjugates to yield the corresponding aglycones and metabolites. 
Four groups were investigated: a purified control diet group, a FOS diet group (5% FOS), an 
isoflavone diet group (0.2% isoflavone conjugates), and a FOS and isoflavone diet group (5% 
FOS and 0.2% isoflavone conjugates). After six weeks, the mice were killed and the blood 
and femora were sampled immediately. They proved that FOS increased cecal βglucosidase 
activity and equol production from daidzein in both OVX and surgical control mice fed 
isoflavone conjugates. However, the best result for the equol production was achieved with 
the group that was fed with FOS and isoflavones. These results suggest that FOS increase the 
bioavailability of isoflavones, leading to cooperative effects in the prevention of osteopenia in 
OVX mice.  
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2. Determinant factors of equol-producing status 
As aforementioned, equol produced by intestinal bacteria is not produced in all 
healthy adults when challenged with soy foods (SETCHELL et al., 1984). The frequency of 
equol producers can vary among different population groups. The factors that define the (S)-
(−)-equol production are presently unclear but understanding the determinant factors of equol-
producing is important because the health benefits of a soy-based diet appear to be greater in 
equol producers compared to equol non-producers (HONG et al., 2012; LAMPE, 2009; 
NICULESCU et al., 2007; SETCHELL et al., 2005; SETCHELL; BROWN; LYDEKING-
OLSEN, 2002). 
The term “equol-producers” is used to describe those people that can metabolize 
daidzein to equol in response to consuming soy isoflavones. According to SETCHELL; 
BROWN; LYDEKING-OLSEN (2002), people with a concentration of equol in their plasma 
> 83 nmol L-1 can be defined as “equol-producers” and those with concentrations < 40 nmol 
L-1 can be classified as “equol nonproducers”. Cut-off values can also be derived from urinary 
equol levels, with an equol producers classified as excreting > 1,000 nmol L-1 (ROWLAND et 
al., 2000). Some studies have evaluated the effects of dietary intakes, lifestyle factors, and 
demographic and anthropometric data among equol-producers and equol non-producers 
phenotypes. 
The percentage of equol producers in the population varies with geographic 
distribution. Several studies show that only ~25-30% of Western adults are able to produce 
equol when challenged with soy foods (LAMPE et al., 1998; ROWLAND et al., 2000; 
SETCHELL et al., 1984; SETCHELL; COLE, 2006), much lower than the frequency of 
50−70% equol producers reported in vegetarians or Asians (Japan, China, and Korea), where 
the intake of soy based foods is higher than Western populations (AKAZA et al., 2004; ARAI 
et al., 2000; GARDANA; CANZI; SIMONETTI, 2009; HONG et al., 2012; OZASA et al., 
2004; SONG et al., 2006; WATANABE et al., 1998). 
Equol is not produced in neonatal life, and the production of equol may be 
affected by early nutrition. This fact can be observed in a longitudinal prospective study that 
determined the (S)-(−)-equol production in 90 healthy infants who were fed breast milk, soy 
infant formula, or cow’s milk in their first year of life. The results found that in early life, the 
formation of (S)-(−)-equol is a developmentally diet-related and time-dependent process. 
Moreover, the data shows that over the first 3 years of life the trend to higher incidence of 
(S)(−)-equol producers occurred mainly in formula feeding infants (BROWN et al., 2014). 
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Although age does not seem to have an influence on equol production, 
FUJIMOTO et al. (2008) reported that in Japan and Korea the percentage of equol producers 
in older men is significantly higher than in younger men. This difference is probably due to 
changes in the eating habits of the younger generation due to the influence of Western diet, 
which caused decreased intake isoflavones and, consequently, a low incidence of equol 
producers in this group. 
Diet is another factor that influences an individual's ability to produce equol. 
Although the presence of specific intestinal bacteria that are able to metabolize daidzein to 
(S)-(−)equol is the main factor that lead to equol production, other dietary factors can play an 
important role in equol production even if the intestinal bacteria are present (BOLCA et al., 
2007; GARDANA; CANZI; SIMONETTI, 2009; HANNA; FRACGP; LYONS-WALL, 
2010; LAMPE et al., 2001; LYDEKING–OLSEN et al., 2004; ROWLAND et al., 2000). 
Healthy adults (n=159) from 2 different countries, United States and Australia, who 
consumed a typical Western diet, were evaluated in order to investigate the relation between 
the ability to produce equol and dietary composition. No significant differences in the total 
macronutrient intake between equol producers and non-producers were observed. However, 
the higher intake of some micronutrients like vitamins A and E, polyunsaturated fatty acids, 
and maltose and a lower intake of cholesterol may affect daidzein metabolism. Other factors 
that may affect the capacity of equol production are short chain fatty acids and arginine. 
These compounds can enhance more than four times the capability of Asaccharobacter 
celatus to metabolize daidzein to equol (NETTLETON et al., 2005). 
LU et al. (1996) showed in their study that long-term soy ingestion could convert 
equol non-producers into equol producers and, in contrast, SETCHELL; COLE (2006) 
proposed that “once an equol producer, always an equol producer” by a study with 
premenopausal women. In general, the role of diet on the individual's ability to produce equol 
remains uncertain. Considering that dietary factors play an important role in the (S)-(−)-equol 
production, some strategies may be developed to improve the metabolism of daidzein to equol 
in non-producers individuals. Several antibiotics used to eliminate the colonic bacteria for the 
treatment of infections have been shown to affect in vivo and in vitro equol production 
(BRAIDMAN et al., 2001; SEHMISCH et al., 2010). 
The influence of antibiotic treatment in the daidzein metabolism was evaluated 
with 350 postmenopausal women in a randomized study, double-blind, placebo-controlled soy 
intervention. After the antibiotic treatment no significant differences were observed on the 
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capacity for equol production. Similarly, the duration of the treatment, antibiotic type or class, 
and the dose showed no consistent influence on metabolize daidzein to equol (FRANKE et 
al., 2012). 
SUTHERLAND et al. (2012) showed that different classes of antibiotics had 
different effects on equol production by colonic bacteria of monkeys in vitro. The metabolism 
of daidzein by the cultures was not affected by the exposure to ceftriaxone. However, the 
exposure to tetracycline completely removed the bacteria metabolizing daidzein; however, the 
exposure to ciprofloxacin improved equol production by the bacteria. Moreover, colonic 
bacteria of monkeys treated with 4 µg mL-1 of ciprofloxacin metabolized more daidzein 
compared to untreated cultures. The antibiotic treatment can eliminate the bacteria which is 
able to metabolize daidzein to equol in colonic microbiota but also enrich them by eliminating 
the non-metabolizing strains, or not affect them at all (ATKINSON et al., 2004; FRANKE et 
al., 2012; SETCHELL; COLE, 2006). 
 
3. Clinical implications 
Clinical and epidemiological research has evaluated the association between 
intake of isoflavones and progression of human diseases (ACHARJEE et al., 2015; CANO; 
GARCÍA-PÉREZ; TARÍN, 2010; CRAWFORD et al., 2013; JOU et al., 2008; LECLERCQ; 
JACQUOT, 2014; MAHMOUD; YANG; BOSLAND, 2014; MOUROUTI; 
PANAGIOTAKOS, 2013; PARK; WEAVER, 2012; SCALBERT et al., 2005; SHOR et al., 
2012; YU et al., 2015).  
Several papers have already reviewed the hypothesis that appropriate isoflavone 
consumption can decrease cancer risk (DONG et al., 2012; IMHOF; MOLZER; IMHOF, 
2008; MIYANAGA et al., 2012; PABONA et al., 2013; TRAVIS et al., 2009; XU et al., 
2010). In breast cancer cells, for instance, ERβ regulates the genes that control cell cycle 
progression and usually represses the proliferation, whereas activation of ERα has the reverse 
effect (CHANG et al., 2006). According to GOODMAN et al. (2009) and LIU et al. (2010), a 
relationship between production of equol and reduction of breast cancer risk has been noted. 
Human studies show that the protective effect in equol producers is more apparent 
than that in equol non-producers, and the ethnic difference in daidzein metabolism may 
partially explain the different frequency of prostate cancer among ethnic groups (OZASA et 
al., 2004). Confirming this statement, AKAZA et al. (2004) studied Americans, Koreans, and 
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Japanese, and they concluded that the proportion of equol producers is significantly higher in 
the Asian population and lower in patients with prostate cancer. 
Research has shown that isoflavones can exert antioxidant effects in vitro and in 
vivo (HUANG et al., 2008; MA et al., 2013; RODRÍGUEZ-ROQUE et al., 2013). Lotions of 
genistein from red clover (Trifolium pratense) and the metabolites equol, isoequol, and 
dehydroequol have shown strong potential to decrease inflammatory edema reactions. 
Furthermore, lotions containing equol protected the immune system from photosuppression 
(WIDYARINI et al., 2001). Moreover, comparative studies of phenolic compounds in vitro 
have demonstrated that equol is a potent antioxidant that exhibits higher antioxidant capacity 
than vitamins C and E (RÜFER; GLATT; KULLING, 2006). 
Due to the similarity with the hormone 17β-estradiol, the isoflavones have also 
been used as an alternative hormonal replacement therapy to minimize menopause symptoms. 
While pharmaceutical hormone replacement therapy is effective in most cases, this option has 
not been common, because its use can increase the risk of developing breast cancer (BERAL, 
2003; CAVALLINI; ROSSI, 2009; SCHAIRER et al., 2000). According to HOWES; 
HOWES; KNIGHT (2006), phytoestrogens intake has shown moderate estrogenic effects in 
postmenopausal women, causing symptom improvement. JOU et al. (2008) perform a clinical 
trial to evaluate the effect of daily ingestion of 135 mg of isoflavones on menopausal 
symptoms in female equol producers and non-producers. The results indicated that 
supplementation with isoflavones was effective in reducing menopausal symptoms only in 
female equol producers. 
The decline in the estrogen level in postmenopausal women is partially 
responsible for the development of osteoporosis; a disease characterized by enhanced bone 
resorption, accelerated bone loss, and increased risk of fractures as well as impaired healing 
of fractured bone (YINGJIE et al., 2007). Estrogen replacement therapy has been utilized to 
decrease the risk of osteoporosis, and estrogenic effects of phytoestrogens have been 
suggested to prevent bone resorption and promote increment bone density (ETTINGER, 
1988; PATISAUL; JEFFERSON, 2010; TOUSEN et al., 2011). YAMORI et al. (2002) found 
that postmenopausal women that consume higher amount of soy-based products have better 
femoral and/or lumbar spine density when compared to women who consume less soy. 
However, bone-sparing benefits may depend on the capacity to convert daidzein to equol. The 
equol production may in part explain why the beneficial effects of isoflavones noticed in 
laboratory rodents have not been easily replicated in humans, because rodents produce high 
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levels of equol, approximately, a third to half greater than the human population (LAMPE et 
al., 1998; SETCHELL et al., 2003).   
Increasing risk of ischemic heart disease between postmenopausal women is 
related with a deficit of gonadal steroid production. Indeed, estrogen replacement therapy has 
been used to enhance HDL cholesterol and reduce LDL cholesterol, thus preventing heart 
disease. It has been suggested that phytoestrogens may act as estrogen agonists, effecting 
lipoproteins similar to those induced by estrogen (KURZER; XU, 1997). Significant 
diminution in LDL cholesterol levels are usually small and only seen in individuals with high 
cholesterol who replace a considerable part of their animal protein intake with soy, consuming 
among 40 and 318 mg of isoflavones per day (SACKS et al., 2006). According to JACKMAN 
et al. (2007) and CHENG et al. (2010), the equol has vasodilator activity, induces nitric oxide 
synthase-dependent endothelial relaxation, and may reduce the risk of cardiovascular 
diseases. 
 
4. Conclusion 
Most isoflavones require enzymatic transformations to become bioavailable for 
the human body. These biotransformations are carried out by intestinal microbiota of 
individuals capable of hydrolyzing the conjugated isoflavones into aglycones. The aglycones, 
like daidzein for example, are then metabolized into equol and O-DMA. Overall, recent 
evidence suggests the importance of equol as a therapeutic agent for the population, mainly 
for non-equol producers. The potential beneficial effects of soy consumption led to an 
increased interest in soy products and in the development of new isoflavone and soy-enriched 
foods and supplements. However, additional research is needed to evaluate the safety and 
efficacy of (S)-(−)-equol and (R)-(+)-equol in controlled clinical trials. In this review, we 
discussed the importance of equol, a metabolite of daidzein, and its beneficial effects on the 
human health. 
 
5. Current & future developments 
A way to circumvent the limitation of equol production is to develop equol as a 
pharmaceutical or nutraceutical agent. In the last few years, many innovative approaches have 
focused on the pharmacology and safety of equol. This compound can be produced by an 
innovative patented process by biotransformation of daidzein to (S)-(−)-equol using specific 
microorganisms or by chemical process to synthesize the 2 different enantiomeric forms, (S)-
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(−)-equol and (R)-(+)equol. The patents listed in Table 1.1 provide some processes related to 
equol production, in order to increase their content and consequently to improve the potential 
bioactivity of soy-based products. 
 
Table 1.1 A few patents launched for production of equol. 
Patent no.  Description  Function  Reference  
TW  
200712211  
   
Microbiological process for the 
coproduction of isoflavone 
metabolites-equol and O-DMA and 
probiotics, and to screen a large 
number of domestication and 
reproduction of intestinal probiotics 
body.  
This invention is a microbiological manufacturing process of lower 
molecular metabolites (S)-(−)-equol, (R)-(+)-equol, O-DMA and 6'-
hydro-O-DMA from the microbiologically and enzymatically 
biotransformation of daidzin and genistin (soy isoflavones), by the 
screening, selection, acclimation, multiplication and metabolization 
of multi-strain gastrointestinal probiotics.  
WANG 
(2007) 
CN  
102021130  
   
Degradation of daidzein into equol 
using new Clostridium bifermentans 
zx-7 strain, for preparing animal 
fodder, a preparation for eliminating 
cholesterol and a fermented product 
of soy or bean pulp.  
Clostridium bifermentans zx-7 strain was used for perform the 
degradation of daidzein into equol with fungicidal composition for 
preparing animal fodder, for eliminating cholesterol and a 
fermented product of soy or bean pulp. This strain has the skill to 
lower serum low-density lipoprotein levels and enhance high-
density lipoprotein and low-density lipoprotein ratio.  
ZHANG et 
al. (2011) 
US  
201101891 
34  
Fermentation product containing 
equol-producing microorganism 
having maintained equol-producing 
ability, and method for producing 
same.  
This innovation provides a fermented product containing equol-
producing microorganisms in the state of living cells by which 
equol production ability is maintained.  
ISONO et al. 
(2011a) 
JP2011083 
273   
Manufacture of fermented material 
for fermented product involves 
preparing mother starter by 
performing anaerobic fermentation 
using equol production 
microorganisms in culture medium 
containing daidzein.  
The method provides fermented product with equol production 
microorganisms by which equol production ability is maintained in 
state of living microbe.  
ISONO et al. 
(2011b) 
WO20120 
33150  
   
Preparation and recovery of equol by 
fermentation of daidzein using 
anaerobic microbe under gaseous 
phase, for preventing and/or treating 
breast cancer, and menopausal 
disorder.  
Development of a method for the equol production from anaerobic 
microorganisms, able to generate this metabolite from daidzein 
fermentation under gaseous phase including one or more gas 
containing hydrogen. This process is useful for the preparation of 
equol used in food-drinks or pharmaceutical for preventing and/or 
treating breast cancer, prostatic cancer, osteoporosis, 
hypercholesterolemia, cardiac disease, and menopausal disorder.  
NIKAIDO; 
TOMITA 
(2012)  
US201200 
94336   
Synthesis of different isofalvones and 
derivatives of equol in a simple 
manner.  
This innovation is a method for the production of isoflavanes from 
isoflavones, whereby in a first reaction step the 4-keto group of the 
isoflavone is reduced in a enantioselective manner, whilst the 2,3-
double bond is maintained, to the 4-hydroxy compound.  
STEFFAN 
(2012)  
US2013023 
1291   
Fermented soya based mixture 
comprising isoflavones-aglicones, 
equol and lunasil,  
process for the preparation and uses 
thereof in food, medical and cosmetic 
fields.  
This invention concerns a mixture comprising isoflavones 
aglicones, such as daidzein, genistein and glycitein, in addition to 
equol and lunasin, said mixture being based on soya fermented 
using lactic acid bacteria isolated from food matrices and use of 
said mixture for protection of skin and adnexa and of human 
intestinal cells with particular reference to prevention of 
inflammatory state and protection of barrier functions and hair loss 
treatment.  
GIULIANI et 
al., (2013) 
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US876544 
5   
Equol-producing lactic acid 
bacteriacontaining composition.  
The invention relates to equol-producing lactic acid bacterial strain, 
a composition comprising said lactic acid bacterial strain, and a 
method of producing equol by utilizing said lactic acid bacterial 
strain.  
UCHIYAMA; 
UENO; 
SUZUKI 
(2014)  
CN104031 
875  
A new engineered bacteria derived 
from lactic acid bacteria 
(Lactococcus 20-92), useful for the 
production of (S)-(−)-equol.  
The engineered bacteria are obtained by cloning L-dihydrodaidzein 
racemase, L-daidzein reductase, L-dihydropteridine reductase and 
L-tetrahydrodaidzein reductase genes from Lactococcus sp. 20-92 
to Escherichia coli BL21 (D3) and transforming. The production of 
(−)-(−)-equol provided by the invention are simple in fermentation 
condition, convenient to use, stable in system, and wide in 
application. This engineering bacteria have the ability of 
transforming daidzein in brain-heart infusion (BHI) and lysogeny 
broth (LB) culture media into (S)-(−)-equol whether under an 
anaerobic condition or an aerobic condition, and have the ability of 
transforming bean pulp in BHI and LB into (S)-(−)-equol.  
YIN; 
WANG  
(2014)  
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Abstract 
Soy isoflavones have been associated with several beneficial effects to human 
health including estrogenic action. Due to the risks associated with pharmaceutical hormone 
replacement therapy, soy extracts rich in isoflavones and metabolites appear as a safe 
alternative for menopausal women. This study aimed to improve the process conditions for 
enzymatic biotransformation of soymilk polyphenols by tannase and β-glycosidase to obtain 
higher amounts of isoflavone aglycones and metabolites, such as equol. The estrogenic 
potential of the biotransformed soymilk was evaluated in in vitro assays. The enzymatic 
biotransformation of soymilk with free and immobilized tannase was responsible for the 
increase of 36−46 times in the content of aglycones daidzein and genistein. For 
biotransformed soymilk with immobilized β-glycosidase (SIB), the rise was corresponding to 
35−38 fold. In addition, the equol metabolite was identified in the biotransformed soymilk 
with free tannase (SFT), corresponding to 0.26 ± 0.03 µg mL-1 of sample. Moreover, the 
biotransformed soymilk by tannase, especially that one treated with free tannase, presented 
higher estrogenic action in the MCF-7 BUS cell line assay, making it a promising 
nutraceutical with possible effects in the attenuation or treatment of menopause symptoms. 
Keywords: bioactivity; enzymatic biotransformation; equol; estrogenic potential; 
soy isoflavones; tannase 
 
1. Introduction 
Soy-based products, an important source of nutrients and phytochemicals, have 
been appreciated worldwide as health promoting foods. Isoflavones, a class of phytoestrogens 
present in high concentration in soybeans, have been widely investigated because of their 
potential health-enhancing properties, including prevention and therapy of some chronic 
diseases such as cancers and cardiovascular diseases as well as their ability to relieve the 
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symptoms of menopause in women (RIMBACH et al., 2008; SUNITA; PATTANAYAK, 
2011; UIFĂLEAN et al., 2016). 
Soybean seeds contain four distinct chemical structures of isoflavones known as 
aglycone (genistein, daidzein, and glycitein), glycoside (genistin, daidzin, and glycitin), acetyl 
glycoside (acetyl genistin, acetyl daidzin, and acetyl glycitin), and malonyl glycoside 
(malonyl genistin, malonyl daidzin, and malonyl glycitin) (KUDOU et al., 1991; NAIM et al., 
1973; OHTA et al., 1979, 1980; WALTER, 1941; WALTZ, 1931). The biological activity of 
these compounds in the human body depends on their chemical forms. Among them, 
isoflavone aglycones seem to have higher beneficial effects on human health than other forms 
(IZUMI et al., 2000). Fortunately, isoflavone glycosides can be enzymatically converted to 
their respective aglycones, which has a significant effect on their bioavailability (ISMAIL; 
HAYES, 2005). Moreover, the isoflavone aglycones can be metabolized to many specific 
compounds in the human gut, with emphasis to equol, a most bioavailable metabolite and 
directly associated with the clinical efficacy of isoflavones (ROWLAND et al., 2003). Equol 
[7-hydroxy-3-(4-hydroxyphenyl)-chroman] is a nonsteroidal estrogen produced by daidzein 
metabolism and, according to the present literature, is formed exclusively by intestinal 
bacteria (SETCHELL; BROWN; LYDEKING-OLSEN, 2002; YUAN; WANG; LIU, 2007). 
Therefore, there is growing interest in soy-based products with high bioactivity, being 
important to generate a commercial source of isoflavone aglycones and bioactive metabolite, 
such as equol. 
A common method to convert glycosides to bioactive aglycones is enzymatic 
hydrolysis, which is considered more specific than chemical hydrolysis. The β-glycosidase, an 
enzyme naturally presents in soybeans and produced by various microorganisms, is able to 
catalyze the hydrolysis of isoflavone glycosides (CHEN et al., 2013; PARK et al. 2001). The 
use of β-glycosidase to produce food supplements rich in more bioavailable soy isoflavones is 
the subject of a patent with commercial exploitation (PARK et al., 2004). 
Our research group proposes the application of a different enzyme, named tannin 
acyl hydrolase (E.C. 3.1.1.20), which has great potential to bioconvert the soy isoflavones 
into aglycones and further. DE QUEIRÓS; MACEDO; MACEDO (2016) demonstrated the 
potential of aglycones production and equol generation by this enzyme in soymilk 
bioprocessing. This was the first study that was able to produce equol through an enzymatic 
process of biotransformation of soy isoflavones. 
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Tannase is an esterase enzyme largely characterized by its activity on phenolic 
complex and its ability to perform hydrolysis reactions on ester bond and depside linkages of 
hydrolysable and condensed tannins (GARCÍA-CONESA et al., 2001). Furthermore, this 
extracellular enzyme also exhibits deglycosylation activity, demonstrating great potential 
(FERREIRA et al., 2013). 
In view of the knowledge accumulated by our research group and the broad range 
of action of tannase on phenolics in foods, it was important to further evaluate the capacity of 
the enzyme to biotransform soy isoflavones, since tannase has presented a more extensive 
action on phenolics than β-glycosidase, as well as higher bioactive potential on the generated 
extracts. 
According to some authors, isoflavones present structural and functional 
similarities to the 17β-estradiol hormone, demonstrating affinity for estrogen receptors. The 
isoflavones can bind to both estrogen receptor subtypes (ERα and ERβ), which exert distinct 
biological functions, with a slightly greater affinity to bind to ERβ (WUTTKE; JARRY; 
SEIDLOVÁ-WUTTKE, 2007; ZHAO; MU, 2011). ERα is present mainly in mammary gland, 
uterus, ovary (thecal cells), and hypothalamic tissue, whereas ERβ is found in kidney, brain, 
bone, ovary (granulosa cells), heart, lungs, intestinal mucosa, prostate, and endothelial cells 
(BAI; GUST, 2009; TAYLOR et al., 2009).  
In hormone dependent tissues, estrogens play an essential role in several 
physiological processes, including cell proliferation, differentiation, or apoptosis. However, 
elevated levels of estrogens are a main risk factor for the progress of hormone dependent 
diseases, increasing the risk of developing breast, endometrial, and ovary cancers (KUMAR et 
al., 2010; SCHAIRER et al., 2000; UIFĂLEAN et al., 2016).  
Therefore, due to the risks mentioned above, pharmaceutical hormone 
replacement therapy, although effective in most cases, does not seem to be the best treatment 
option in menopause. So, soy extracts rich in isoflavones and metabolites appear as an 
alternative to relieve and improve the symptoms in menopausal women. 
Continuing the endeavors of our research group, this study aimed to improve the 
process conditions for biotransformation of soymilk polyphenols by tannase to obtain higher 
amounts of isoflavone aglycones and metabolites, such as equol. The estrogenic potential of 
the obtained extracts in in vitro assays were also verified. The traditional enzymatic 
biotransformation of soy isoflavones with β-glycosidase was performed altogether to compare 
the results with an established process. 
52 
 
 
 
2. Materials and methods 
2.1 Materials 
Soybean seeds (IAC Foscarin 31 variety, 15/2015 lot, 85% germination, produced 
at Mococa, SP, Brazil) were obtained at the Agronomic Institute of Campinas, Campinas, SP, 
Brazil. Analytical standards daidzin, genistin, daidzein, genistein, and equol, gallic and tannic 
acids, β-glycosidase enzyme (naringinase from Penicillium decumbens), sodium alginate, 
Folin-Ciocalteau reagent, sulforhodamine B sodium salt and Trizma® base were purchased 
from Sigma-Aldrich (Steinheim, Germany). All other chemicals were acquired in the grade 
commercially available. Cell culture reagents were purchased from Invitrogen®. 
 
2.2 Soymilk preparation 
Soymilk was prepared following the methodology developed by Embrapa Soja, 
Brazil, with modifications (MANDARINO; CARRÃO-PANIZZI, 1999). Whole soybean 
seeds were macerated in distilled water (1:3 w/v) for 6 h at room temperature. After that, the 
beans were boiled (1:6 w/v) for 5 min and then blended in distilled water (1:6 w/v) for 2 min. 
The resultant slurry was centrifuged at 4612×g for 15 min at room temperature (Megafuge 
16R, Thermo Electron Led GmbH, Langenselbold, Germany). The supernatant, designated 
soymilk, was pasteurized in thermostated bath (model B12D, Micronal, São Paulo, Brazil) at 
85 °C for 15 s, freeze-dried (Liotop L101, Liobras, São Carlos, Brazil) at -40 °C for 48 h, and 
stored at -20 °C. 
 
2.3 Enzymes 
Tannase from Paecilomyces variotii was obtained according to a previously 
published procedure by BATTESTIN; MACEDO (2007). For comparison, commercial β-
glycosidase enzyme (naringinase from Penicillium decumbens) was also used in the present 
study. 
For tannase and β-glycosidase immobilization, sodium alginate (viscosity 
20,000−40,000 cps) was used as carrier for ionic gelation. Fifteen milliliters of the 5% sodium 
alginate media were mixed with 200 mg of tannase or 1050 mg of β-glycosidase powder, 
based on enzymatic activity (β-glycosidase activity of 4.2 U mg-1 was fixed to both enzymes). 
The mixture was dropped into 90 mL of 0.1 M calcium chloride using a peristaltic pump to 
obtain equally sized polymeric beads (20 mm) composed of calcium alginate. After repose for 
6 h at 7 °C, the beads were washed with 200 mL of distilled water to remove the excess 
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calcium ions and the unbound enzyme. The beads were dried for 16 h in refrigerated 
environment and stored in the same conditions until analysis (MOHAPATRA; MONDAL; 
PATI, 2007).  
Both enzymes (from P. variotii and P. decumbens) were assayed for β-
glycosidase activity. Free and immobilized enzymes were tested according to MATSUURA; 
SASAKI; MURAO (1995), with modifications, using the chromogenic substrate ρ-
nitrophenyl-β-D-glucopyranoside (ρ-NPG). The enzymatic activity was evaluated by 
monitoring the release of ρ-nitrophenol at 410 nm, using a standard curve of ρ-nitrophenol, 
ranging from 0.036−0.576 µmol mL-1. One unit of β-glycosidase activity (U) was defined as 
the amount of enzyme required to release 1 μmol of ρ-nitrophenol per minute of reaction.  
Tannase activity of enzyme from P. variotii, in free and immobilized forms, was 
also evaluated according to SHARMA; BHAT; DAWRA (2000), adapted using tannic acid as 
substrate. The enzymatic activity was measured by monitoring the release of gallic acid at 520 
nm, using a calibration curve of gallic acid ranging from 0.013−0.321 µmol mL-1. One unit of 
tannase activity (U) was defined as the amount of enzyme that released 1 µmol min-1 of gallic 
acid.  
For specific enzymatic activity calculation, the protein content was determined 
according to BRADFORD (1976). 
 
2.4 Biotransformation process parameters 
The first set of conditions were fixed as soy extract (lyophilized powder) at the 
concentration of 200 mg mL-1 of distilled water, pH 6.5, temperature of 40 °C and reaction 
time of 30 min, based on previous work by DE QUEIRÓS; MACEDO; MACEDO (2016). In 
this condition, the concentrations of immobilized tannase tested were 1, 5, 10, and 15% (w/v). 
After the concentration of enzyme was fixed, the following variables were tested one at a 
time: hydrogen potential – pH (5, 6, 6.5, and 7), temperature (30, 40, 50, and 60 °C), and 
reaction time (15, 30, 45, and 60 min). The samples were incubated in thermostated bath 
(model B12D, Micronal, São Paulo, Brazil) with stirring at 100 rpm and the reaction was 
stopped collecting the immobilized enzyme by filtration. 
After selecting the best parameters of reaction with immobilized tannase, the 
biotransformed soymilk with commercial β-glycosidase in immobilized form was tested in the 
same conditions in order to compare with the established process.  
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For free tannase, according to DE QUEIRÓS; MACEDO; MACEDO (2016), the 
soymilk was incubated with 20 mg of tannase powder (β-glycosidase activity of 4.2 U mg-1), 
also with the best conditions fixed above (pH, temperature, and reaction time), and the 
hydrolysis process was stopped by placing the reaction in an ice bath for 15 min.  
As control, soymilk (lyophilized powder) at the concentration of 200 mg mL-1 of 
distilled water was submitted to the same conditions and it was evaluated for the isoflavones 
profiles. 
Each reaction product was analyzed by High Performance Liquid 
Chromatography coupled to Diode Array Detector (HPLC-DAD) as describe in section 2.5.1.  
 
2.5 Characterization of soy extracts 
2.5.1 Identification and quantification of isoflavones and equol by HPLC-DAD  
The extraction of isoflavones and metabolite from soymilk (biotransformed and 
control) was performed according to AGUIAR et al. (2003), with modifications. Aliquots 
(1 mL) of soymilk, before and after biotransformation, were mixed with 5 mL of methanol 
(80% v/v) at 25 °C for 2 min at 500 rpm. The mixture was centrifuged for 15 min at 5000 
rpm, and the supernatants were filtered through a 0.45 μm membrane before undergoing 
HPLC analyses. 
HPLC analyses of soy extracts were performed on a Dionex UltiMate 3000 
(Germany) liquid chromatograph, equipped with a RP18 XTerra® column (Waters, 5 μm, 4.6 
× 150 mm) maintained at 30 °C. The detection was carried out using a UV/VIS detector 
(DAD-3000) and the mobile phases were: A (water/formic acid, 99.9:0.1 v/v) and B 
(methanol). The gradient elution was as follows: 20% B (0−15 min), 20-80% B (15−75 min), 
80-100% B (75−80 min), 100-20% B (80−90 min) and 20% B (90−95 min), with a flow rate 
of 0.5 mL min-1. The spectra were registered at 190 and 480 nm, and the chromatograms 
processed at 254 nm. 
Isoflavonoids were identified by comparing their retention time and absorbance 
spectrum. Quantification of individual polyphenols was carried out using calibration curves of 
standards (daidzin, genistin, daidzein, genistein, and equol). Results were expressed as µg of 
each phenolic compound mL-1 of the sample (MAUBACH et al., 2003). 
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2.5.2 Equol metabolite confirmation by GC-MS analyses 
To confirm the presence of equol metabolite, the biotransformed soymilk with 
free tannase (SFT) was derivatized with N’O-bis(trimethylsilyl)trifluoroacetamide (BSTFA, 
Sigma-Aldrich, Steinheim, Germany) and analyzed by gas chromatograph mass spectrometer 
(GC-MS), according to KO et al. (2010), with modifications. 
For extracting of metabolite, 1 mL of sample was mixed in vortex with 50 μL of 
12 N HCl for 1 min. The mixture was heated at 100 °C for 60 min. After cooling to room 
temperature, 1 mL of carbonate buffer solution (1.5 M, pH 8.5) and 4 mL ethyl acetate (EA) 
were added and mixed for 10 min. Then, the EA layer was removed and dried with nitrogen. 
The residue was dissolved in 100 μL EA and 40 μL BSTFA reagent, followed by incubation 
at 80 °C for 60 min. The final reactant was analyzed by GC-MS. 
Analyses were carried out in a gas chromatograph mass spectrometer (GCMS-
QP2010S Shimadzu), in selective ion monitoring (SIM) mode, using RTX-5 capillary column 
(Restek, 5% diphenyl, 95% dimethyl-polysiloxane), with 30 m length × 0.25 mm diameter 
inner × 0.25 µm film thickness. The operating conditions of the chromatograph were: injector 
temperature 250 °C; ion source 230 °C; quadrupole 150 °C; injection volume 1 µL in splitless 
mode; carrier gas of helium at constant flow rate of 1 mL min-1; oven program temperature 
160 °C maintained for 2 min and increased at 13 °C min-1 to 290 °C and held an additional 2 
min; and GC-MS interface temperature 290 °C. 
 
2.5.3 Total phenolic content 
Total phenolic content of soy extracts, before and after biotransformation, was 
determined by Folin-Ciocalteau assay according to SWAIN; HILLIS (1959). Gallic acid was 
used as the standard and a calibration curve was plotted in a concentration range of 25–250 µg 
mL-1. All analyses were performed in triplicate, and results were expressed as µg of gallic 
acid equivalents (GAE) mL-1 of extract. 
 
2.6 Cell culture assay 
2.6.1 Cell culture and maintenance 
MCF-7 BUS cell line, a human breast carcinoma which overexpresses estradiol 
receptors (ER), was kindly donated by Dr. Ana Lúcia Tasca Gois Ruiz (CPQBA/UNICAMP). 
The cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium 
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supplemented with 5% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37 °C in a 
5% CO2 humidified atmosphere. 
 
2.6.2 Cytotoxicity assay 
The evaluation of the cytotoxicity of the soy extracts, before and after 
biotransformation, in a range of concentrations in the MCF-7 BUS cell line was tested 
according to MONKS et al. (1991). Cells in 96-well plates (inoculation density of 6 x 104 
cells mL-1) were exposed to different concentrations of samples (0.005−1 µL mL-1) in 
triplicate, for 24 h and 144 h at 37 °C and 5% of CO2. After that, cells were fixed in situ with 
cold 50% trichloroacetic acid (TCA, 50 µL/well) followed by staining with sulforhodamine B 
(SRB) solution (0.4% w/v in 1% acetic acid, 50 µL/well). Bound stain was solubilized with 
10 mM Trizma base (pH 10.5, 150 µL/well), and the absorbance was measured at 540 nm 
using an automated spectrophotometric plate reader.  
 
2.6.3 E-screen assay (estrogenic activity assay) 
The E-screen assay was carried out as described by RASMUSSEN; NIELSEN 
(2002). Briefly, MCF-7 BUS cells (1 x 104 cells/well) were seeded in 12-well plates in RPMI 
1640 supplemented with 5% FBS. After 24 h incubation, the medium was replaced for phenol 
red-free RPMI 1640 supplemented with 5% charcoal stripped FBS and 1% penicillin-
streptomycin. The cells were incubated for 72 h and after that they were treated with soymilk 
samples, before and after biotransformation, at concentrations of 0.1 and 1 µL mL-1, in the 
presence and absence of 17β-estradiol (E2, 10-9 M). After 144 h of incubation, cells were fixed 
with TCA and stained with SRB as describe in section 2.6.2. 
 
2.7 Statistical analysis 
Results of isoflavones and equol quantification by HPLC-DAD, total phenolics, 
and E-screen assay were expressed as means ± standard deviation (SD). The statistical 
difference between the treatment groups was analyzed using analysis of variance (ANOVA). 
Post hoc comparison was performed by Tukey’s multiple comparisons test. Differences were 
considered significant when p < 0.05 and the analyses were performed using the GraphPad 
Prism version 7.0 (GraphPad Software Inc.). 
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3. Results and discussion 
3.1 Selected biotransformation process conditions 
For biotransformation process, preliminary tests were performed and the 
concentrations of 1 and 5% (w/v) of immobilized tannase were eliminated, because the 
conversion of the glycosylated isoflavones to aglycones was shown to be lower than others 
(data not shown). Therefore, it was decided to work with 10% (w/v) immobilized enzyme, 
since the concentration of 15% (w/v) resulted in a lower yield of soymilk after 
biotransformation [3.5 times less compared to concentration of 10% (w/v), since the alginate 
capsules containing the enzyme absorbed the soymilk during the biotransformation process]. 
The pH 6.5 (pH of powder soymilk dissolved in distilled water) and temperature 
of 50 °C were selected for the reaction. The pH 6.5 showed the maximum concentration 
increase of bioactive aglycones compared to the other tested conditions. For temperature, 
although the variable of 60 °C showed higher percentage of aglycones, it was decided to work 
with 50 °C because the immobilized enzyme swelled at 60 °C, and could rupture in reaction 
times longer than 30 min. 
The condition “reaction time” included the interval of 60 min. However, this 
interval was infeasible for the test, because the capsules containing the immobilized enzyme 
ruptured during biotransformation. Thus, the interval of 45 min was select for the reaction. 
As mentioned, the best conditions after the studies, which increased the amount of 
bioactive isoflavones, were defined as: 10% (w/v) of immobilized tannase concentration, pH 
6.5, temperature of 50 °C, and reaction time of 45 min. The results of enzymatic optimization 
process are presented in Table 2.1. 
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Table 2.1 Concentration of isoflavones (µg mL-1) by HPLC-DAD from the different tested 
conditions in the biotransformation process for immobilized tannase. 
  Isoflavones content (µg mL-1) 
Variables Glycosylated Aglycones 
  Daidzin Genistin Daidzein Genistein 
Enzyme 10% (w/v) 15.33 28.44 75.87 70.22 
concentration 15% (w/v) 7.66 13.56 80.45 78.96 
 5.0 29.05 48.96 50.10 43.15 
 6.0 41.17 65.44 46.99 38.66 
pH 6.5 15.33 28.44 75.87 70.22 
 7.0 52.04 78.21 35.33 28.12 
 30 °C 34.72 57.52 41.32 33.62 
 40 °C 15.33 28.44 75.87 70.22 
Temperature 50 °C 6.17 6.85 82.53 84.09 
 60 °C 5.32 6.06 81.68 84.56 
Reaction 15 min 15.54 28.85 53.89 48.88 
time 30 min 6.17 6.85 82.53 84.09 
 45 min 6.16 7.52 97.45 102.40 
 
The best conditions of each variable are in bold. 
 
 
3.2 Characterization of soy extracts 
The HPLC-DAD analyses clearly demonstrated the change in isoflavones profile 
in soymilk. The analyses showed that all enzymatic biotransformation processes with tannase 
and β-glycosidase enzymes, in free and immobilized forms, were able to promote significant 
changes in isoflavones profiles in soymilk, bioconverting glycosidic forms (daidzin and 
genistin) in their respective aglycone forms (daidzein and genistein). Moreover, we were able 
to identify the equol metabolite in SFT. The chromatograms obtained by HPLC-DAD are 
showed in Fig. 2.1. 
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Figure 2.1 Chromatograms obtained by HPLC-DAD from samples (A) SC, (B) SIT, (C) SIB, 
and (D) SFT. Abbreviations: SC, soymilk control; SIT, soymilk + immobilized tannase; SIB, 
soymilk + immobilized β-glycosidase; SFT, soymilk + free tannase. 
 
A 
B 
C 
D 
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The enzymatic biotransformation of phenolic compounds has been presented as an 
alternative strategy to attenuate the variability in the digestive efficiency of isoflavones 
(CHEN et al., 2013; DE QUEIRÓS; MACEDO; MACEDO, 2016; PARK et al., 2001). In 
work developed by PARK et al. (2001) it was studied the defatted soy flour, aiming to 
analyze the content of isoflavone aglycones after heating process and reaction with β-
glycosidase from Aspergillus oryzae. The application of heat treatment at 121 °C and the 
reaction by β-glycosidase combined were able to hydrolyze the glycoside and malonyl 
glycoside forms into aglycone forms. From this finding, other studies have demonstrated the 
action of β-glycosidase enzyme (from Aspergillus niger, Debaryomyces hansenii UFV-1, 
Escherichia coli, and almonds) on isoflavones hydrolysis, in both free and immobilized forms 
(CHEN et al., 2013; ISMAIL; HAYES, 2005; MAITAN-ALFENAS et al., 2014). 
Specific attention should be given to tannase due to the great potential of the 
enzyme, attributed to its strong action on phenolics in foods. A previous study of our research 
group evaluated the effect of tannase extract of P. variotii to modify the profile of polyphenol 
composition of orange juice. The authors found that the enzyme does not only exhibit the 
esterase and depsidic activities already described in literature, but also deglycosylated action, 
acting in the bond between aglycone and disaccharide molecules of flavonoids (FERREIRA 
et al., 2013).  
As shown in Table 2.2, the glycosidic forms of isoflavones were predominant in 
the SC. On the other hand, after soymilk reaction with tannase and β-glycosidase enzymes, 
the concentration of daidzein and genistein increased by 35−40 and 38−46 times, respectively, 
compared to control of untreated soymilk (SC). Comparing all samples with SC, SFT showed 
the highest content of daidzein and genistein aglycones, corresponding to 115.75 ± 1.28 and 
124.89 ± 3.79 µg mL-1 of sample, respectively. The findings suggest that the glycosidic forms 
of isoflavones were converted into aglycones forms, and other substrates like acetyl and 
malonyl glycosides may also have been transformed into daidzein and genistein. Our results 
are in agreement with data observed by DE QUEIRÓS; MACEDO; MACEDO (2016) when 
applying tannase to soymilk. They suggest the ability of the enzyme to generate free 
aglycones from substrates different than daidzin and genistin, possibly from polymerized 
substrates. 
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Table 2.2 Concentration of isoflavones and equol (µg mL-1) by HPLC-DAD of the 
biotransformed samples at the best selected conditions. 
 Isoflavones and metabolite content (µg mL-1) 
Samples                  Glycosylated            Aglycones Metabolite 
 
Daidzin Genistin Daidzein Genistein Equol 
SC 119.33a ± 1.03 145.77a ± 2.36 2.87c ± 0.24 2.73c ± 0.57 n/d1 
SIT 8.05c ± 0.08 18.86c ± 2.93 102.53b ± 7.75 104.68b ± 8.23 n/d 
SIB  22.27b ± 1.21 49.38b ± 2.50 99.42b ± 1.87 104.29b ± 2.27 n/d 
SFT 5.54c ± 1.46 13.88c ± 1.28 115.75a ± 1.28 124.89a ± 3.79 0.26 ± 0.03 
 
Results are expressed as mean ± standard deviation (n = 3). For each column, values with different lowercase letters are 
significant at p < 0.05 by Tukey’s test. 1 n/d, not detected, under detection limit for this methodology and equipment. 
Abbreviations: SC, soymilk control; SIT, soymilk + immobilized tannase; SIB, soymilk + immobilized β-glycosidase; SFT, 
soymilk + free tannase. 
 
The equol metabolite was quantified only in SFT, corresponding to 0.26 ± 0.03 µg 
mL-1 of sample. This finding is probably due to the higher performance of the free form of 
tannase when compared to immobilized form. To confirm the peak identified in HPLC 
analysis, SFT was investigated by GC-MS. As shown in Fig. 2.2, the equol metabolite was 
confirmed by mass spectrum. 
 
 
 
A 
B 
 
Figure 2.2 Mass spectra of equol identified in (A) SFT and (B) standard equol. Abbreviation: 
SFT, soymilk + free tannase. 
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The total detectable phenolic content of the samples varied from 1432 ± 53 to 
1543 ± 30 µg of GAE mL-1 of samples. There was no statistical difference between 
biotransformed samples with immobilized enzymes and SC (p < 0.05). However, for SFT, a 
statistical difference was observed compared to SC, increasing from 1434 to 1543 µg mL-1, an 
increase of 7%. 
These results suggest that the process with tannase in free form improves the 
release of phenolic compounds from soymilk matrix. Moreover, the activity of tannase in free 
form appeared to be more extensive than the biotransformation performed by the immobilized 
enzymes. SFT presented the highest increase in the aglycone forms of isoflavones, which 
correlate with the total phenolic content assay, evidencing that the tannase presented broader 
action and did not only act as β-glycosidase but was able to produce the equol metabolite and 
generate aglycones from other substrates. 
The gut microbiota is responsible for converting the aglycone daidzein into equol, 
involving several intestinal bacteria in this process (SETCHELL; BROWN; LYDEKING-
OLSEN, 2002; YUAN; WANG; LIU, 2007). However, studies have also considered the equol 
production during soymilk fermentation without intestinal bacteria, correlating the synthesis 
of equol and the use of enzymes like β-glycosidase from microorganisms (DI CAGNO et al., 
2010; REKHA; VIJAYALAKSHMI, 2011).  
Moreover, our study identified equol in soymilk biotransformed with only free 
tannase, without fermentative process. Our hypothesis is that the presence of equol metabolite 
is probably due to the broad catalytic performance of free form of tannase in other substrates 
(other than daidzein) existing in the sample, since the crude enzyme extract present a complex 
composition. Similar results were found by DE QUEIRÓS; MACEDO; MACEDO (2016) 
using the same crude tannase extract from P. variotii in soymilk biotransformation. The 
authors analyzed the production of equol by bioprocess "in vitro", changes in the profile of 
isoflavones and antioxidant activity of soymilk. Biotransformation processes based on 
soymilk fermentation by probiotic lactic bacteria and enzymatic process with tannase were 
performed. The results showed that both enzymatic and fermentation processes were able to 
hydrolyze the glycosidic form into aglycone form and increased the equol content. Although 
both biotransformation processes were effective in this study, the results indicated that the 
action of tannase was better than fermentation process in increasing aglycones, in antioxidant 
activity, and in the equol content in soymilk. So, further investigation studies are necessary to 
find out the possible substrate for this equol production by tannase catalyzes.  
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3.3. Influence of biotransformation process on in vitro estrogenic activity 
Natural isoflavones present structural similarity with 17β-estradiol hormone 
demonstrating binding affinities for both estrogen receptors subtypes (ERα and ERβ) 
(WUTTKE; JARRY; SEIDLOVÁ-WUTTKE, 2007). Estrogens play a fundamental role in 
many physiological processes in hormone dependent tissues, such as cell proliferation, 
differentiation, or programmed cell death. However, elevated levels of estrogens are associate 
with an increased risk of developing hormone dependent diseases, including breast, 
endometrial, and ovary cancers (KUMAR et al., 2010; SCHAIRER et al., 2000; UIFĂLEAN 
et al., 2016).  
Therefore, hormone replacement therapy for women in menopause has some risks 
that cannot be neglected. Thus, the discovery of safer ligands in estrogen receptors activation 
is promising and soy products rich in isoflavones and metabolite appear as a healthy 
alternative to relieve and improve the symptoms in menopausal women (SUNITA; 
PATTANAYAK, 2011). 
The present study evaluated the soymilk samples in vitro to evidence their ability 
to binding to estrogen receptors. First, MCF-7 BUS cells were exposed to the samples to 
determine the higher non-cytotoxic concentration; none of the extracts reduced cell viability 
after 24 or 144 h of exposure (Table 2.3). Thus, for the E-screen assay the concentrations 
selected were 0.1 and 1 µL mL-1. 
 
Table 2.3 Relative cell viability* (%) of MCF-7 BUS cell line by Sulforhodamine B assay. 
                       Incubation for 24 h      Incubation for 144 h 
Samples Samples concentration (µL mL-1) 
 0.005 0.01 0.1 0.5 1 0.005 0.01 0.1 0.5 1 
SC 94% 95% 97% 110% 117% 99% 99% 99% 101% 102% 
SIT 104% 105% 106% 118% 124% 99% 100% 99% 101% 101% 
SIB 99% 103% 114% 114% 126% 96% 97% 99% 102% 101% 
SFT 95% 97% 105% 106% 113% 97% 96% 101% 103% 103% 
 
*Results are expressed as percentages of cell viability compared to cell control (cell without any treatment) − 100% of cell 
viability. Abbreviations: SC, soymilk control; SIT, soymilk + immobilized tannase; SIB, soymilk + immobilized β-
glycosidase; SFT, soymilk + free tannase. 
 
The E-screen assay was developed to elucidate estrogenic/antiestrogenic activity 
by changes in proliferation of MCF-7 BUS cell line, a human breast carcinoma which 
64 
 
 
 
overexpresses estradiol receptors. Thus, all samples exhibited enhanced cell proliferation in 
comparison to untreated cells (Fig. 2.3). 
 
         
 
     
Figure 2.3 Cell proliferation of MCF-7 BUS regarding to samples treatment in concentration 
of 0.1 µL mL-1 (A and B) and 1 µL mL-1 (C and D) in the absence and presence of 17β-
estradiol. Different lowercase and capital letters indicate significant differences by Tukey’s 
test (p < 0.05) in relation to cell control and positive control, respectively. Abbreviations: SC, 
soymilk control; SIT, soymilk + immobilized tannase; SIB, soymilk + immobilized β-
glycosidase; SFT, soymilk + free tannase; E2, 17β-estradiol. 
 
At the lower concentration tested (0.1 µL mL-1), immobilized tannase or -
glycosidase treatment did not increase the ability of the soymilk to enhance cell proliferation. 
Moreover, free tannase treatment resulted in an increase of 2.6 times, compared to untreated 
cells, which is as effective as 17β-estradiol (10-9 M, Fig. 2.3A). When MCF-7 BUS cells were 
B 
C D 
A 
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co-treated with soymilk or biotransformed soymilk samples and E2 (Fig. 2.3B), E2 
proliferative action significantly increased, which suggests an additive effect. 
For the higher concentration (1 µL mL-1), both tannase treatments (free and 
immobilized) increased the cell proliferation 3.2 and 3.3 times, respectively, compared to 
untreated cells (Fig. 2.3C), which is slightly more effective than E2 (19.4 and 20.4% higher, 
respectively). In relation to co-treatment with E2, all samples were able to enhance the cell 
proliferation, potentiating the 17β-estradiol action (Fig. 2.3D). 
Equol, a daidzein metabolite, occurs in two different enantiomeric forms (R)- and 
(S)-equol, and the (S)-equol is the only form produced by human microbiota (SETCHELL et 
al., 2005). Both forms show distinct performance in binding affinities with ERα and ERβ. The 
(S)-equol has higher affinity for binding to ERβ and exhibits a binding preference greater than 
its precursor, daidzein, whereas the (R)-equol shows preference for binding selectivity to ERα 
(MUTHYALA et al., 2004).  
In our study, the equol metabolite was detected only in SFT. It is noteworthy that 
this sample suffered major modifications, although we haven’t trace all of them yet. So, the 
data allow us to infer the differentiated action of this sample in in vitro assays, like the 
increased estrogenic potential observed in this work. Even if the yield of equol generation is 
quite low, the results make it seems to be enough to improve the bioactive potential of the 
bioprocessed soymilk, producing a functional ingredient of high health promoting potential. 
According to literature, the presence of soy isoflavones and their metabolites in 
human blood were able to stimulate proliferation of MCF-7 cells, and this effect is dependent 
of the estrogen concentration in the media. Thus, at very low levels of estrogen (20 pM), soy 
isoflavones were able to inhibit cell proliferation; while at higher estrogen levels, isoflavones 
can stimulate cell proliferation (IMHOF; MOLZER; IMHOF, 2008). Moreover, for genistein, 
the ERα/ERβ ratio also influences the estrogenic effect. The induction of cell proliferation 
and programmed cell death inhibition by genistein was observed in MCF-7 cells (with high 
ERα/ERβ ratio), but not in T47D cells (with low ERα/ERβ ratio) and MDA-MB-231 (ER 
negative) (PONS et al., 2014). These results are in agreement with our study, since the 
treatment with isoflavone aglycone-enriched extracts and E2 enhanced the proliferation of 
MCF-7 BUS, that overexpresses estradiol receptors (ERα). 
In breast cancer cells, the estrogen receptor β regulates the set of genes evolved 
with control of cell cycle progression and generally suppress the proliferation, whereas the 
estrogen receptor α activation has an opposite effect (CHANG et al., 2006). This statement 
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also applies to our work, since the ERα probably was activated by isoflavone aglycones and 
equol, resulting in increased cell proliferation. 
 
4. Conclusions 
The enzymatic biotransformation by tannase and β-glycosidase is an efficient 
strategy to improve bioactive potential of soymilk. The use of free tannase proved that it is 
possible to produce equol in soymilk using in vitro enzymatic bioprocess, which confirms the 
great potential of this enzyme. Moreover, the biotransformed soymilk by tannase, especially 
that one treated with free tannase, presented higher estrogenic action, making it a promising 
nutraceutical with possible effects to treat or improve menopausal symptoms. 
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CHAPTER 3. EFFECT OF BIOTRANSFORMED SOY EXTRACTS ON 
ANTI-INFLAMMATORY, ANTIOXIDANT, AND ANTI-LIPOGENIC POTENTIAL 
(ORIGINAL RESEARCH PAPER SUBMITTED TO THE JOURNAL OF 
NUTRITIONAL BIOCHEMISTRY) 
Amanda Rejane Alves de Ávila, Lívia Dias de Queirós, Tatiane Mayumi Ueta, 
Gabriela Alves Macedo, Juliana Alves Macedo 
  
Abstract 
Soy isoflavones have been associated with several beneficial effects on human 
health, playing an important role in prevention and therapy of some diseases. Thus, this study 
aimed to investigate the anti-lipogenic and anti-inflammatory effects as well as the 
antioxidant capacity of biotransformed soymilk by tannase and β-glycosidase enzymes. The 
results showed a significant enhancement of the antioxidant capacity, especially to the 
biotransformed soymilk with free tannase (SFT), corresponding to an increase of 2.3 and 1.25 
times by ORAC and FRAP assays, respectively; for biotransformed soymilk with 
immobilized tannase (SIT) and soymilk with immobilized β-glycosidase (SIB) there was not 
significant rise in the antioxidant potential. The anti-lipogenic effects by in vitro assay with 
murine 3T3-L1 adipocytes were not significant. However, the anti-inflammatory responses 
were very expressive. In LPS-stimulated RAW 264.7 macrophage cells, SFT reduced in about 
37 times TNF-α content at the highest tested concentration, while IL-6 was not detected in the 
same experimental condition. Nitric oxide was not detected when the cells were treated by 
SIT or SIB at intermediate tested concentration. Based on these findings, the biotransformed 
soy extracts, especially those treated with free tannase, present great potential to act as a 
nutraceutical, protecting the cells against oxidative damage and helping maintain health under 
inflammatory stress. 
Keywords: anti-inflammatory activity; antioxidant capacity; enzymatic 
biotransformation; soy isoflavones; tannase 
 
1. Introduction 
Soybean seeds and its derivative products are an important dietary source of 
polyphenols, which are commonly associated with benefits to human health. The major 
phenolic constituents found in soy products are flavonoids, especially isoflavones in their 
glycoside (genistin, daidzin, and glycitin), aglycone (genistein, daidzein, and glycitein), acetyl 
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glycoside (acetyl genistin, acetyl daidzin, and acetyl glycitin), and malonyl glycoside 
(malonyl genistin, malonyl daidzin, and malonyl glycitin) forms (KUDOU et al., 1991; NAIM 
et al., 1973; OHTA et al., 1979, 1980; WALTER, 1941; WALTZ, 1931). However, the 
biological activity of isoflavones depends on their chemical forms, and aglycones and 
metabolites seem to have higher health benefits (IZUMI et al., 2000; SHAO et al., 2011). For 
this reason, the enrichment of isoflavone aglycones and metabolites in soy-based products has 
attracted growing attention.  
In order to increase the bioactive potential of soy extracts, our research group has 
been studying the application of tannase enzyme in the biotransformation of soy isoflavones. 
DE ÁVILA et al. (2018) and DE QUEIRÓS; MACEDO; MACEDO (2016) described the 
potential of tannase in the production of aglycones and generation of equol from soymilk. The 
results have been extremely encouraging and deserve further investigation, such as the 
biological potential evaluation of the biotransformed extracts. 
Bioactive isoflavones have several beneficial effects for human health, including 
antioxidant, anti-inflammatory, and anti-lipogenic properties (HE et al., 2016; KAWAHARA 
et al., 2015; SZYMCZAK et al., 2017). Besides that, some authors have found a correlation 
between chronic inflammation, obesity, and oxidative stress (PINENT et al., 2011; 
SEQUEIRA; RAO; RAO, 2012).  
Macrophages are heterogeneous immune cells, and in response to 
microenvironmental stimuli, can be polarized into the pro-inflammatory M1 or anti-
inflammatory M2 phenotypes. During the inflammatory process, the M1 phenotype is 
activated, resulting in high expression of pro-inflammatory markers (WU et al., 2016). These 
markers, like cytokines, can contribute to a diversity of metabolic disorders, including the 
obesity-related inflammatory diseases (MURRAY; WYNN, 2011). For example, the 
hypertrophied adipocytes, present in adipose tissue of obese patients, can induce macrophage 
infiltration and consequent increase in insulin resistance factors secretion, such as tumor 
necrosis factor (TNF-α) and interleukin 6 (IL-6) (OKABE et al., 2014). Thus, considering the 
enhanced secretion of pro-inflammatory cytokines (adipokines) in obesity, the risk increases 
for developing metabolic syndrome and its components such as type 2 diabetes mellitus, 
elevated blood pressure, dyslipidemia, and cardiovascular diseases (BALISTRERI; 
CARUSO; CANDORE, 2010; VOLP et al., 2008). Moreover, the oxidative stress, 
characterized as an imbalance between the production of highly oxidative compounds and 
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antioxidant defenses, can lead to chronic inflammation and other related disorders (HUSSAIN 
et al., 2016).  
In this context, the study evaluated the role of biotransformed soy extracts in 
antioxidant capacity, as well as the effect of these extracts on the response of RAW 264.7 
macrophages to inflammatory lipopolysaccharide in an in vitro model. In addition, the ability 
to reduce lipogenesis in adipocyte cell culture was also investigated. 
 
2. Materials and methods 
2.1 Materials 
Soybean seeds (IAC Foscarin 31 variety, 15/2015 lot, 85% germination, produced 
at Mococa, SP, Brazil) were obtained at the Agronomic Institute of Campinas, Campinas, SP, 
Brazil. Trolox®, 2,2’-azobis(2-amidinopropane) dihydrochloride (97%) (AAPH), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), β-glycosidase enzyme 
(naringinase from Penicillium decumbens), insulin, dexamethasone (DEX), 3-isobutyl-1-
methylxanthine (IBMX), lipopolysaccharide (LPS), and Oil Red O were purchased from 
Sigma-Aldrich (Steinheim, Germany). Fluorescein was purchased from ECIBRA (São Paulo, 
SP, Brazil). All other chemicals were acquired in the grade commercially available. 
 
2.2 Enzymatic biotransformation 
Soymilk enzymatic biotransformation was carried out according to procedure 
described by DE ÁVILA et al. (2018). Briefly, soymilk was prepared following the 
methodology developed by Embrapa Soja, Brazil (MANDARINO; CARRÃO-PANIZZI, 
1999). Soy extracts were biotransformed by tannase obtained from Paecilomyces variotii 
(BATTESTIN; MACEDO, 2007), in free and immobilized forms, and commercial β-
glycosidase (naringinase from Penicillium decumbens), in immobilized form 
(MOHAPATRA; MONDAL; PATI, 2007). For biotransformation with immobilized 
enzymes, the conditions were fixed as: 10% (w/v) of immobilized tannase or β-glycosidase 
concentration, pH 6.5, temperature of 50 °C, and reaction time of 45 min. The reaction was 
stopped by collecting the immobilized enzyme by filtration. cFor biotransformation with free 
tannase, according to DE QUEIRÓS; MACEDO; MACEDO (2016), the soymilk was 
incubated with 20 mg of tannase powder (β-glycosidase activity of 4.2 U mg-1) in the 
conditions fixed above (pH, temperature, and reaction time), and the biotransformation 
process was stalled by putting the reaction in an ice bath for 15 min. As control, soymilk 
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(without enzyme addition) was submitted to the same conditions described for free and 
immobilized enzymes.  
Each reaction product was previously analyzed by High Performance Liquid 
Chromatography coupled to Diode Array Detector (HPLC-DAD) and the polyphenols profiles 
were published by DE ÁVILA et al. (2018). 
 
2.3 Antioxidant potential 
The antioxidant potential of soy extracts (biotransformed and control) was 
investigated by Oxygen Radical Absorbance Capacity (ORAC) assay, as described by 
DÁVALOS et al. (2004) and adapted by MACEDO et al. (2011), and by Ferric Reducing 
Antioxidant Power (FRAP) assay, according to BENZIE; STRAIN (1996). Final values were 
expressed as µmol Trolox equivalent (TE) mL-1 of sample. 
 
2.4 Cell culture assay 
2.4.1 Cell cultures and maintenance 
RAW 264.7 murine macrophages and 3T3-L1 murine preadipocytes were cultured 
in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% (v/v) fetal bovine 
serum (FBS) and 1% penicillin/streptomycin. The cell lines were maintained at 37 °C in a 
humidified atmosphere with 5% CO2. 
 
2.4.2 MTT assay 
Cell viability was evaluated by MTT assay, according to MOSMANN (1983). 
Briefly, RAW 264.7 cells in 96-well plates (inoculation density of 1.0 × 105 cells mL-1) were 
exposed to different concentrations of samples (2.5−150 µL mL-1) for 24 h at 37 °C and 5% 
of CO2. After treatment, the medium was removed and 90 μL of phosphate buffered saline 
(PBS) and 10 μL of MTT solution (5 mg mL-1) were added to each well. The cells were 
incubated for 3 h at 37 °C. The formazan crystals were dissolved in sodium dodecyl sulfate 
(SDS) 10% in HCl 0.01 M for 18 h. The optical density of formazan solution was measured at 
540 nm using an automated spectrophotometric plate reader.  
The same protocol was used for 3T3-L1 cells. However, after adding MTT 
solution, the cells were incubated for 4 h. 
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2.4.3 Preadipocytes differentiation 
The 3T3-L1 cells (inoculation density of 2.0 × 104 cells mL-1) were cultured in 
24-well plates. Two days post-confluency, designated as day 0, the cells were stimulated to 
differentiate into adipocytes by addition of the differentiation medium (DMEM supplemented 
with 0.5 mM IBMX, 10 µg ml-1 insulin, and 1 µM DEX). After 72 h (day 3), the medium was 
replaced with maturation medium (DMEM added with 10 µg ml-1 insulin). The cells were 
cultured in maturation medium until day 12, after which mature adipocytes containing lipid 
droplets were formed. 
 
2.4.4 Oil Red O staining 
Samples in different concentrations (2.5, 10, and 25 µL mL-1) were tested in two 
stages of adipocyte differentiation. In the first treatment, cells were exposed to the samples in 
the differentiation medium followed by maturation medium (without samples addition). The 
second treatment was carried out adding the samples only in the maturation medium.  
In both treatments, on day 12, the 3T3-L1 differentiated adipocytes were fixed 
with formaldehyde 10% in PBS for 60 min at room temperature. After washing with 60% 
isopropanol twice, the cells were stained with 2.1 mg mL-1 Oil Red O solution with 60% 
isopropanol for 60 min. Excess Oil Red O dye was washed with distilled water for five times 
and the wells were dried in room temperature. The Oil Red O in the stained cells was eluted 
with 100% isopropanol and the absorbance was measured at 492 nm in an automated 
spectrophotometric plate reader.  
 
2.4.5 RAW 264.7 inflammatory assay 
RAW 264.7 macrophages were cultured in 24-well plates (inoculation density of 
1.0 × 105 cells/well) for 24 h. Different concentrations of samples (2.5, 5, and 10 µL mL-1) 
plus LPS (100 ng mL-1) were added to the plates in the treatment group and only medium or 
LPS was added to the control group (without samples). After LPS stimulation for 24 h, the 
cell-free supernatants were collected and analyzed for TNF-α and IL-6 levels using the 
commercial enzyme-linked immunosorbent assay (ELISA) kits Mouse TNF ELISA Set II and 
Mouse IL-6 ELISA Set (BD OptEIA™) respectively, according to manufacturer’s 
instructions. The optical density was read at 450 nm using an automated spectrophotometric 
plate reader. 
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The cell-free supernatant was also used to evaluate the nitric oxide (NO) 
concentration, according to a previously published procedure by GREEN et al. (1982). Nitrite 
concentration was used as an indicator of NO production by Griess reaction. Briefly, 100 µL 
of the cell-free supernatant, blank or standard curve of sodium nitrite (1−50 mM) plus an 
equal volume of Griess reagent [1% sulfanilamide, 5% phosphoric acid, and 0.1% N-(1-
naphthyl)ethylenediamine] were added in 96-well plate. The absorbance was measured at 540 
nm and the nitrite concentration was calculated by comparison to standard curve. 
 
2.5 Statistical analysis 
Results of antioxidant, anti-lipogenic, and anti-inflammatory assays were 
expressed as means ± standard deviation (SD). All measurements were performed in 
triplicate. The statistical difference between the treatment groups was analyzed using analysis 
of variance (ANOVA). Post hoc comparison was performed by Dunnett’s or Tukey’s tests. 
Differences were considered significant when p < 0.05 and the analyses were performed using 
the GraphPad Prism version 5.0 (GraphPad Software, Inc.). 
 
3. Results and discussion 
3.1 Characterization of biotransformed soy extracts 
According to our previous results, published by DE ÁVILA et al. (2018), all 
enzymatic biotransformation processes with tannase and β-glycosidase, in free and 
immobilized forms, were able to promote significant changes in isoflavones profiles in 
soymilk, bioconverting glycosidic forms (daidzin and genistin) into aglycone forms (daidzein 
and genistein). SFT and SIT had higher content of bioactive aglycones, an increase of 36−46 
times compared to soymilk control (SC). The equol metabolite was also quantified in SFT, 
corresponding to 0.26 ± 0.03 µg mL-1 of sample. 
 
3.2 Antioxidant potential 
The antioxidant capacity of soymilk, before and after biotransformation process, 
was evaluated using ORAC and FRAP methods. The results demonstrated a significant 
increase in the antioxidant capacity of the SFT in both assays (p < 0.05).  
Besides, immobilized enzymes were not able to produce biotransformed samples 
with higher antioxidant activity than SC by ORAC assay. The same profile was observed by 
FRAP method; however, SIT not significantly differed from SFT (Table 3.1). 
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Table 3.1 Antioxidant activity of soy extracts from ORAC and FRAP assays. 
Samples ORAC  FRAP  
  
(µmol equivalent Trolox 
mL-1 of extract) 
(µmol equivalent Trolox 
mL-1 of extract) 
SC 26,185a ± 1,605 5,643a ± 141 
SIT 32,344a ± 1,328 6,462ab ± 507 
SIB 32,109a ± 3,669 5,443a ± 466 
SFT 60,616b ± 2,876 7,047b ± 796 
 
Results are presented as means ± standard deviation (n = 3). For each column, values with different lowercase letters are 
significant at p < 0.05 by Tukey’s test. Abbreviations: SC, soymilk control; SIT, soymilk + immobilized tannase; SIB, 
soymilk + immobilized β-glycosidase; SFT, soymilk + free tannase. 
 
As shown in Table 3.1, the enzymatic biotransformation process of SFT had the 
highest increase in the antioxidant capacity compared to the untreated soymilk (SC), 
corresponding to rise of 2.3 and 1.25 times by the ORAC and FRAP assays, respectively. This 
finding is probably due to the higher performance of the free form of tannase to release the 
phenolic compounds from soymilk matrix, hydrolyzing the glycosidic forms into aglycones 
and generating equol, as demonstrated by DE ÁVILA et al. (2018) and DE QUEIRÓS; 
MACEDO; MACEDO (2016). This probably contributed to the significant increase of the 
antioxidant power.  
The enhancement in the antioxidant capacity of a food matrix rich in polyphenols 
modified by biotransformation processes was previously observed by our research group. The 
antioxidant capacity of green tea and yerba mate extracts after biotransformation with tannase 
from P. variotii was evaluated by MACEDO et al. (2011). The results showed an increase in 
the antioxidant activity of 43 and 55%, respectively, by ORAC method.  
MARTINS et al. (2017) also investigated the antioxidant potential of grape 
pomace extract after treatment with tannase from P. variotii. The authors observed that the 
tannase treatment significantly increased the antioxidant activity by ORAC and FRAP assays 
in 215 and 12%, respectively, compared to grape pomace control.  
Our data are consistent with the results presented by DE QUEIRÓS; MACEDO; 
MACEDO (2016), using the same crude tannase enzyme extract from P. variotii in soymilk 
biotransformation. The authors analyzed the antioxidant activity by ORAC and DPPH assays 
for different biotransformation processes based on the fermentation by lactic bacteria and the 
application of tannase. The results showed a significative increase in the antioxidant power by 
ORAC assay, especially for the SFT, corresponding to rise of 3.95 times compared to control.  
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These results demonstrate that the enzymatic biotransformation with tannase in 
different substrates tested may be able to catalyze hydrolysis of glycosidic bonds, and the 
products of this reaction possibly contribute to the elevated antioxidant potential. According 
to NIELSEN; WILLIAMSON (2007), the aglycone forms contribute to the increased 
antioxidant capacity since they are known to be more bioactive than their respective 
glycosides. In addition, the treatment of SFT generated the equol metabolite, identified in our 
previous studies (DE ÁVILA et al., 2018; DE QUEIRÓS; MACEDO; MACEDO, 2016) and 
considered highly bioactive.  
 
3.3 Anti-lipogenic assay in 3T3-L1 cell line 
According to the cytotoxicity assay (MTT assay), SFT promoted a significant 
decrease in the cellular viability at concentrations above 50 µL mL-1, while all the other 
samples were cytotoxic above 100 µL mL-1 (Figure 1). Thus, the other evaluations were 
carried out using 2.5, 10, and 25 µL mL-1 concentrations for all samples. 
 
Figure 3.1 Cell viability (% of control cells) of 3T3-L1 cell line according to MTT assay. 
Abbreviations: SC, soymilk control; SIT, soymilk + immobilized tannase; SIB, soymilk + 
immobilized β-glycosidase; SFT, soymilk + free tannase. 
 
To study the adipocyte differentiation, 3T3-L1 murine preadipocytes are 
commonly employed in cell models. During usual growth, these cells have a fibroblast-like 
morphology. However, in appropriate conditions, they differentiate into an adipocyte-like 
phenotype: assume a spherical shape, accumulate lipid droplets, and gradually acquire the 
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morphological and biochemical characteristics of a mature adipocyte (GREGOIRE; SMAS; 
SUL, 1998).  
In the present study, it was evaluated the ability of biotransformed soymilk 
samples in the influence the final oil content in 3T3-L1 intracellular vesicles. The intervention 
with the samples occurred at two different times. In the first assay, cells were exposed to the 
samples in the differentiation medium. This treatment evaluated wheter the extracts could 
interfere in the preadipocytes differentiation. The second intervention consisted of the 
sample’s addition only in the maturation medium, and this procedure aimed to verify if the 
extracts could affect the lipogenesis process. 
The analysis of Oil Red O staining showed a discreet effect in the total lipid 
accumulation when the samples were added in the differentiation medium (Table 3.2). The 
best result was observed to SC in the concentration of 25 µL mL-1, with 8.5% reduction in the 
lipid accumulation in relation to control cells without any treatment. However, statistical 
difference among the samples was not observed in this treatment condition. 
 
Table 3.2 Oil Red O staining with samples added in the differentiation medium, % in relation 
to cell control*. 
Samples                             Concentration   
 2.5 µL mL-1 10 µL mL-1 25 µL mL-1 
                SC 110.5 ± 2.96ac 104.38 ± 1.49a 91.47 ± 6.78a 
                SIT         104.1 ± 2.95a 93.37 ± 1.69b 98.25 ± 6.32a 
                SIB                            94.46 ± 3.57b  97.87 ± 6.08ab 100.24 ± 4.82a 
                SFT 112.4 ± 0.00c  97.37 ± 1.11ab 105.95 ± 7.67a 
 
Results are presented as means ± standard deviation (n = 3). For each column, values with different lowercase letters are 
significant at p < 0.05 by Tukey’s test. *cell without any treatment; 100% cell viability. Abbreviations: SC, soymilk control; 
SIT, soymilk + immobilized tannase; SIB, soymilk + immobilized β-glycosidase; SFT, soymilk + free tannase. 
 
The administration of the samples in the cell differentiation phase, at the three 
tested concentrations, did not result in substantial differences in the final lipid content 
accumulated by the mature adipocytes. So, the samples did not influence the cell 
differentiation process in this condition. 
On the other hand, the addition of the samples in the maturation medium caused 
significantly increased accumulation of the lipid content compared to differentiation medium 
(Table 3.3). This enhance was observed for all samples, especially for SIB, which increased 
approximately 2.2 times in relation to cell control without any treatment. A hypothesis for this 
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finding is the presence of higher amount of free glucose of this sample, due to the 
deglycosylation catalyzed by β-glycosidase enzyme.  
 
Table 3.3 Oil Red O staining with samples added in the maturation medium, % in relation to 
cell control*. 
Samples                          Concentration   
  2.5 µL mL-1 10 µL mL-1 25 µL mL-1 
SC 110.98 ± 0.92a 118.72 ± 2.09a 125.83 ± 2.47a 
SIT 144.62 ± 2.56b 166.60 ± 3.40b 170.69 ± 1.87b 
                    SIB                           212.56 ± 1.00c 220.93 ± 9.33c 227.59 ± 3.77c 
SFT 112.46 ± 1.31a 107.14 ± 0.92a 122.55 ± 0.87a 
 
Results are presented as means ± standard deviation (n = 3). For each column, values with different lowercase letters are 
significant at p < 0.05 by Tukey’s test. *cell without any treatment; 100% cell viability. Abbreviations: SC, soymilk control; 
SIT, soymilk + immobilized tannase; SIB, soymilk + immobilized β-glycosidase; SFT, soymilk + free tannase. 
 
 
Reports have indicated that a diet rich in polyphenols, such as flavonoids, may 
cause a decrease of lipogenesis, induction of lipolysis process, as well as programmed adipose 
cell death (ENGIN et al., 2018; RAYALAM; DELLA-FERA; BAILE, 2008). HWANG et al. 
(2015) presented results that are consistent with this observation. These authors evaluated the 
anti-obesity effect of soy extract fermented by Bacillus subtilis MORI (BTD-1) in 3T3-L1 cell 
culture. The results showed that fermented soy extract decreased lipid accumulation by 
suppressing the adipocytes differentiation. Similarly, HE et al. (2016) analyzed the anti-
obesity effect of daidzein in 3T3-L1 cells. The authors verified that elevated levels of daidzein 
significantly inhibited preadipocyte proliferation and fat deposition in 3T3-L1 adipocytes, 
with possible effects in prevention and treatment of obesity and related metabolic disorders. 
However, our findings could not corroborate these studies, as the soy extracts, 
biotransformed or control, were not able to significantly reduce lipid accumulation by 
adipocytes. So, based on one preliminary in vitro test, our samples did not indicate good 
potential as remediators of adipogenesis or lipogenesis processes associated with obesity. 
 
3.4 Inflammatory assay with RAW 264.7 stimulated by LPS 
According to the MTT assay, all the samples caused significant losses of cellular 
viability in concentrations higher than 50 µL mL-1 (Fig. 3.2). However, SFT was cytotoxic 
above 25 µL mL-1. So, it was considered safe to continue with the following cellular assays 
using 2.5, 5, and 10 µL mL-1 concentrations for all the samples. 
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Figure 3.2 Cell viability (% of control cells) of RAW 264.7 cell line according to MTT assay. 
Abbreviations: SC, soymilk control; SIT, soymilk + immobilized tannase; SIB, soymilk + 
immobilized β-glycosidase; SFT, soymilk + free tannase. 
 
Murine macrophages RAW 264.7 cells are widely used in in vitro inflammatory 
study models. When activated by LPS or interferon-γ, the cells express a M1 phenotype of 
highly inflamed macrophages (KUDA et al., 2012; MURRAY; WYNN, 2011). In the present 
study, LPS-induced RAW 264.7 cells presented an increase in TNF-α, IL-6, and NO 
concentrations in the positive control, confirming the occurrence of the inflammatory stimulus 
(Table 3.4). 
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Table 3.4 Cytokines and nitric oxide concentrations in RAW 264.7 supernatant after 24 h of treatment with samples. 
  
Negative 
control* 
(cell)  
Positive  
Control 
(cell + LPS) 
Sample 
concentrations  
(µL mL-1) 
SC  
+ LPS 
SIT  
+ LPS 
SIB  
+ LPS 
SFT  
+ LPS 
TNF-α 2,109 ± 98 60,054 ± 2965 2.5 9,376 ± 629a 8,638 ± 1077a 10,395 ± 799a 15,023 ± 635b 
(pg mL-1)   5 3,914 ± 279a 5,203 ± 106b 5,222 ± 429b 4,004 ± 153a 
      10 3,344 ± 307a 4,241 ± 22b 4,247 ± 56b 1,606 ± 73c 
IL-6 118 ± 11 2,029 ± 115 2.5 383 ± 8a 438 ± 32a 163 ± 7b 689 ± 48c 
(pg mL-1)   5 574 ± 60a 668 ± 42a 118 ± 1b 187 ± 13b 
      10 508 ± 25a 651 ± 24b 110 ± 1c n/d 
NO n/d1 15 ± 0.2 2.5 0.5 ± 0.3a 0.6 ± 0.2a 1.4 ± 0.6a 13 ± 0.2b 
(µM)   5 0.2 ± 0.1a n/d n/d 11 ± 0.4b 
      10 0.5 ± 0.1a 0.9 ± 0.1a 0.5 ± 0.1a 8 ± 0.5b 
 
Results are presented as means ± standard deviation (n = 3). All samples treatment presented significant difference compared to positive control (cells stimulated with LPS and without samples) 
by Dunnett’s test (p < 0.05). Different lowercase letters indicate significant difference among the samples in the same concentration by Tukey’s test (p < 0.05).  
* cells without LPS stimulus or extract; 1 n/d, not detected. Abbreviations: SC, soymilk control; SIT, soymilk + immobilized tannase; SIB, soymilk + immobilized β-glycosidase; SFT, soymilk + 
free tannase; LPS, lipopolysaccharide. 
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According to literature, the pro-inflammatory cytokines such as interleukin 1β 
(IL-1β), IL-6, and TNF-α are commonly induced together. IL-6 is a cytokine produced by 
cells in response to infection and injury, while TNF-α, when released systemically in response 
to sepsis, causes shock, disseminated intravascular coagulation, and multiorgan failure 
(GRAY; BLOCH, 2012; SPOOREN et al., 2011). 
In our study, all sample’s treatment caused an expressive decrease in the secretion 
of inflammatory markers. From the results shown in Table 3.4, the lower concentration (2.5 
µL mL-1) of the tested extracts led to a reduction of about 6 times in the TNF-α concentration 
of the treated cells compared to the positive control. For all extracts, there was an inversely 
proportional relationship between the dose administered and the reduction of TNF-α 
concentration. The most significant reduction of the pro-inflammatory cytokine TNF-α was 
observed when the cells were treated with SFT in the concentration of 10 µL mL-1, a decrease 
of about 37 times compared to macrophage stimulated with only LPS.  
Similar behavior pattern was observed by the pro-inflammatory cytokine IL-6, 
which was not detected in the cell supernatant after treatment with the highest concentration 
(10 µL mL-1) of SFT. 
Nitric oxide (NO) is a highly reactive free radical evolved in various pathological 
and physical processes. Additionally, NO play a role as a cytotoxic agent in immunological 
interactions between microorganisms and macrophages (STUEHR; NATHAN, 1989). In this 
work, responses to the sample’s treatments were quite homogeneous and, in general, they all 
reduced the NO concentration in the cell supernatant in relation to the positive control. The 
lower concentration of the tested extracts (2.5 µL mL-1) led to a reduction of about 1.1−30 
times in the NO concentration of the treated cells compared to the positive control. In 
addition, NO was not detected in the cell supernatant after treatment with 5 µL mL-1 of 
biotransformed extracts with immobilized enzymes. SFT reduced NO less than the other 
samples. However, this sample was the one that most decreased the other anti-inflammatory 
markers in our study (Table 3.4). 
Reports have indicated the beneficial properties of soymilk and its isoflavones in 
the anti-inflammatory activity. KAWAHARA et al. (2015) studied the anti-inflammatory 
properties of soymilk in murine macrophage RAW 264.7 cells. The fermented soymilk with 
Lactococcus lactis subsp. lactis S-SU2 enhanced NO secretion in the cells without LPS. On 
the other hand, LPS-induced NO secretion was suppressed by both fresh and fermented 
soymilk, correlating with our findings. 
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In a study conducted by VALLES et al. (2010), the inflammatory process in 
astrocytes in primary culture was stimulated by amyloid beta (Aβ) and inflammatory 
mediators, such as cyclooxygenase 2 (COX-2), IL-1β, inducible nitric oxide synthase (iNOS), 
and TNF-α, were induced. The results demonstrated that the pre-treatment with 17β-estradiol 
or genistein was able to prevent all these expressions, confirming the anti-inflammatory 
effects of these compounds. 
The importance of genistein in anti-inflammatory capacity is also supported by 
another study performed by DHARMAPPA et al. (2010). The genistein was able to inhibit 
phospholipase A2 enzymes of inflammatory exudates and snake venoms in a concentration 
dependent manner with IC50 values between 5.75 to 11.75 µM. The results explain the anti-
inflammatory activity conferred to herbs with genistein in their composition.  
Similarly, we observed a significant reduction of pro-inflammatory markers in 
macrophages stimulated by LPS after treatment with biotransformed soy extracts. The 
enzymatic biotransformation process generated extracts rich in bioactive aglycones, such as 
genistein and daidzein, resulting in better anti-inflammatory effects. 
According to our results, the indicatives of the anti-inflammatory potential of the 
samples, especially those biotransformed by tannase, were very promising and can contribute 
in the prevention and treatment of anti-inflammatory process.  
 
4. Conclusions 
Soymilk biotransformation with free and immobilized enzymes was able to 
improve its bioactive potential. The highest antioxidant activity was detected for SFT by both 
assays. Although the anti-lipogenic effects were not significant, anti-inflammatory responses 
were very expressive, and extremely encouraging. SFT significantly decreased pro-
inflammatory cytokines and nitric oxide was not detected when cells were treated by SIT and 
SIB at intermediate concentration. Thus, the biotransformed soymilk, especially that one 
treated with free tannase, have great potential to act as a nutraceutical, protecting the cells 
against the oxidative damage and contributing in the prevention and treatment of anti-
inflammatory process. 
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CHAPTER 4. BIOTRANSFORMED SOY ISOFLAVONES 
MODULANTING MICROGLIA INFLAMMATION 
(ORIGINAL RESEARCH PAPER SUBMITTED TO FOOD & FUNCTION) 
Amanda Rejane Alves de Ávila, Lívia Dias de Queirós, Claudia Marques, 
Conceição Calhau, Gabriela Alves Macedo, Ana Faria, Juliana Alves Macedo 
 
Abstract 
Soy isoflavones have been extensively investigated due to potential benefits on 
human health. However, there are no data in literature relating biotransformed soy extracts by 
tannase and neuroprotection. Thus, this study aimed to investigate the expression of pro-
inflammatory markers on microglia M1 phenotype in response to treatment of soymilk 
biotransformed by tannase and β-glycosidase enzymes, and its relation in the neuronal 
response. N9 microglia cell line was activated by lipopolysaccharide (LPS) and was exposed 
to the biotransformed samples. To evaluate the expression of synapsin I synaptic molecule, 
SH-SY5Y cells were treated with microglia conditioned medium. The results showed a less 
pro-inflammatory profile on microglia cells after exposure to biotransformed extracts. 
Significant decreased TNF-α and IL-1β mRNA expressions were induced by biotransformed 
soymilk with free tannase (SFT), corresponding to reduction of 3.1 and 2.8 times, 
respectively, in comparison to LPS treatment; for soymilk with immobilized tannase (SIT) 
and soymilk with immobilized β-glycosidase (SIB) were not observed significant decrease in 
inflammatory markers. However, microglia conditioned media of soy extracts treatments did 
not impact the neuronal expression of synapsin I. Although the microglia-neuron interaction 
was not observed in this study, SFT presented a significant increase in anti-inflammatory 
power on microglia M1 phenotype, protecting the cells against inflammatory stress and acting 
as a potent neuroprotective agent. These results highlight the tannase application in food 
technology with a relevant impact in human nutrition and health. 
Keywords: anti-inflammatory; biotransformation; microglia; neuroprotection; soy 
isoflavones; tannase  
 
1. Introduction 
Soy isoflavones have attracted great attention due to their potential benefits on 
human health. These compounds, found in high amounts in soybeans and soy-based products, 
can act as phytoestrogen due to structural and functional similarities with 17β-estradiol 
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(WUTTKE; JARRY; SEIDLOVÁ-WUTTKE, 2007). Concerning to chemical structures, 
isoflavones can be found as glycosides (genistin, daidzin, and glycitin), aglycones (genistein, 
daidzein, and glycitein), acetyl glycosides (acetyl genistin, acetyl daidzin, and acetyl glycitin), 
and malonyl glycosides (malonyl genistin, malonyl daidzin, and malonyl glycitin) (KUDOU 
et al., 1991; NAIM et al., 1973; OHTA et al., 1979, 1980; WALTER, 1941; WALTZ, 1931). 
These chemical differences affect their bioavailability and studies have related aglycones and 
their metabolites, such as equol, to the higher health benefits compared to other forms 
(IZUMI et al., 2000; NIELSEN; WILLIAMSON, 2007).  
Since isoflavones exist predominantly in glycoside forms in soybeans and soy 
derivatives, our research group has been studying the application of tannase enzyme in the soy 
isoflavones biotransformation. DE ÁVILA et al. (2018) and DE QUEIRÓS; MACEDO; 
MACEDO (2016) demonstrated the potential of this enzyme on aglycones and equol 
generation in soymilk bioprocessing. The results have been extremely encouraging and are 
leading to further investigation. 
Studies have reported the protective effects of soy isoflavones in neuronal 
disorders (CHEN et al., 2008; CHINTA et al., 2013; MIRAHMADI et al., 2018; PARK et al., 
2007). For investigate these effects, microglia in vitro model has been widely used (KIM et 
al., 2016; XIANG et al., 2018; ZHANG et al., 2018). Microglia is described as the tissue-
resident macrophages of the central nervous system (CNS) which protect the neural cells 
against infectious agents and maintain the brain homeostasis (COLONNA; BUTOVSKY, 
2017; LI; BARRES, 2017). However, these cells can acquire different activation states or 
phenotypes, such as inflammatory M1 or immunosuppressive M2, depending on types of 
stimuli received (COLTON; WILCOCK, 2010). The M1 microglial phenotype, designated as 
classical activation, can be stimulated by LPS or interferon-γ (IFN-γ) resulting in expression 
of pro-inflammatory markers like tumor necrosis factor alpha (TNF-α), interleukin 1-beta 
(IL1-β), interleukin 6 (IL-6) and inducible nitric oxide synthase (iNOS). On the other hand, 
the M2 phenotype, named as alternative activation, can be induced by interleukins 4 (IL-4) or 
13 (IL-13) and is involved in repair and control of inflammation (ORIHUELA; 
MCPHERSON; HARRY, 2016). Besides that, microglia cells are intimately associated with 
regulation of neuronal function and modulation of synaptic structures in the healthy brain, 
presenting a key role in the dynamic bidirectional communication between microglia-neuron. 
However, neuroinflammation and altered neuron-microglia signaling can potentially 
contribute for initiation and progress of many neurological disorders (WU et al., 2015). 
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In this context, this study aimed to analyze the expression of pro-inflammatory 
markers in LPS-induced microglia M1 phenotype in response to treatment of biotransformed 
soy extracts by tannase and β-glycosidase enzymes. Also, as microglia is involved in 
modulation of synaptic structures, the expression of synapsin I in neurons was evaluated after 
exposure to microglia conditioned medium. 
 
2. Materials and methods 
2.1 Materials 
Soybean seeds (IAC Foscarin 31 variety, 15/2015 lot, 85% germination, produced 
at Mococa, SP, Brazil) were obtained at the Agronomic Institute of Campinas, Campinas, SP, 
Brazil. Lipopolysaccharide (LPS from Escherichia coli 011:B4), β-glycosidase enzyme 
(naringinase from Penicillium decumbens), RPMI 1640 medium, fetal bovine serum (FBS), 
DMEM-F12Ham medium, and 17β-estradiol were purchased from Sigma-Aldrich (Sigma-
Aldrich Chemicals®, Madrid, Spain). All other chemicals were acquired in the grade 
commercially available.  
 
2.2 Enzymatic biotransformation 
Soymilk enzymatic biotransformation was carried out according to procedure 
described by DE ÁVILA et al. (2018). Briefly, soymilk was prepared following the 
methodology developed by Embrapa Soja, Brazil (MANDARINO; CARRÃO-PANIZZI, 
1999) and was used as substrate for enzymatic hydrolysis by tannase obtained from 
Paecilomyces variotii (BATTESTIN; MACEDO, 2007), in free and immobilized forms, and 
commercial β-glycosidase (naringinase from Penicillium decumbens), in immobilized form 
(MOHAPATRA; MONDAL; PATI, 2007). For biotransformation with immobilized 
enzymes, the conditions were fixed as: 10% (w/v) of immobilized tannase or β-glycosidase 
concentration, pH 6.5, temperature of 50 °C, and reaction time of 45 min. The reaction was 
stopped by collecting the immobilized enzyme by filtration. For free tannase, according to DE 
QUEIRÓS; MACEDO; MACEDO (2016), the soymilk was incubated with 20 mg of tannase 
powder (β-glycosidase activity of 4.2 U mg-1) in the conditions fixed above (pH, temperature, 
and reaction time). The hydrolysis process was stalled by putting the reaction in an ice bath 
for 15 min. As control, soymilk (without enzyme addition) was submitted to the same 
conditions described for free and immobilized enzymes.  
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Each reaction product was previously analyzed by High Performance Liquid 
Chromatography coupled to Diode Array Detector (HPLC-DAD) and the polyphenol profiles 
were published by DE ÁVILA et al (2018).  
 
2.3 Cell culture assays 
2.3.1 Cell cultures and maintenance 
Microglia cell line N9 was kindly provided by Claudia Verderio (National 
Research Council, Milan, Italy). Cells were cultured in Roswell Park Memorial Institute 1640 
medium (RPMI 1640, Sigma-Aldrich Chemicals®, Madrid, Spain) supplemented with 5% 
(v/v) FBS, 25 mM glucose, 100 µg mL-1 streptomycin and 0.25 µg mL-1 amphotericin B.  
The neuroblastoma cell line SH-SY5Y was cultured in Dulbecco’s Modified 
Eagle’s Medium/Nutrient Mixture F-12Ham (DMEM-F12Ham, Sigma-Aldrich Chemicals®, 
Madrid, Spain), containing 1.19 g L-1 NaHCO3, 3.47 g L-1 HEPES, 5% (v/v) FBS, 100 µg mL-
1 streptomycin and 0.25 µg mL-1 amphotericin B. 
The cell lines were incubated at 37 °C and maintained in a humidified atmosphere 
with 5% CO2−95% air. 
 
2.3.2 LDH assay 
The effect of soy extracts on N9 microglia cells viability was monitored by lactate 
dehydrogenase (LDH) assay, according to RUSSO et al. (2003). In 24-well plates, cells 
(inoculation density of 6 x 104 cells mL-1) were exposed to different samples concentrations 
(0.1; 1; and 10 μL mL-1) in triplicate, for 24 h. For reading the extracellular content, aliquots 
(25 μL) of supernatant corresponding to each treatment were transferred to 96-well plate and 
150 μL of reduced NADH (11.3 mM β-NADH) in phosphate/pyruvate buffer solution (50 
mM phosphate, pH 7.5, 0.63 mM pyruvate) were added. For intracellular content reading, 
cells were washed with phosphate buffer solution (PBS) and 300 μL of 0.1% Triton X-100 in 
Tris-HCl (5 mM, pH 7.4) were added to each well. After incubation at 37 °C for 30 minutes, 
aliquots (25 μL) of cell lysate were transferred to 96-well plate. LDH was quantified by 
kinetic absorbance measurements at 340 nm during 2 minutes for both extracellular (culture 
supernatant) and intracellular (cell lysate) contents.  
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2.3.3 Treatment conditions and microglia stimulation 
Microglia cells were seeded at a density of 3 x 105 cells/well in 6-well plates. 
After 24 h of incubation, cells were treated with: LPS (100 ng mL-1, Sigma-Aldrich 
Chemicals®, Madrid, Spain); samples [soymilk control (SC), soymilk + immobilized tannase 
(SIT), soymilk + immobilized β-glycosidase (SIB), and soymilk + free tannase (SFT); 
samples concentration of 1 µL mL-1) plus LPS; 17β-estradiol (E2, 1 ρM, Sigma-Aldrich 
Chemicals®, Madrid, Spain) plus LPS; or vehicle alone, for more 24 h before qRT-PCR 
analysis. For studies involving microglia conditioned medium (CM), the medium (1.5 
mL/well) was collected from microglia after activation with LPS and treatment conditions. 
 
2.3.4 SH-SY5Y studies 
SH-SY5Y neuroblastoma cells were used as undifferentiated neuron model and 
were treated with CM. Cells were seeded at a density of 2 x 105 cell/well in a 6-well plate and 
cultured in DMEM/Nutrient Mixture F-12 Ham for 24 h. After that, the medium was replaced 
by CM and incubated for 24 h before qRT-PCR analysis. 
 
2.3.5 RNA isolation and quantitative real-time polymerase chain reaction (qRT-PCR) 
Total RNA from treated cells was isolated using Nzyol reagent (NZYTech, 
Portugal) according to the manufacturer's instructions. RNA samples were treated with DNase 
I (RQ1 RNase-free DNase, Promega, Portugal). cDNA was synthesized from 1 μg of mRNA 
treated with NZY First-Strand cDNA Synthesis kit (NZYTech, Portugal). Quantitative real-
time polymerase chain reaction was performed on Lightcycler®96 (Roche Diagnostics, USA). 
Reactions with 10 μL were established in 96-well microplates using 0.2 μM of each primer 
and 5 μL of Fast-Start Essential DNA Green Master (Roche Diagnostics, USA). Cycling 
conditions were as follows: denaturation (95 °C for 10 min), amplification and quantification 
(95 °C for 10 s, annealing temperature for 10 s, and 72 °C for 10 s, with a single fluorescence 
measurement at the end of the 72 °C for 10 s segment) repeated for 45 cycles, and a final 
melting at 95 °C for 10 s, 65 °C for 60 s and 97 °C for 1 s. The sequences of specific primers 
used in this study are described on Table 4.1. Data were analyzed using LightCycler®96 SW 
analysis Software v1.1. The results obtained were normalized for housekeeping genes HPRT 
(hypoxanthine-guanine-phosphoribosyltransferase) for N9 cells; and Eif4a2 (eukaryotic 
translation initiation factor 4a2) for SH-SY5Y cells, both by the 2-(∆Ct) method (PENNA et al., 
2011; SCHMITTGEN; LIVAK, 2008; VANDESOMPELE et al., 2002). 
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Table 4.1 Sequences of primers and respective annealing temperature (AT). 
  Forward Reverse AT (°C) 
N9    
HPRT1 5´ TGCTGACCTGCTGGATTACA 3’ 5’ TTTATGTCCCCTGTTGACTGG 3’ 58 
TNF-α 5’ GATCGGTCCCCAAAGGGATG 3’ 5’ TGAGGGTCTGGGCCATAGAA 3’ 63 
IL-1β 5′ TGGCATTGATCTGGTTCATC 3′ 5’GTTTAGGAATCTTCCCACTT 3′ 60 
IL-6 5’ GTTCTCTGGGAAATCGTGGA 3’ 5’ TTCTGCAAGTGCATCATCGT 3’ 59 
iNOS 5’ GACGAGACGGATAGGCAGAG 3’ 5’ GTGGGGTTGTTGCTGAACTT3’ 59 
MCP1 5’CCAACAGCTTCCACGCTGAAAC 3’ 5’GCAGTTAGGGAAAGCCGGAAGA 3’ 65 
    
SH-SY5Y    
Eif4a2 5’ CGGTTTTGAGAAGCCTTCCG 3’ 5’ GCCAGTACCTGACTGAGCTT 3’ 60 
Synapsin I 5’ AAATATGACGTGCGTGTCCA 3’ 5’ TGGTCTTCCAGTTCCCTGAC 3’ 59 
 
2.4 Statistical analysis 
Results of N9 and SH-SY5Y cell lines assays were expressed as means ± standard 
deviation (SD). The statistical difference between the treatment groups was analyzed using 
one-way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test. 
Differences were considered significant when p < 0.05 and the analyses were performed using 
GraphPad Prism version 5.0 (GraphPad Software, Inc.). 
 
3. Results and discussion 
3.1 Characterization of biotransformed soy extracts 
According to our previous results, published by DE ÁVILA et al. (2018), all 
enzymatic biotransformation processes with tannase and β-glycosidase, in free and 
immobilized forms, were able to promote significant changes in isoflavones profiles in 
soymilk, bioconverting glycosidic forms (daidzin and genistin) into aglycone forms (daidzein 
and genistein). SFT and SIT had higher content of bioactive aglycones, an increase of 36−46 
times compared to untreated soymilk (SC). The equol metabolite was also quantified in SFT, 
corresponding to 0.26 ± 0.03 µg mL-1 of sample. 
 
3.2 Effect of soy extracts under microglia LPS-stimulation 
Lactate dehydrogenase (LDH) assay was performed to stablish the higher sample 
concentration that did not affect the N9 cell viability. LDH is a soluble cytosolic enzyme and 
its presence in the culture medium can be used as a marker of cell death, since the enzyme is 
release into the extracellular medium when occurs cell membrane lysis (KAJA et al., 2015). 
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N9 microglia cells were exposed to the samples (0.1; 1; and 10 µL mL-1) to 
determine the higher non-cytotoxic concentration (Fig. 4.1). It was observed that 10 µL mL-1 
concentration caused significant cell death, while cell viability varied between 63% and 154% 
at the concentration of 1 µL mL-1. For the following assay, all biotransformed soymilk 
samples were tested at 1 µL mL-1. 
 
Figure 4.1 Cell viability (% of control cells) of N9 microglia cell line according to LDH 
assay. Abbreviations: SC, soymilk control; SIT, soymilk + immobilized tannase; SIB, 
soymilk + immobilized β-glycosidase; SFT, soymilk + free tannase. 
 
Microglia are the resident immune cells at the CNS, protecting the neural 
cells from some threats (AKIYAMA; MCGEER, 1990). When activated by LPS or IFN-γ, 
microglia express a M1 phenotype (WANG; LIANG; ZEN, 2014). So, these cells are widely 
used as in vitro neuroinflammatory study models (KIM et al., 2016; XIANG et al., 2018; 
ZHANG et al., 2018).  
According to some authors, microglia contribute to the inflammatory process as 
major player when is unregulated or hyper-activated. In these states, microglia secrets various 
cytokines and pro-inflammatory mediators such as nitric oxide (NO), TNF-α, iNOS, IL-1β, 
and IL-6, which are related to the pathogenesis of neurodegenerative and neuroinflammatory 
disorders (EKDAHL; KOKAIA; LINDVALL, 2009; ORIHUELA; MCPHERSON; HARRY, 
2016).  
In our study, LPS-stimulated microglia were treated with samples or 17β-estradiol 
to evaluate the effectiveness of these treatments to combat the neuroinflammation. So, mRNA 
expression of specific markers of M1 phenotype like TNF-α, IL-1β, IL-6, iNOS, and 
monocyte chemoattractant protein-1 (MCP1) were analyzed (Table 4.2). The results 
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demonstrated a significant decrease in TNF-α and IL-1β mRNA expression (3.1 and 2.8 times 
lower than LPS control, respectively) after the treatment with SFT (p < 0.05). More, the IL-6 
expression was under detection level for all tested conditions. Curiously, iNOS and MCP1 
expression for SC presented significant increase of 5.5 and 1.7 times, respectively, compared 
to “cell + LPS”, potentiating the inflammation. On the other hand, the treatment with 
enzymatically biotransformed samples did not affect these pro-inflammatory markers. 
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Table 4.2 Effect of biotransformed soy extracts (1 µL mL-1 concentration) on the transcription of microglia markers in induced N9 microglia cell 
line. 
N9 Cell control* 
Cell 
+ LPS 
17β-estradiol 
+ LPS 
              SC 
             + LPS 
           SIT 
        + LPS 
          SIB 
       + LPS 
  SFT 
+ LPS 
TNF-α 0.03 ± 0.02 0.25 ± 0.07a 0.14 ± 0.06 0.16 ± 0.02 0.13 ± 0.10 0.16 ± 0.09 0.08 ± 0.04b 
IL-1β 0.01 ± 0 0.71 ± 0.25a 0.34 ± 0.04 0.72 ± 0.33 0.33 ± 0.16 0.41 ± 0.23 0.25 ± 0.06b 
IL-6 n/d1 n/d n/d n/d n/d n/d n/d 
iNOS 0.02 ± 0.01 0.13 ± 0.04 0.09 ± 0.04 0.72 ± 0.33b 0.07 ± 0.05 0.06 ± 0.03 0.03 ± 0.02 
MCP1 0.12 ± 0.05 3.04 ± 0.77a 3.05 ± 0.64 5.11 ± 2.15b 2.57 ± 0.43 2.81 ± 0.47 1.67 ± 0.27 
 
Results obtained were normalized for housekeeping gene HPRT by the 2-(∆Ct) method and are presented as mean ± standard deviation (n = 4). Statistical significance was assessed by one-way 
ANOVA followed by Bonferroni’s multiple comparison test. 
* cells without LPS stimulus or extract; 1 n/d, not detected. 
a p < 0.05 vs cell control. 
b p < 0.05 vs cell + LPS. 
Abbreviations: SC, soymilk control; SIT, soymilk + immobilized tannase; SIB, soymilk + immobilized β-glycosidase; SFT, soymilk + free tannase; LPS, lipopolysaccharide. 
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As shown in Table 4.2, the enzymatic biotransformation process of SFT presented 
the highest decrease in pro-inflammatory markers compared to SC. While SC (without 
enzyme addition) increased some pro-inflammatory markers, tannase in free form was able to 
decrease them, confirming the great potential of enzyme.  
An important point to be considerate is the ligand interactions with estrogen 
receptor (ER) in the brain. Natural isoflavones present structural similarity to 17β-estradiol, 
acting as phytoestrogen with binding affinities for both estrogen receptors subtypes, ER-alpha 
(ERα) and ER-beta (ERβ) (WUTTKE; JARRY; SEIDLOVÁ-WUTTKE, 2007). ERα is 
commonly expressed in regions of the brain involved in reproductive functions, such as 
medial hypothalamic nucleus, ventromedial nucleus, bed nucleus of stria terminalis, and 
posterodorsal part of the medial amygdala. On the other hand, ERβ is widely distributed in 
hippocampus and amygdala, regions normally associated to depression, anxiety, memory, and 
learning, besides being expressed in dorsal raphe nucleus (MITRA et al., 2003). According to 
literature, neuroprotection exerted by estradiol appears to be related to inhibition of oxidative 
stress and regulation of glial cells (LIU et al., 2005; SAWADA et al., 1998). Thus, by 
activation of both ER (α and β), the estrogens inhibit the microglia activation and 
consequently exert a neuroprotective action (LIU et al., 2005). 
In this study, all enzymatically biotransformed samples, especially SFT, presented 
a decrease in expression of pro-inflammatory markers compared to LPS treatment, being as 
effective and, in most of the times, acting better than the 17β-estradiol hormone. According to 
BANG et al. (2004), 17β-estradiol has a limited clinical use due to increased risk of 
developing some cancers in cells responsive to estrogen. So, considering the risks involved in 
hormone therapy, soy biotransformed samples may be an alternative to estrogen to combat 
neuroinflammation.  
Studies involving isoflavones and neuroinflammation have been proposed to 
elucidate the benefits of these compounds in maintenance the brain homeostasis. In work 
develop by CHEN et al. (2008) it was evaluated the effect of isoflavones (formononetin, 
daidzein, pratensein, calycosin, and irilone) from Trifolium pretense in dopaminergic 
neurodegeneration induced by LPS. The results showed the inhibition of microglia activation 
and consequent decrease in expression of pro-inflammatory factors such as TNF-α, 
superoxide, and NO in mesencephalic neuron-glia and microglia-enriched cultures, suggesting 
that all isoflavones studied protected dopaminergic neurons from LPS-induced damage. 
CHINTA et al. (2013) also investigated the role of isoflavone daidzein in the attenuation of 
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release of inflammatory mediators in LPS-induced BV-2, a murine microglial cell line. The 
authors observed significant suppress of pro-inflammatory markers, like IL-6 and NO. 
Furthermore, the treatment with conditioned medium from BV-2 cells pre-treated with 
daidzein resulted in a significant reduction in dopaminergic neurotoxicity in comparison to 
LPS control. Similarly, in the present study we observed a significant reduction of pro-
inflammatory mediators after biotransformed isoflavones treatment in microglia LPS-
stimulation. The enzymatic biotransformation of soy isoflavones generated extracts rich in 
bioactive aglycones, such as daidzein and genistein, resulting in a better effect than those 
observed to soy extracts without any processing. 
In research conducted by PARK et al. (2007), anti-inflammatory activity of 
isoflavones in microglia stimulated by LPS was explored. The results indicated that three 
types of isoflavones and metabolites (irisolidone, tectorigenin, and glycitein), isolated from 
flowers of Pueraria thunbergiana, suppressed the release of NO and TNF-α in BV2 
microglial cell line and primary cultured microglia. However, isoflavone glycosides 
(kakkalide, tectoridin, and glycitin) presented no significant inhibition. These data are 
consistent with our findings, since enzymatic bioprocesses responsible for bioactive 
aglycones and metabolites generation can potentiate beneficial effects in health. In general, 
our investigation showed that SFT was responsible to exhibit the highest decrease of pro-
inflammatory markers after microglia activation by LPS. The probable hypotheses for this 
observation are the high performance of tannase in free form to release the phenolic 
compounds from soymilk matrix, hydrolyzing the glycosidic forms into aglycones, and 
generating equol; and the binding ability of isoflavone aglycones and metabolite for estrogen 
receptors present in microglia, attenuating the M1 phenotype. 
 
3.3 Neuronal response to conditioned medium of microglia stimulated with LPS in the 
presence of soy extracts 
Microglia and neurons participate in a dynamic bidirectional communication that 
is essential for brain development and homeostasis (SIMON; OBST; GOMEZ-NICOLA, 
2018). According to WERNEBURG et al. (2017), microglial cytokine signaling at synapses 
has important consequences for disease. Microglia-derived molecules regulate synaptic 
connectivity including synapse maturation, synaptogenesis, synaptic pruning, functional 
synapse plasticity, and basal synaptic transmission (WU et al., 2015). Although microglia 
present a defensive role in a normal physiological condition, it can cause severe damage to 
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neuronal cells when hyper-activated leading to an overproduction of free radicals, NO and 
pro-inflammatory cytokines, resulting in destruction of neurons and axonal fibers 
(HARTUNG et al., 1992). So, microglia and cytokines act as modulators of neural circuits in 
healthy brain, with implications for several neurological disorders with disruptions in synaptic 
function and structure (WERNEBURG et al., 2017). 
Synapsins are a family of pre-synaptic vesicle-associated phosphoproteins and are 
involved in the release of neurotransmitters (CESCA et al., 2010). Synapsin I is found 
abundantly in the brain and is present in functional synapses of the CNS, being essential for 
synaptic plasticity and for clustering of synaptic vesicles at active zones (KHVOTCHEV; 
SUN, 2009).  
In the present study, SH-SY5Y cell line was used as undifferentiated neuron 
model. As microglia is implicated in modulation of synaptic structures, the neurons were 
treated with microglia conditioned medium, previously activated by LPS and exposed to 
biotransformed soy extracts or 17β-estradiol. As shown in Table 4.3, LPS does not 
significantly altered the synapsin I mRNA expression in comparison to cell control. 
Curiously, 17β-estradiol presented the highest decrease of synapsin I expression compared to 
cell control, although without statistical significance. For all sample’s treatments, it was not 
observed differences in synapsin I expression compared to LPS or cell control. 
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Table 4.3 Effect of microglia conditioned medium (CM) stimulated with lipopolysaccharide (LPS) in the presence of biotransformed soy extracts 
on the neuronal transcription of synapsin I. 
 
SH-SY5Y Cell control* 
Cell 
+ LPS 
17β-estradiol 
+ LPS 
SC 
+ LPS 
SIT 
+ LPS 
SIB 
+ LPS 
SFT 
+ LPS 
Synapsin I 0.019 ± 0.006 0.010 ± 0.003 0.008 ± 0.002    0.015 ± 0.006      0.009 ± 0.003 0.014 ± 0.005 0.011 ± 0.004 
 
Results obtained were normalized for housekeeping gene Eif42a by the 2-(∆Ct) method and are presented as mean ± standard deviation (n = 4). Statistical significance was assessed by one-way 
ANOVA followed by Bonferroni’s multiple comparison test. 
* cells without LPS stimulus or extract. 
Abbreviations: SC, soymilk control; SIT, soymilk + immobilized tannase; SIB, soymilk + immobilized β-glycosidase; SFT, soymilk + free tannase; LPS, lipopolysaccharide. 
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Compounds that reduce microglia inflammation are recognized as beneficial for 
brain health. For successful microglia-neuron interaction, the neuroprotective effects 
conferred by estrogen would be also related to an increase in expression levels of synaptic 
proteins in neurons. For this reason, the assay involving SH-SY5Y cells and microglia 
conditioned medium was performed with the purpose to clarify the role of phytoestrogens in 
the expression of synapsin I. 
In study developed by PAN et al. (2010), the effect of estradiol and soy germ 
phytoestrogens in the modulation of synaptic formation proteins in ovariectomized rats was 
studied. The results showed that dietary supplementation with 1.6 g kg-1 phytoestrogens or 
0.15 g kg-1 17β-estradiol for 12 weeks caused a significant increase mRNA expression of 
synapsin I, synaptophysin, and spinophilin in hippocampal tissue of the animals. Similar 
results were also found by ZHOU; HU (2004). The authors analyzed the effect of 17β-
estradiol on synapsin I expression in cultured cerebral and hippocampal neurons. Topological 
and immunocytochemical analyses indicated an increase in synapsin I clusters in dendritic 
spines and shafts after 17β-estradiol treatment for 24h.  
OHTANI-KANEKO et al. (2010) presented results that are consistent with our 
observations. The authors evaluated the effects of 17β-estradiol on developing hypothalamic 
neurons with emphasis on a pre-synaptic protein, synapsin I. Hypothalamic cells from fetal 
rats were treated with 17β-estradiol (100 nM) for 7 days and the effects on synapsin I 
expression were investigated. Analyses by immunoblotting and qRT-PCR showed that 17β-
estradiol did not increase mRNA expression of synapsin I. Similarly, in our study microglia 
conditioned media of 17β-estradiol treatment did not result in increase of mRNA expression 
of synapsin I in SH-SY5Y cells, as neither the treatments with biotransformed soy extracts. 
Besides the classical estrogen receptor pathway, other mechanisms may be 
involved in the effects of 17β-estradiol or phytoestrogens on the neuronal expression of 
synapsin I. So, due to importance of synaptic formation proteins to successful of microglia-
neurons interaction and consequent neuroprotective effects, further studies should be 
proposed to clarify the role of soy isoflavones in modulation of synaptic structures. 
 
4. Conclusions 
Although the microglia-neuron interaction was not observed, SFT presented a 
significant increase in anti-inflammatory power on microglia induced by LPS. For SIT and 
SIB were not observed substantial decrease in inflammatory markers. So, we can infer that 
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SFT, rich in bioactive isoflavones and metabolite, appear as a possible neurotherapeutic 
strategy, inhibiting pro-inflammatory factors generation by microglia M1 phenotype. Further 
studies will be needed and randomized controlled trials (RCTs) will be designed in near future 
to explore a clinical application. 
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GENERAL DISCUSSION 
 
1. Biotransformation process and characterization of soy extracts 
The bioconversion conditions were improved in this study in order to increase the 
bioactive potential of soymilk. After selecting the best parameters, the soymilk was submitted 
to enzymatic biotransformation process, and the obtained extracts [soymilk control (SC), 
soymilk + immobilized tannase (SIT), soymilk + immobilized β-glycosidase (SIB), and 
soymilk + free tannase (SFT)] were characterized as to the total phenolic content, 
identification and quantification of isoflavones and metabolite, and antioxidant capacity 
determined by Folin-Ciocalteau assay, HPLC analyses, and ORAC and FRAP methods, 
respectively.  
The total phenolic content of the extracts varied from 1432 ± 53 to 1543 ± 30 µg 
of GAE mL-1 of the sample. A statistical difference was only observed to SFT, with increase 
of 7% compared to SC. The Folin-Ciocalteau method is widely used to provide an overview 
of phenolic compounds present in the samples. Its color reaction is based on the presence of 
polyphenols but can also be caused by other compounds with reducing power (HUANG; OU; 
PRIOR, 2005). Thus, additional tests, such as chromatographic analysis, are necessary for a 
more detailed evaluation of phenolic compounds. 
The changes in isoflavones profile after enzymatic biotransformation were clearly 
demonstrated by HPLC analyses. In our study, the glycosidic forms of isoflavones were 
predominant in SC. On the other hand, after soymilk reaction with tannase and β-glycosidase 
enzymes, the concentration of aglycone forms increased significantly. The highest enhance 
was observed to SFT, corresponding to a rise of 40 and 46 times in the content of daidzein 
and genistein, respectively. Moreover, the equol metabolite was quantified in this sample 
using only an enzymatic bioprocess, without gut microbial intervention. This statement is 
very important because it is opposite to current literature, which affirms that equol is formed 
exclusively by action of several intestinal bacteria (SETCHELL; BROWN; LYDEKING-
OLSEN, 2002; YUAN; WANG; LIU, 2007). Similar results to our study were found by DE 
QUEIRÓS; MACEDO; MACEDO (2016) using the same crude tannase enzyme extract from 
P. variotii in soymilk biotransformation. The results showed that both enzymatic and 
fermentation processes studied by these authors were able to hydrolyze the glycosidic form 
into aglycone form and increased the equol content.  
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Our findings suggest that the glycosidic forms of isoflavones were converted into 
aglycones forms, and other substrates, such as acetyl and malonyl glycosides, were also 
transformed into daidzein and genistein. In addition, our hypothesis is that the presence of 
equol metabolite is probably due to the broad catalytic performance of free form of tannase 
enzyme in other substrates (other than daidzein) existing in this sample, since the crude 
enzyme extract present a complex composition. Further investigation studies are necessary to 
find out the possible substrate for this equol production by tannase catalyzes. 
SFT was responsible for a significant increase in the antioxidant capacity, 
corresponding to an enhance of 2.3 and 1.25 times, by the ORAC and FRAP assays, 
respectively. The increase in the antioxidant capacity of a food matrix rich in polyphenols and 
modified by biotransformation processes was observed in previous studies of our research 
group (FERREIRA et al., 2013; MACEDO et al., 2011; MARTINS et al., 2017). Our data are 
also consistent with the results presented by DE QUEIRÓS; MACEDO; MACEDO (2016), 
which evaluated the antioxidant capacity by ORAC and DPPH assays for three different 
soymilk biotransformation processes, based on the fermentation by lactic bacteria and the 
application of tannase enzyme. It was verified a significative rise in the antioxidant power by 
ORAC assay, especially for the SFT, corresponding to an increase of 3.95 times compared to 
control, similarly to our study. According to NIELSEN; WILLIAMSON (2007), the aglycone 
forms contribute to the enlargement antioxidant capacity as they are known to be more 
bioactive than their respective glycosides.  
Based on these results, our study suggests that the bioprocess with free tannase 
improves the release of phenolic compounds from soymilk matrix. The SFT showed the 
highest increase in the aglycone forms of isoflavones, which correlate with the total phenolic 
content and antioxidant assays. So, these results evidence that the tannase has presented 
broader action and did not act only as β-glycosidase but was able to produce the equol 
metabolite and generate aglycones from other substrates different than genistein and daidzein. 
 
2. Cell assays 
2.1 Influence of biotransformed process on in vitro estrogenic activity 
Isoflavones present structural and functional similarities with 17β-estradiol 
hormone demonstrating binding affinities to both estrogen receptor subtypes (ERα and ERβ) 
(WUTTKE; JARRY; SEIDLOVÁ-WUTTKE, 2007). So, the ability of soy extracts to bind to 
estrogen receptors was investigated by our study.  
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The E-screen assay was developed to elucidate the estrogenic/antiestrogenic 
activity by changes in proliferation of MCF-7 BUS cell line, a human breast carcinoma that 
overexpresses estradiol receptors. The efficacy of samples to induce a positive estrogenic 
effect was observed by the present study. In both concentrations tested (0.1 and 1 µL mL-1), 
SFT treatment resulted in increase of cell proliferation compared to untreated cells, which was 
as effective as 17β-estradiol (E2). In addition, co-treatment with all biotransformed samples 
and 17β-estradiol resulted in significantly increase of E2 proliferation action, suggesting an 
additive effect. IMHOF; MOLZER; IMHOF (2008) showed that the presence of soy 
isoflavones in human blood were able to stimulate proliferation of MCF-7 cells. The authors 
observed that this effect was dependent on the estrogen concentration in the medium: at very 
low levels of estrogen (20 pM), soy isoflavones were able to inhibit cell proliferation; on the 
other hand, at higher estrogen levels, isoflavones stimulated cell proliferation.  
Estrogens play a fundamental role in many physiological processes in hormone 
dependent tissues. However, elevated levels are associated with an increased risk of 
developing hormone dependent diseases, including breast, endometrial, and ovary cancers 
(KUMAR et al., 2010; SCHAIRER et al., 2000; UIFĂLEAN et al., 2016). Therefore, 
hormone replacement therapy for women in menopause involves some risks that cannot be 
neglected. So, the discovery of safer ligands in estrogen receptors activation is promising and 
natural products rich in isoflavones and metabolite appear as a healthy alternative to relieve 
and improve the symptoms in menopausal women (SUNITA; PATTANAYAK, 2011). 
In our study, the increase of aglycone isoflavones and the presence of equol in 
SFT is noteworthy, since the extract was responsible for the highest estrogenic effect in E-
screen assay. The presence of equol only in this sample suggests a differentiated action of this 
extract, but further investigations are necessary to clarify the mechanisms involved in 
increased estrogenic effect conferred by isoflavones and their respective metabolites. 
 
2.2 Anti-lipogenic assay in 3T3-L1 cell line 
The present study evaluated the biotransformed soymilk samples to verify their 
ability to influence the final oil content in 3T3-L1 intracellular vesicles. In general, the 
administration of the samples in the cell differentiation phase, in the three concentrations 
tested, did not result in significant differences in the final lipid content accumulated by mature 
adipocytes. Apparently, the evaluated samples did not influence the process of cell 
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differentiation. The different concentrations tested also did not show a dose-dependent 
response.  
Differently, the addition of the samples in the maturation medium caused 
significantly increased accumulation of the lipid content. Some increase was observed in all 
samples, especially in SIB. A hypothesis for this finding is the presence of higher amount of 
free glucose of this sample, due to deglycosylation catalyzed by β-glycosidase enzyme.  
According to literature, a diet rich in polyphenols, such as flavonoids, may cause 
decrease of lipogenesis, induction of lipolysis process, as well as programmed adipose cell 
death (ENGIN et al., 2018; RAYALAM; DELLA-FERA; BAILE, 2008). HWANG et al. 
(2015) evaluated the anti-obesity effect of soybean extract fermented by Bacillus subtilis 
MORI (BTD-1) using 3T3-L1 preadipocytes. The results showed that fermented soybean 
extract reduced lipid accumulation by suppressing the differentiation of 3T3-L1 adipocytes. 
Similar results were also found in a study developed by HE et al. (2016), which evaluated the 
anti-obesity effect of daidzein and the mechanism of lipid metabolism for adipogenesis in 
3T3-L1 adipocytes. The results indicated that high concentrations of daidzein significantly 
inhibited preadipocyte proliferation and fat deposition in 3T3-L1 adipocytes.  
However, our findings could not corroborate these studies, as the soy extracts 
were not able to significantly reduce lipid accumulation by adipocytes. So, based on one 
preliminary in vitro test, our samples did not indicate good potential as remediators of 
adipogenesis or lipogenesis processes associated with obesity. 
 
2.3 Inflammatory assay with RAW 264.7 stimulated by LPS 
RAW 264.7 cell line LPS-stimulated presented increased TNF-α, IL-6, and NO 
concentrations, confirming the occurrence of the inflammatory stimulus. In general, the 
treatment of inflamed macrophages with all samples caused an expressive reduction in the 
secretion of pro-inflammatory markers. The most significant reduction of TNF-α was 
observed when the cells were treated with SFT in the concentration of 10 µL mL-1, decrease 
of about 37 times compared to cells stimulated with LPS. Similar behavior pattern was 
observed for the secretion of IL-6, which was not detected in the cell supernatant after 
treatment with the highest concentration (10 µL mL-1) of the same sample. 
VALLES et al. (2010) presented results that are similar to our findings. The 
inflammatory process in astrocytes in primary culture was stimulated by amyloid beta and 
inflammatory mediators, such as cyclooxygenase 2, IL-1β, inducible nitric oxide synthase, 
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and TNF-α, were induced. The results demonstrated that the pre-treatment with 17β-estradiol 
or genistein was able to prevent all these expressions, confirming the anti-inflammatory 
effects of these compounds. In our study, the enzymatic biotransformation of soy isoflavones 
generated extracts rich in bioactive aglycones, for instance daidzein and genistein, which 
could explain the anti-inflammatory effects observed. 
In this study, responses to the sample treatments were quite homogeneous and, in 
general, they all reduced the NO concentration in the cell supernatant in relation to the 
positive control. SFT reduced NO less than the other samples. However, this sample was the 
one that most reduced the other anti-inflammatory markers in our study. KAWAHARA et al. 
(2015) investigated the anti-inflammatory properties of soymilk in murine macrophage RAW 
264.7 cells. The fermented soymilk with Lactococcus lactis subsp. lactis S-SU2 enhanced NO 
secretion in the cells without LPS. Conversely, LPS-induced NO secretion was suppressed by 
both fresh and fermented soymilk, presenting similarities with our findings. 
According to our results, the indicatives of the anti-inflammatory potential of the 
samples, especially those biotransformed by tannase, were very promising and can contribute 
in the prevention and treatment of anti-inflammatory process.  
 
2.4 Effect of soy extracts under microglia LPS-stimulation and neuronal response 
The expression of pro-inflammatory markers in microglia M1 phenotype induced 
by LPS in response to treatment of soy extracts or 17β-estradiol was investigated by this 
study. Our results demonstrated significant decrease in TNF-α and IL-1β mRNA expressions 
on the treatment with SFT, in comparison to LPS control. IL-6 expression was under 
detection levels for all conditions tested. Curiously, iNOS and MCP1 expression for SC 
presented significant increase compared to cell + LPS, potentiating the inflammation. While 
SC (without enzyme addition) increased some pro-inflammatory markers, SFT was able to 
decrease them, confirming the great potential of enzyme.  
Our findings corroborate results found by CHEN et al. (2008) and CHINTA et al. 
(2013). The first authors evaluated the effect of isoflavones in dopaminergic 
neurodegeneration induced by LPS. The results showed the inhibition of microglia activation 
and consequent decrease in expression of pro-inflammatory factors such as TNF-α, 
superoxide, and nitric oxide (NO) in mesencephalic neuron-glia and microglia-enriched 
cultures. In the second study, the authors investigated the role of isoflavone daidzein in the 
attenuation of release of inflammatory mediators in LPS-induced BV-2, a murine microglial 
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cell line, and observed a significantly suppress of pro-inflammatory markers, like IL-6 and 
NO. Similarly, in the present study we observed a significant reduction of pro-inflammatory 
mediators after biotransformed isoflavones treatment in microglia LPS-stimulation. The 
enzymatic biotransformation of soy isoflavones generated extracts rich in daidzein and 
genistein, resulting in a better effect than those observed to soy extracts without any 
processing. 
An important point to be considerate is the ligand interactions with estrogen 
receptor (ER) in the brain. In the present study, as well as 17β-estradiol, all enzymatically 
biotransformed samples, especially the SFT, presented decrease in expression of pro-
inflammatory markers compared to LPS treatment, being as effective as and, in most of the 
times, acting better than the hormone. According to literature, neuroprotection exert by 
estradiol appears to be related to inhibition of oxidative stress and regulation of glial cells 
(LIU et al., 2005; SAWADA et al., 1998). However, 17β-estradiol has a limited clinical use 
due to increased risk of developing some cancers in cells responsive to estrogen (BANG et al., 
2004). So, considering the risks involved in hormone therapy, soy biotransformed samples 
maybe an alternative to estrogen to combat neuroinflammation.  
Microglia and neurons participate in a dynamic bidirectional communication that 
is essential for brain development and homeostasis (SIMON; OBST; GOMEZ-NICOLA, 
2018). For investigation of neuronal expression of synaptic structure, SH-SY5Y cells were 
therefore treated with microglia conditioned medium. LPS did not alter significantly the 
synapsin I mRNA expression in comparison to cell control and for all samples treatments, it 
was not observed significant increase in synapsin I expression. 
Compounds that reduce microglia inflammation are recognized as being 
beneficial to brain health. For successful microglia-neuron interaction, the neuroprotective 
effects conferred by estrogen would be related to some increase in expression levels of 
synaptic proteins in neurons. PAN et al. (2010) observed the effect of estradiol and soy germ 
phytoestrogens in the modulation of synaptic formation proteins in ovariectomized rats. The 
results showed that dietary supplementation with phytoestrogens or 17β-estradiol caused 
significant increase mRNA expressions of synapsin I, synaptophysin, and spinophilin in 
hippocampal tissue of the animals. Similar results were also found by ZHOU; HU (2004). The 
authors analyzed the effect of 17β-estradiol on synapsin I expression in cultured cerebral and 
hippocampal neurons. Topological and immunocytochemical analyses indicated increase in 
synapsin I clusters in dendritic spines and shafts after 17β-estradiol treatment.  
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On the other hand, OHTANI-KANEKO et al. (2010) presented results that are 
consistent with our observations. The authors evaluated the effects of 17β-estradiol on 
developing hypothalamic neurons with emphasis on a pre-synaptic protein, synapsin I. 
Hypothalamic cells from fetal rats were treated with 17β-estradiol and the effects on synapsin 
I expression were investigated. Analyses by immunoblotting and qRT-PCR showed that 17β-
estradiol did not increase mRNA expression of synapsin I. Similarly, in our study 17β-
estradiol treatment did not also result in increase of mRNA expression of synapsin I in SH-
SY5Y cells, as well as all treatments with biotransformed soy extracts.  
Besides the classical estrogen receptor pathway, other mechanisms may be 
involved in the effects of 17β-estradiol or phytoestrogens on the neuronal expression of 
synapsin I. So, due to the importance of synaptic formation proteins to successful microglia-
neurons interaction and consequent neuroprotective effects, more studies should be proposed 
to explain the role of soy isoflavones in modulation of synaptic structures. 
It is worth mentioning that, based on all cell assays, the maximum concentration 
tested of soymilk, biotransformed or not, was 25 µL mL-1, observing beneficial effects in a 
concentration range of 0.1−25 µL mL-1 according to each test. Thus, even considering the 
losses by bioavailability of soymilk assets, the intake volumes would be higher than the 
volumes tested in in vitro assays.  
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GENERAL CONCLUSION  
 
Enzymatic biotransformation with tannase and β-glycosidase is an efficient 
strategy to improve the bioactive potential of soymilk. The selected biotransformation process 
in this study was able to modify the isoflavones profile of soymilk, increasing the content of 
aglycones (daidzein and genistein), compounds found in low concentration in soy extracts 
without any processing. Moreover, the use of free tannase proved that it is possible to produce 
equol in soymilk using only in vitro enzymatic bioprocess, and even if the yield of equol 
generation is quite low, the results seem to be enough to improve the bioactivity of the 
bioprocessed soymilk, producing a functional ingredient of high health promoting potential.   
According to our findings, biotransformed soymilk with tannase, especially that 
one treated with free tannase, has shown the best results in in vitro assays (estrogenic, 
antioxidant, anti-inflammatory, and neuroprotective). Although the anti-lipogenic effects and 
microglia-neuron interaction were not observed, the soy extracts presented several beneficial 
health properties. The antioxidant capacity was significantly increased, as well as the anti-
inflammatory potential in macrophages and in microglia cells, inhibiting pro-inflammatory 
factors generation and appearing as a possible neurotherapeutic strategy. The estrogenic 
effects were also potentiated by biotransformed soy extracts, with promising results in the 
attenuation or treatment of menopause symptoms. 
Thus, we can infer that the biotransformed soymilk with tannase, especially in 
free form, have great potential to act as a nutraceutical, contributing to improvement or 
treatment of several health disorders. 
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APPENDIX 
 
APPENDIX 1 – Artigo de revisão bibliográfica do grupo de pesquisa intitulado 
“Bioconversion of isoflavones into bioactive equol: state of the art”, publicado na revista 
Recent Patents on Food, Nutrition & Agriculture. 
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Abstract: Background: Soy isoflavones, an important class of phytoestrogens, are suggested to be 
responsible for a number of biological activities associated with health benefits, including defense 
against various chronic diseases, including breast and prostate cancer, cardiovascular disorders, and 
osteoporosis, and they may alleviate the symptoms of menopause.  
Methods: However, current researches have shown that the clinical efficacy of these phenolic 
compounds is related to the ability of an individual to biotransform isoflavones into equol, which is 
a metabolite of daidzein formed exclusively by the intestinal microbiota.  
Results: This biologically active metabolite presents greater effects than other isoflavones; however, 
only about 30-50 % of people have a microbiota that is able to produce equol from dietary daidzein. 
Concern has recently grown about applications to improve the production of this metabolite. 
Conclusion: This paper summarizes the metabolism of equol, its production, and clinical  
implications. 
Keywords: Bioavailability, Daidzein, Daidzin, Equol, Fecal microbiota, Isoflavones, Phytoestrogens, Soy. 
1. INTRODUCTION 
 Isoflavones are phenolic compounds from the secondary 
metabolism of plants, and belong to the class of flavonoids 
acting as phytoestrogens due to their structural similarity 
with 17β-estradiol hormone. They have a restricted distribu-
tion in nature but are found in relatively high concentrations 
in leguminous plants, especially soybeans [1]. In plants, 
isoflavones most often are conjugated to sugar residues and 
are bound as β-glycosides as in daidzin, glycitin, and genis-
tin, or as aglycones: daidzein, glycitein, and genistein. There 
are also acetylglucoside forms: 6˝-O-acetyldaidzin, 6˝-O-
acetylglicitin, and 6˝-O-acetylgenistin; and malonylglucoside 
forms: 6˝-O-malonyldaidzin, 6˝-O-malonylglicitin, and 6˝-O-
malonylgenistin, but in a minor concentration [2-5]. 
 Isoflavones are predominantly present as glycosides in 
foods. The bioactivity and bioavailability of glycosidic 
isoflavones are relatively low due to their high molecular 
weight and hydrophilicity [5-8]. However, after ingestion,  
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isoflavone glycosides can be partially hydrolyzed in the 
small intestine, thus releasing their aglycone counterparts, 
including daidzein, genistein and, to a less extent, glycitein 
[9-12]. 
 It has been demonstrated that aglycones are absorbed 
more rapidly and in higher concentrations than their gly-
cosides and acetyl and malonyl-glucoside forms in human 
intestines [13]. The transformations required, as described 
below, are mostly performed by the enzymes of the gut mi-
crobiota that are responsible for the hydrolysis of the conju-
gated isoflavones. However, our knowledge about gut mi-
crobes, their enzymes, and the pathways involved in the me-
tabolism of isoflavones is still limited [14-17]. It is known 
that transformation of a conjugated isoflavone to its aglycone 
occurs in sequential steps involving several enzymes pro-
duced by a number of microbial types [4, 17]. Usually, the 
first step in polyphenol degradation involves the release of 
aglycones and oligomers via the action of gastric acid pH, 
esterases, and microbial glycosyl hydrolases (members of the 
β-glucosidase family). All these three actions can carry out 
the hydrolysis of the sugar moiety, facilitating and enhancing 
their absorption, which happens in the upper small intestine 
by passive diffusion [16, 18, 19]. After conversion to the 
aglycone form, approximately one-third is absorbed through 
the gut epithelium as free isoflavone. The remainder pro-
ceeds in a second step, known as intestinal and hepatic  
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phase, in which microbial glucuronidases (UDP-glucuronyl 
transferases) and sulfatases (PAPS-sulfotransferases) achieve 
the corresponding conjugation with glucuronic acid and sul-
fate. These conjugated compounds can be then excreted by 
both renal and biliary pathways; the later suffering enterohe-
patic recirculation, which leads to deconjugation, reabsorp-
tion, and further metabolism [15]. Finally, in the third step, 
some microbial transformations of the polyphenolic core, 
like ring fission by Eubacterium ramulus [18], produce me-
tabolites that may have changed bioactivities with respect to 
human health, originating from compounds either of greater 
biological activity, such as equol [7-hydroxy-3-(4-
hydroxyphenyl)-chroman] and 5-hydroxy equol, or inactive 
molecules, such as O-demethylangolensin (O-DMA) and p-
ethylphenol, which will be absorbed in the intestinal lumen 
[17, 20]. 
 In the specific case of daidzein, the unabsorbed portion is 
hydrogenated, which leads to dihydrodaidzein (DHD), and 
this is converted into O-DMA or equol [15, 21, 22]. For the 
equol production, the three steps occur in this way: daidzin is 
first hydrolyzed to remove the glycoside residue and release 
the bioavailable form daidzein. The hydrolysis is extremely 
efficient and is performed by the action of the membrane-
bound enzyme, found in the brush-border of the small intes-
tine, and by the action of intestinal bacterial β-glucosidases 
[9]. The isoflavone aglycones are, then, directly absorbed 
through the intestinal epithelium or are subjected to a new 
metabolism by the action of colonic microbiota [11, 23]. 
After hydrolysis, under the reducing conditions of the colon, 
unabsorbed aglycones will be hydrogenated by intestinal 
bacteria, resulting in DHD, which will be transformed in O-
DMA or equol, as already mentioned [23-25]. The equol, a 
metabolite of daidzein biotransformation, is produced exclu-
sively by the intestinal bacteria [22, 23], and probably, by 
the joint action of a variety of bacteria [26-28]. The compo-
sition of the microbiota is a determinant factor for the nature 
of the metabolites formed, and varies among individuals [29, 
30]. Only approximately one third of humans harbor an in-
testinal microbiota that is able to transform daidzein into 
equol, who are named equol producers; O-DMA production 
is spread more widely and is not directly related to equol [26, 
31, 32].  
 Numerous studies have demonstrated that equol 
(C15H14O3) is the most important product of the soy isofla-
vone daidzein [14, 26, 33-35], and can also be converted into 
six other metabolites, mainly 3'-hydroxy-equol, and 6-
hydroxy-equol [36]. They have attracted great interest due to 
their high affinity for estrogen receptors, greater absorption 
efficiency, antioxidant properties, and anticarcinogenic ef-
fects [26, 37]. 
 Equol has a heterocyclic structure with a chiral carbon 
atom in C3 position and may occur in two distinct enanti-
omeric forms, (R)-(+)-equol and (S)-(−)-equol, with different 
biological activities. Both forms show very different per-
formance in terms of their binding affinities with estrogen 
receptor α (ERα) and estrogen receptor β (ERβ). In humans, 
metabolism of daidzein only produces (S)-(−)-equol [27, 38]. 
This form has a higher affinity for binding to ERβ, whereas 
the (R)-(+)-equol shows preference for binding to ERα. (S)-
(−)-equol also binds ERβ better than daidzein [39]. 
 Many studies have documented the fundamental role of 
intestinal microbiota in the equol formation [4, 40-42]. 
Several of them have isolated and identified bacteria of 
animal and human origins that can convert daidzein into 
equol. Elghali et al. [43] incubated Bifidobacteria species 
with daidzein and the equol production started during the 
first 6 h of fermentation using Bifidobacterium longum 
BB536 and Bifidobacterium breve ATCC 15700. Levels of 
equol increased during the incubation period, indicating 
that equol was stable in the medium and was not converted 
to other metabolites. A high concentration of equol was 
obtained after 96 h of fermentation, achieving 314 µmol/L 
using B. longum and 291 µmol/L with B. breve. Tamura et 
al. [44] studied the production of equol by Lactobacillus 
rhamnosus JCM 2771. They detected, in a fecal microbiota 
suspension from a male equol producer with daidzein, the 
equol production achieved 95 µmol/L. A supplementation 
with a high concentration of L. rhamnosus was made in this 
fecal microbiota suspension, and the equol production in-
creased, obtaining around 150 µmol/L. Raimond et al. [45] 
screened twenty-two strains of Bifidobacterium for their 
ability to transform the isoflavones daidzin and daidzein. 
Most of the strains released the aglycone from daidzin and 
12 gave yields higher than 90 %. However, all the strains 
failed to transform daidzein into reduced metabolites, like 
S-equol. Results suggested that selected probiotic strains, 
all species of human origin, can be used to speed up the 
release of daidzein, which improves its bioavailability for 
absorption by colonic mucosa and/or biotransformation to 
S-equol by other intestinal microorganisms. 
 It is clear that the intestinal bacteria perform an impor-
tant role in daidzein metabolism, and in equol production 
[14]. Nevertheless, dietary compounds, such as prebiotics 
and fibers, influence intestinal microbial populations, and 
their activities also contribute to the production of equol, 
acting on its absorption and bioavailability [46, 47]. 
Zheng et al. [48] studied the effect of lactulose as a poten-
tial equol-promoting prebiotic in vitro. The effect of lac-
tulose on transformation of daidzein into equol by sows’ 
fecal microbiota was investigated, and results showed that 
lactulose treatment improved bacteria growth parameters, 
changing the kinetics of fermentation in vitro. Lactulose 
combined with daidzein altered the microbiota profile, 
increased equol production, reduced methanogen produc-
ing bacteria, and increased sulfate-reducing bacteria 
within 24 h. Tousen et al. [49] investigated the combined 
effects of daidzein and resistant starch (RS) intake on 
equol production and on intestinal microbiota in ovariec-
tomized (OVX) mice. The resistant starch is not absorbed 
in the proximal intestine and acts as a dietary fiber in the 
colon. After six weeks, urinary equol concentration was 
significantly higher in the OVX mice treated with 0.1 % 
daidzein and 12 % RS-supplemented diet. The occupation 
ratios of Bifidobacterium spp. in the cecal microbiota in 
groups fed just with 12 % RS were significantly higher 
than those in the other groups. The study showed that a 
diet supplemented with daidzein and RS significantly al-
tered the intestinal microbiota and increased equol pro-
duction. Ohta et al. [50] tested the effect of the combina-
tion of isoflavones and fructooligosaccharides (FOS) on 
the equol production of OVX and surgical control rats. 
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FOS stimulates the growth of bifidobacteria, which cleave 
isoflavone conjugates to yield the corresponding agly-
cones and metabolites. Four groups were investigated: a 
purified control diet group, a FOS diet group (5 % FOS), 
an isoflavone diet group (0.2 % isoflavone conjugates), 
and a FOS and isoflavone diet group (5 % FOS and 0.2 % 
isoflavone conjugates). After six weeks, the mice were 
killed and the blood and femora were sampled immedi-
ately. They proved that FOS increased cecal β-
glucosidase activity and equol production from daidzein 
in both OVX and surgical control mice fed isoflavone 
conjugates. However, the best result for the equol produc-
tion was achieved with the group that was fed with FOS 
and isoflavones. These results suggest that FOS increase 
the bioavailability of isoflavones, leading to cooperative 
effects in the prevention of osteopenia in OVX mice. 
2. DETERMINANT FACTORS OF EQUOL-
PRODUCING STATUS 
 As aforementioned, equol produced by intestinal bacteria 
is not produced in all healthy adults when challenged with 
soy foods [51]. The frequency of equol producers can vary 
among different population groups. The factors that define 
the (S)-(−)-equol production are presently unclear, but un-
derstanding the determinant factors of equol-producing is 
important because the health benefits of a soy-based diet 
appear to be greater in equol producers compared to equol 
non-producers [26, 27, 52-54]. 
 The term “equol-producers” is used to describe those 
people that can metabolize daidzein to equol in response to 
consuming soy isoflavones. According to Setchell et al. [26], 
people with a concentration of equol in their plasma > 83 
nmol/L can be defined as “equol-producers” and those with 
concentrations < 40 nmol/L can be classified as “equol non-
producers”. Cut-off values can also be derived from urinary 
equol levels, with an equol producers classified as excreting 
> 1,000 nmol/L [31]. Some studies have evaluated the ef-
fects of dietary intakes, lifestyle factors, and demographic 
and anthropometric data among equol-producers and equol 
non-producers phenotypes. 
 The percentage of equol producers in the population var-
ies with geographic distribution. Several studies show that 
only ~25-30 % of Western adults are able to produce equol 
when challenged with soy foods [31, 51, 55, 56], much lower 
than the frequency of 50-70 % equol producers reported in 
vegetarians or Asians (Japan, China, and Korea), where the 
intake of soy based foods is higher than Western populations 
[24, 54, 57-60]. 
 Equol is not produced in neonatal life, and the production 
of equol may be affected by early nutrition. This fact can be 
observed in a longitudinal prospective study that determined 
the (S)-(−)-equol production in 90 healthy infants who were 
fed breast milk, soy infant formula, or cow’s milk in their 
first year of life. The results found that in early life, the for-
mation of (S)-(−)-equol is a developmentally diet-related and 
time-dependent process. Moreover, the data shows that over 
the first 3 years of life the trend to higher incidence of (S)-
(−)-equol producers occurred mainly in formula feeding in-
fants. 
 Although age does not seem to have an influence on 
equol production, Fujimoto et al. [62] reported that in Japan 
and Korea the percentage of equol producers in older men is 
significantly higher than in younger men. This difference is 
probably due to changes in the eating habits of the younger 
generation due to the influence of Western diet, which 
caused decreased intake isoflavones and, consequently, a low 
incidence of equol producers in this group. 
 Diet is another factor that influences an individual's abil-
ity to produce equol. Although the presence of specific intes-
tinal bacteria that are able to metabolize daidzein to (S)-(−)-
equol is the main factor that lead to equol production, other 
dietary factors can play an important role in equol produc-
tion even if the intestinal bacteria are present [31, 32, 60, 63-
65]. Healthy adults (n=159) from 2 different countries, 
United States and Australia, who consumed a typical West-
ern diet, were evaluated in order to investigate the relation 
between the ability to produce equol and dietary composi-
tion. No significant differences in the total macronutrient 
intake between equol producers and non-producers were 
observed. However, the higher intake of some micronutrients 
like vitamins A and E, polyunsaturated fatty acids, and mal-
tose and a lower intake of cholesterol may affect daidzein 
metabolism. Other factors that may affect the capacity of 
equol production are short chain fatty acids and arginine. 
These compounds can enhance more than four times the ca-
pability of Asaccharobacter celatus to metabolize daidzein 
to equol [66].  
 Lu et al. [67] showed in their study that long-term soy 
ingestion could convert equol non-producers into equol pro-
ducers and, in contrast, Setchell and Cole [56] proposed that 
“once an equol producer, always an equol producer” by a 
study with premenopausal women. In general, the role of 
diet on the individual's ability to produce equol remains un-
certain. Considering that dietary factors play an important 
role in the (S)-(−)-equol production, some strategies may be 
developed to improve the metabolism of daidzein to equol in 
non-producers individuals. Several antibiotics used to elimi-
nate the colonic bacteria for the treatment of infections have 
been shown to affect in vivo and in vitro equol production 
[68, 69].   
 The influence of antibiotic treatment in the daidzein me-
tabolism was evaluated with 350 postmenopausal women in 
a randomized study, double-blind, placebo-controlled soy 
intervention. After the antibiotic treatment no significant 
differences were observed on the capacity for equol produc-
tion. Similarly, the duration of the treatment, antibiotic type 
or class, and the dose showed no consistent influence on 
metabolize daidzein to equol [70]. 
 Sutherland et al. [71] showed that different classes of 
antibiotics had different effects on equol production by colo-
nic bacteria of monkeys in vitro. The metabolism of daidzein 
by the cultures was not affected by the exposure to ceftriax-
one. However, the exposure to tetracycline completely re-
moved the bacteria metabolizing daidzein; however, the ex-
posure to ciprofloxacin improved equol production by the 
bacteria. Moreover, colonic bacteria of monkeys treated with 
4 µg/mL of ciprofloxacin metabolized more daidzein com-
pared to untreated cultures. The antibiotic treatment can  
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eliminate the bacteria which is able to metabolize daidzein to 
equol in colonic microbiota but also enrich them by eliminat-
ing the non-metabolizing strains, or not affect them at all 
[30, 56, 70]. 
3. CLINICAL IMPLICATIONS 
 Clinical and epidemiological research has evaluated the 
association between intake of isoflavones and progression of 
human diseases [72-82].  
 Several papers have already reviewed the hypothesis 
that appropriate isoflavone consumption can decrease can-
cer risk [83-88]. In breast cancer cells, for instance, ERβ 
regulates the genes that control cell cycle progression and 
usually represses the proliferation, whereas activation of 
ERα has the reverse effect [89]. According to Goodman  
et al. [90] and Liu et al. [91], a relationship between pro-
duction of equol and reduction of breast cancer risk has 
been noted.  
 Human studies show that the protective effect in equol 
producers is more apparent than that in equol non-producers, 
and the ethnic difference in daidzein metabolism may par-
tially explain the different frequency of prostate cancer 
among ethnic groups [92]. Confirming this statement, Akaza 
et al. [58] studied Americans, Koreans, and Japanese, and 
they concluded that the proportion of equol producers is sig-
nificantly higher in the Asian population and lower in pa-
tients with prostate cancer. 
 Research has shown that isoflavones can exert antioxi-
dant effects in vitro and in vivo [93-95]. Lotions of genistein 
from red clover (Trifolium pratense) and the metabolites 
equol, isoequol, and dehydroequol have shown strong poten-
tial to decrease inflammatory edema reactions. Furthermore, 
lotions containing equol protected the immune system from 
photosuppression [96]. Moreover, comparative studies of 
phenolic compounds in vitro have demonstrated that equol is 
a potent antioxidant that exhibits higher antioxidant capacity 
than vitamins C and E [36]. 
 Due to the similarity with the hormone 17β-estradiol, the 
isoflavones have also been used as an alternative hormonal 
replacement therapy to minimize menopause symptoms. 
While pharmaceutical hormone replacement therapy is effec-
tive in most cases, this option has not been common, because 
its use can increase the risk of developing breast cancer [97-
99]. According to Howes et al. [100], phytoestrogens intake 
has shown moderate estrogenic effects in postmenopausal 
women, causing symptom improvement. Jou et al. [73] per-
form a clinical trial to evaluate the effect of daily ingestion 
of 135 mg of isoflavones on menopausal symptoms in fe-
male equol producers and non-producers. The results indi-
cated that supplementation with isoflavones was effective in 
reducing menopausal symptoms only in female equol pro-
ducers. 
 The decline in the estrogen level in postmenopausal 
women is partially responsible for the development of osteo-
porosis; a disease characterized by enhanced bone resorp-
tion, accelerated bone loss, and increased risk of fractures as 
well as impaired healing of fractured bone [101]. Estrogen 
replacement therapy has been utilized to decrease the risk of 
osteoporosis, and estrogenic effects of phytoestrogens have 
been suggested to prevent bone resorption and promote in-
crement bone density [49, 102, 103]. Yamori et al. [104] 
found that postmenopausal women that consume higher 
amount of soy-based products have better femoral and/or 
lumbar spine density when compared to women who con-
sume less soy. However, bone-sparing benefits may depend 
on the capacity to convert daidzein to equol. The equol pro-
duction may in part explain why the beneficial effects of 
isoflavones noticed in laboratory rodents have not been eas-
ily replicated in humans, because rodents produce high lev-
els of equol, approximately, a third to half greater than the 
human population [55, 105].  
 Increasing risk of ischemic heart disease between post-
menopausal women is related with a deficit of gonadal 
steroid production. Indeed, estrogen replacement therapy 
has been used to enhance HDL cholesterol and reduce LDL 
cholesterol, thus preventing heart disease. It has been sug-
gested that phytoestrogens may act as estrogen agonists, 
effecting lipoproteins similar to those induced by estrogen 
[106]. Significant diminution in LDL cholesterol levels are 
usually small and only seen in individuals with high choles-
terol who replace a considerable part of their animal protein 
intake with soy, consuming among 40 and 318 mg of 
isoflavones per day [107]. According to Jackman et al. 
[108] and Cheng et al. [109], the equol has vasodilator ac-
tivity, induces nitric oxide synthase-dependent endothelial 
relaxation, and may reduce the risk of cardiovascular dis-
eases. 
CONCLUSION 
 Most isoflavones require enzymatic transformations to 
become bioavailable for the human body. These biotrans-
formations are carried out by intestinal microbiota of indi-
viduals capable of hydrolyzing the conjugated isoflavones 
into aglycones. The aglycones, like daidzein for example, are 
then metabolized into equol and O-DMA. Overall, recent 
evidence suggests the importance of equol as a therapeutic 
agent for the population, mainly for non-equol producers. 
The potential beneficial effects of soy consumption led to an 
increased interest in soy products and in the development of 
new isoflavone and soy-enriched foods and supplements. 
However, additional research is needed to evaluate the safety 
and efficacy of (S)-(−)-equol and (R)-(+)-equol in controlled 
clinical trials. In this review, we discussed the importance of 
equol, a metabolite of daidzein, and its beneficial effects on 
the human health. 
CURRENT & FUTURE DEVELOPMENTS 
 A way to circumvent the limitation of equol production is 
to develop equol as a pharmaceutical or nutraceutical agent. 
In the last few years, many innovative approaches have fo-
cused on the pharmacology and safety of equol. This com-
pound can be produced by an innovative patented process by 
biotransformation of daidzein to (S)-(−)-equol using specific 
microorganisms or by chemical process to synthesize the 2 
different enantiomeric forms, (S)-(−)-equol and (R)-(+)-
equol. The patents listed in Table (1) provide some processes 
related to equol production, in order to increase their content 
and consequently to improve the potential bioactivity of soy 
based products. 
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Table 1. A few patents launched for production of equol. 
Patent no. Description Function Reference 
TW 
200712211 
  
Microbiological process for the co-
production of isoflavone metabolites-equol 
and O-DMA and probiotics, and to screen a 
large number of domestication and repro-
duction of intestinal probiotics body. 
This invention is a microbiological manufacturing process of lower molecular 
metabolites (S)-(−)-equol, (R)-(+)-equol, O-DMA and 6'-hydro-O-DMA  
from the microbiologically and enzymatically biotransformation of daidzin 
and genistin (soy isoflavones), by the screening, selection, acclimation,  
multiplication and metabolization of multi-strain gastrointestinal probiotics. 
Wang 
[110] 
CN 
102021130 
  
Degradation of daidzein into equol using 
new Clostridium bifermentans zx-7 strain, 
for preparing animal fodder, a preparation 
for eliminating cholesterol and a fermented 
product of soy or bean pulp. 
Clostridium bifermentans zx-7 strain was used for perform the degradation of 
daidzein into equol with fungicidal composition for preparing animal fodder, 
for eliminating cholesterol and a fermented product of soy or bean pulp. This 
strain has the skill to lower serum low-density lipoprotein levels and enhance 
high-density lipoprotein and low-density lipoprotein ratio. 
Zhang et 
al. [111] 
US 
201101891
34 
Fermentation product containing equol-
producing microorganism having maintained 
equol-producing ability, and method for 
producing same. 
This innovation provide a fermented product containing equol-producing 
microorganisms in the state of living cells by which equol production ability 
is maintained. 
Isono et 
al. [112] 
JP2011083
273  
Manufacture of fermented material for fer-
mented product involves preparing mother 
starter by performing anaerobic fermentation 
using equol production microorganisms in 
culture medium containing daidzein. 
The method provides fermented product with equol production microorgan-
isms by which equol production ability is maintained in state of living mi-
crobe. 
Isono et 
al. [113] 
WO20120
33150 
  
Preparation and recovery of equol by fer-
mentation of daidzein using anaerobic mi-
crobe under gaseous phase, for preventing 
and/or treating breast cancer, and meno-
pausal disorder. 
Development of a method for the equol production from anaerobic microor-
ganisms, able to generate this metabolite from daidzein fermentation under 
gaseous phase including one or more gas containing hydrogen. This process is 
useful for the preparation of equol used in food-drinks or pharmaceutical for 
preventing and/or treating breast cancer, prostatic cancer, osteoporosis, hy-
percholesterolemia, cardiac disease, and menopausal disorder. 
Nikaido 
and To-
mita [114] 
US201200
94336  
Synthesis of different isofalvones and de-
rivatives of equol in a simple manner. 
This innovation is a method for the production of isoflavanes from isofla-
vones, whereby in a first reaction step the 4-keto group of the isoflavone is 
reduced in a enantioselective manner, whilst the 2,3-double bond is main-
tained, to the 4-hydroxy compound. 
Steffan 
[115] 
US201323
1291  
Fermented soya based mixture comprising 
isoflavones-aglicones, equol and lunasil, 
process for the preparation and uses thereof 
in food, medical and cosmetic fields. 
This invention concerns a mixture comprising isoflavones aglicones, such as 
daidzein, genistein and glycitein, in addition to equol and lunasin, said mix-
ture being based on soya fermented using lactic acid bacteria isolated from 
food matrices and use of said mixture for protection of skin and adnexa and of 
human intestinal cells with particular reference to prevention of inflammatory 
state and protection of barrier functions and hair loss treatment. 
Giuliani et 
al., [116] 
US876544
5  
Equol-producing lactic acid bacteria-
containing composition. 
The invention relates to equol-producing lactic acid bacterial strain, a compo-
sition comprising said lactic acid bacterial strain, and a method of producing 
equol by utilizing said lactic acid bacterial strain. 
Uchiyama 
et al. 
[117]  
CN104031
875 
A new engineered bacteria derived from 
lactic acid bacteria (Lactococcus 20-92), 
useful for the production of (S)-(−)-equol. 
The engineered bacteria are obtained by cloning L-dihydrodaidzein racemase, 
L-daidzein reductase, L-dihydropteridine reductase and L-tetrahydrodaidzein 
reductase genes from Lactococcus sp. 20-92 to Escherichia coli BL21 (D3) and 
transforming. The production of (−)-(−)-equol provided by the invention are 
simple in fermentation condition, convenient to use, stable in system, and wide 
in application. This engineering bacteria have the ability of transforming 
daidzein in brain-heart infusion (BHI) and lysogeny broth (LB) culture media 
into (S)-(−)-equol whether under an anaerobic condition or an aerobic condition, 
and have the ability of transforming bean pulp in BHI and LB into (S)-(−)-equol. 
Yin and 
Wang 
[118] 
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A B S T R A C T
Soy isoflavones have been associated with several beneficial effects to human health including estrogenic action.
Due to the risks associated with pharmaceutical hormone replacement therapy, soy extracts rich in isoflavones
and metabolites appear as a safe alternative for menopausal women. This study aimed to improve the process
conditions for biotransformation of soymilk polyphenols by tannase to obtain higher amounts of isoflavone
aglycones and metabolites such as equol. The estrogenic potential of the extracts was evaluated in in vitro assays.
The results showed that the aglycones increased 36–46 times after reaction with tannase and proved that it is
possible to produce equol in soymilk using an enzymatic bioprocess, without gut microbial intervention.
Moreover, the soymilk biotransformed by tannase presented higher estrogenic action in the MCF-7 BUS cell line
assay, making it a promising nutraceutical with possible effects in the attenuation or treatment of menopause
symptoms.
1. Introduction
Soy-based products, an important source of nutrients and phyto-
chemicals, have been appreciated worldwide as health promoting
foods. Isoflavones, a class of phytoestrogens present in high con-
centration in soybeans, have been widely investigated because of their
potential health-enhancing properties, including prevention and
therapy of some chronic diseases such as cancers and cardiovascular
diseases as well as their ability to relieve the symptoms of menopause in
women (Rimbach et al., 2008; Sunita & Pattanayak, 2011; Uifălean,
Schneider, Ionescu, Lalk, & Iuga, 2016).
Soybeans contain four distinct chemical structures of isoflavones
known as aglycone (genistein, daidzein, and glycitein), glycoside
(genistin, daidzin, and glycitin), acetyl glycoside (acetyl genistin, acetyl
daidzin, and acetyl glycitin), and malonyl glycoside (malonyl genistin,
malonyl daidzin, and malonyl glycitin) (Shao et al., 2011). The biolo-
gical activity of these compounds in the human body depends on their
chemical forms. Among them, isoflavone aglycones seem to have higher
beneficial effects on human health than other forms (Izumi et al.,
2000). Fortunately, isoflavone glycosides can be enzymatically con-
verted to their respective aglycones, which has a significant effect on
their bioavailability (Ismail & Hayes, 2005). Moreover, the isoflavone
aglycones can be metabolized to many specific compounds in the
human gut, with emphasis to equol, a most bioavailable metabolite and
directly associated with the clinical efficacy of isoflavones (Rowland
et al., 2003). Equol [7-hydroxy-3-(4-hydroxyphenyl)-chroman] is a
nonsteroidal estrogen produced by daidzein metabolism and, according
to the present literature, is formed exclusively by intestinal bacteria
(Setchell, Brown, & Lydeking-Olsen, 2002; Yuan, Wang, & Liu, 2007).
Therefore, there is growing interest in soy-based products with high
bioactivity, being important to generate a commercial source of iso-
flavone aglycones and bioactive metabolite, such as equol.
A common method to convert glycosides to bioactive aglycones is
enzymatic hydrolysis, which is considered more specific than chemical
hydrolysis. The β-glycosidase, an enzyme naturally presents in soy-
beans and produced by various microorganisms, is able to catalyze the
hydrolysis of isoflavone glycosides (Chen et al., 2013; Park, Alencar,
Nery, Aguiar, & Pacheco, 2001). The use of β-glycosidase to produce
food supplements rich in more bioavailable soy isoflavones is the sub-
ject of a patent with commercial exploitation (Park, Scamparini, Sato, &
Alencar, 2004).
Our research group proposes the application of a different enzyme,
named tannase (E.C. 3.1.1.20) or tannin acyl hydrolase, which has great
potential to bioconvert the soy isoflavones into aglycones and further.
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De Queirós, Macedo, and Macedo (2016) demonstrated the potential of
aglycones production and equol generation by this enzyme in soymilk
bioprocessing. This was the first study that was able to produce equol
through an enzymatic process of biotransformation of soy isoflavones.
Tannase is an esterase enzyme largely characterized by its activity
on phenolic complex and its ability to perform hydrolysis reactions on
ester bond and depside linkages of hydrolysable and condensed tannins
(García-Conesa, Østergaard, Kauppinen, & Williamson, 2001). Fur-
thermore, this extracellular enzyme also exhibits deglycosylation ac-
tivity, demonstrating great potential (Ferreira, Macedo, Ribeiro, &
Macedo, 2013).
In view of the knowledge accumulated by our research group and
the broad range of action of tannase on phenolics in foods, it was im-
portant to further evaluate the capacity of the enzyme to biotransform
soy isoflavones, since tannase has presented a more extensive action on
phenolics than β-glycosidase, as well as higher bioactive potential on
the generated extracts.
According to some authors, isoflavones present structural and
functional similarities to the 17β-estradiol hormone, demonstrating
affinity for estrogen receptors. The isoflavones can bind to both es-
trogen receptor subtypes (ERα and ERβ), which exert distinct biological
functions, with a slightly greater affinity to bind to ERβ (Wuttke, Jarry,
& Seidlová-Wuttke, 2007; Zhao & Mu, 2011). ERα is present mainly in
mammary gland, uterus, ovary (thecal cells), and hypothalamic tissue,
whereas ERβ is found in kidney, brain, bone, ovary (granulosa cells),
heart, lungs, intestinal mucosa, prostate, and endothelial cells (Bai &
Gust, 2009; Taylor, Levy, Elliott, & Burnett, 2009).
In hormone dependent tissues, estrogens play an essential role in
several physiological processes, including cell proliferation, differ-
entiation, or apoptosis. However, elevated levels of estrogens are a
main risk factor for the progress of hormone dependent diseases, in-
creasing the risk of developing breast, endometrial, and ovary cancers
(Kumar, Lata, Mukhopadhyay, & Mukherjee, 2010; Schairer et al.,
2000; Uifălean et al., 2016).
Therefore, due to the risks mentioned above, pharmaceutical hor-
mone replacement therapy, although effective in most cases, does not
seem to be the best treatment option in menopause. So, soy extracts rich
in isoflavones and metabolites appear as an alternative to relieve and
improve the symptoms in menopausal women.
Continuing the endeavors of our research group, this study aimed to
improve the process conditions for biotransformation of soymilk poly-
phenols by tannase to obtain higher amounts of isoflavone aglycones
and metabolites, such as equol. The estrogenic potential of the obtained
extracts in in vitro assays were also verified. The traditional enzymatic
biotransformation of soy isoflavones with β-glycosidase was performed
altogether to compare the results with an established process.
2. Materials and methods
2.1. Materials
Soybeans (IAC Foscarin 31 variety) were obtained at the Agronomic
Institute of Campinas, Campinas, SP, Brazil. Analytical standards
daidzin, genistin, daidzein, genistein, and equol, gallic and tannic acids,
β-glycosidase enzyme (naringinase from Penicillium decumbens), sodium
alginate, Folin-Ciocalteu reagent, sulforhodamine B sodium salt and
Trizma® base were purchased from Sigma-Aldrich (Steinheim,
Germany). All other chemicals were acquired in the grade commercially
available. Cell culture reagents were purchased from Invitrogen®.
2.2. Soymilk preparation
Soymilk was prepared following the methodology developed by
Embrapa Soja, Brazil, with modifications (Mandarino & Carrão-Panizzi,
1999). Whole soybeans were macerated in distilled water (1:3 w/v) for
6 h at room temperature. After that, the beans were boiled (1:6 w/v) for
5min and then blended in distilled water (1:6 w/v) for 2min. The re-
sultant slurry was centrifuged at 5000 rotations per minute (rpm) for
15min at room temperature (Megafuge 16R, Thermo Electron Led
GmbH, Langenselbold, Germany). The supernatant, designated soymilk,
was pasteurized at 85 °C for 15 s, freeze-dried, and stored at −20 °C.
2.3. Enzymes
Tannase from Paecilomyces variotii was obtained according to a
previously published procedure by Battestin and Macedo (2007). For
comparison, commercial β-glycosidase enzyme (naringinase from Pe-
nicillium decumbens) was also used in the present study.
For tannase and β-glycosidase immobilization, sodium alginate
(viscosity 20,000–40,000 cps) was used as carrier for ionic gelation.
Fifteen milliliters of the 5% sodium alginate media were mixed with
200mg of tannase or 1050mg of β-glycosidase powder, based on en-
zymatic activity (β-glycosidase activity of 4.2 U/mg was fixed to both
enzymes). The mixture was dropped into 90mL of 0.1M calcium
chloride using a peristaltic pump to obtain equally sized polymeric
beads (20mm) composed of calcium alginate. After repose for 6 h at
7 °C, the beads were washed with 200mL of distilled water to remove
the excess calcium ions and the unbound enzyme. The beads were dried
for 16 h in refrigerated environment and stored in the same conditions
until analysis (Mohapatra, Mondal, & Pati, 2007).
Both enzymes (from P. variotii and P. decumbens) were assayed for β-
glycosidase activity. Free and immobilized enzymes were tested ac-
cording to Matsuura, Sasaki, and Murao (1995), with modifications,
using the chromogenic substrate ρ-nitrophenyl-β-D-glucopyranoside (ρ-
NPG). The enzymatic activity was evaluated by monitoring the release
of ρ-nitrophenol at 410 nm, using a standard curve of ρ-nitrophenol,
ranging from 0.036–0.576 µmol/mL. One unit of β-glycosidase activity
(U) was defined as the amount of enzyme required to release 1 μmol of
ρ-nitrophenol per minute of reaction.
Tannase activity of enzyme from P. variotii, in free and immobilized
forms, was also evaluated according to Sharma, Bhat, and Dawra
(2000), adapted using tannic acid as substrate. The enzymatic activity
was measured by monitoring the release of gallic acid at 520 nm, using
a calibration curve of gallic acid ranging from 0.013–0.321 µmol/mL.
One unit of tannase activity (U) was defined as the amount of enzyme
that released 1 µmol/min of gallic acid.
For specific enzymatic activity calculation, the protein content was
determined according to Bradford (1976).
2.4. Optimization of biotransformation process parameters
The first set of conditions were fixed as soymilk (lyophilized
powder) at the concentration of 200mg/mL of distilled water, pH 6.5,
temperature of 40 °C and reaction time of 30min, based on previous
work by De Queirós et al. (2016). In this condition, the concentrations
of immobilized tannase tested were 1, 5, 10, and 15% (w/v). After the
concentration of enzyme was fixed, the following variables were tested
one at a time: hydrogen potential – pH (5, 6, 6.5, and 7), temperature
(30, 40, 50, and 60 °C), and reaction time (15, 30, 45, and 60min). The
samples were incubated in thermostated bath (model B12D, Micronal,
São Paulo, Brazil) with stirring at 100 rpm and the reaction was stopped
collecting the immobilized enzyme by filtration.
After selecting the best parameters of reaction with immobilized
tannase, the soymilk biotransformed with commercial β-glycosidase in
immobilized form was tested in the same conditions in order to com-
pare with the established process.
For free tannase, according to De Queirós et al. (2016), the soymilk
was incubated with 20mg of tannase powder (β-glycosidase activity of
4.2 U/mg), also with the best conditions fixed above (pH, temperature,
and reaction time), and the hydrolysis process was stopped by placing
the reaction in an ice bath for 15min.
As control, soymilk (lyophilized powder) at the concentration of
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200mg/mL of distilled water was submitted to the same conditions and
it was evaluated for the isoflavones profile.
Each reaction product was analyzed by High Performance Liquid
Chromatography coupled to Diode Array Detector (HPLC-DAD) as de-
scribe in Section 2.5.1.
2.5. Characterization of extracts
2.5.1. Identification and quantification of isoflavones and equol by HPLC-
DAD
The extraction of isoflavones and metabolite from samples was
performed according to Aguiar, Suzuki, Paredes-Guzmán, Alencar, and
Park (2003), with modifications. Aliquots (1 mL) of soymilk, before and
after biotransformation, were mixed with 5mL of methanol (80% v/v)
at 25 °C for 2min at 500 rpm. The mixture was centrifuged for 15min at
5000 rpm, and the supernatants were filtered through a 0.45 μm
membrane before undergoing HPLC analyses.
HPLC analyses of extracts were performed on a Dionex UltiMate
3000 (Germany) liquid chromatograph, equipped with a RP18 XTerra®
column (Waters, 5 μm, 4.6×150mm) maintained at 30 °C. The de-
tection was carried out using a UV/VIS detector (DAD-3000) and the
mobile phases were: A (water/formic acid, 99.9:0.1 v/v) and B (me-
thanol). The gradient elution was as follows: 20% B (0–15min),
20–80% B (15–75min), 80–100% B (75–80min), 100–20% B
(80–90min) and 20% B (90–95min), with a flow rate of 0.5 mL/min.
The spectra were registered at 190 and 480 nm, and the chromatograms
processed at 254 nm.
Isoflavonoids were identified by comparing their retention time and
absorbance spectrum. Quantification of individual polyphenols was
carried out using calibration curves of standards (daidzin, genistin,
daidzein, genistein, and equol). Results were expressed as µg of each
phenolic compound mL−1 of the sample (Maubach et al., 2003).
2.5.2. Equol metabolite confirmation by GC–MS analyses
To confirm the presence of equol metabolite, the “soymilk+ free
tannase” sample was derivatized with N’O-bis(trimethylsilyl)tri-
fluoroacetamide (BSTFA, Sigma-Aldrich, Steinheim, Germany) and
analyzed by gas chromatograph mass spectrometer (GC–MS), according
to Ko et al. (2010), with modifications.
For extracting of metabolite, 1 mL of sample was mixed in vortex
with 50 μL of 12 N HCl for 1min. The mixture was heated at 100 °C for
60min. After cooling to room temperature, 1 mL of carbonate buffer
solution (1.5M, pH 8.5) and 4mL ethyl acetate (EA) were added and
mixed for 10min. Then, the EA layer was removed and dried with ni-
trogen. The residue was dissolved in 100 μL EA and 40 μL BSTFA re-
agent, followed by incubation at 80 °C for 60min. The final reactant
was analyzed by GC–MS.
Analyses were carried out in a gas chromatograph mass spectro-
meter (GCMS-QP2010S Shimadzu), in selective ion monitoring (SIM)
mode, using RTX-5 capillary column (Restek, 5% diphenyl, 95% di-
methyl-polysiloxane), with 30m length×0.25mm diameter
inner× 0.25 µm film thickness. The operating conditions of the chro-
matograph were: injector temperature 250 °C; ion source 230 °C;
quadrupole 150 °C; injection volume 1 µL in splitless mode; carrier gas
of helium at constant flow rate of 1mL/min; oven program temperature
160 °C maintained for 2min and increased at 13 °C/min to 290 °C and
held an additional 2min; and GC–MS interface temperature 290 °C.
2.5.3. Total phenolic content
Total phenolic content of soy extracts, before and after bio-
transformation, was determined by Folin-Ciocalteu assay according to
Swain and Hillis (1959). Gallic acid was used as the standard and a
calibration curve was plotted in a concentration range of 25–250 µg/
mL. All analyses were performed in triplicate, and results were ex-
pressed as µg of gallic acid equivalents (GAE)/mL of extract.
2.6. Cell culture assay
2.6.1. Cell culture and maintenance
MCF-7 BUS cell line, a human breast carcinoma which over-
expresses estradiol receptors (ER), was kindly donated by Dr. Ana Lúcia
Tasca Gois Ruiz (CPQBA/UNICAMP). The cells were cultured in
Roswell Park Memorial Institute (RPMI) 1640 medium supplemented
with 5% fetal bovine serum (FBS) and 1% penicillin-streptomycin at
37 °C in a 5% CO2 humidified atmosphere.
2.6.2. Cytotoxicity assay
The evaluation of the cytotoxicity of the soy extracts, before and
after biotransformation, in a range of concentrations in the MCF-7 BUS
cell line was tested according to Monks et al. (1991). Cells in 96-well
plates (inoculation density of 6× 104 cells/mL) were exposed to dif-
ferent concentrations of samples (0.005–1 µL/mL) in triplicate, for 24 h
and 144 h at 37 °C and 5% of CO2. After that, cells were fixed in situ
with cold 50% trichloroacetic acid (TCA, 50 µL/well) followed by
staining with sulforhodamine B (SRB) solution (0.4% w/v in 1% acetic
acid, 50 µL/well). Bound stain was solubilized with 10mM Trizma base
(pH 10.5, 150 µL/well), and the absorbance was measured at 540 nm
using an automated spectrophotometric plate reader.
2.6.3. E-screen assay (estrogenic activity assay)
The E-screen assay was carried out as described by Rasmussen and
Nielsen (2002). Briefly, MCF-7 BUS cells (1× 104 cells/well) were
seeded in 12-well plates in RPMI 1640 supplemented with 5% FBS.
After 24 h incubation, the medium was replaced for phenol red-free
RPMI 1640 supplemented with 5% charcoal stripped FBS and 1% pe-
nicillin-streptomycin. The cells were incubated for 72 h and after that
they were treated with soymilk samples, before and after bio-
transformation, at concentrations of 0.1 and 1 µL/mL, in the presence
and absence of 17β-estradiol (E2, 10−9 M). After 144 h of incubation,
cells were fixed with TCA and stained with SRB as describe in Section
2.6.2.
2.7. Statistical analysis
Results were expressed as means ± standard deviation (SD). The
statistical difference between the groups was analyzed using analysis of
variance (ANOVA). Post hoc comparison was performed by Tukey’s
multiple comparisons test. Differences were considered significant
when P < 0.05 and the analyses were performed using the GraphPad
Prism version 7.0 (GraphPad Software Inc.).
3. Results and discussion
3.1. Enzymatic optimization process
For enzymatic optimization process, preliminary tests were per-
formed and the concentrations of 1 and 5% (w/v) of immobilized
tannase were eliminated, because the conversion of the glycosylated
isoflavones to aglycones was shown to be lower than others (data not
shown). Therefore, it was decided to work with 10% (w/v) immobilized
enzyme, since the concentration of 15% (w/v) resulted in a lower yield
of soymilk after biotransformation [3.5 times less compared to con-
centration of 10% (w/v), since the alginate capsules containing the
enzyme absorbed the soymilk during the biotransformation process].
The pH 6.5 (pH of powder soymilk dissolved in distilled water) and
temperature of 50 °C were selected for the reaction. The pH 6.5 showed
the maximum concentration increase of bioactive aglycones compared
to the other tested conditions. For temperature, although the variable of
60 °C showed higher percentage of aglycones, we decided to work with
50 °C because the immobilized enzyme swelled at 60 °C, and could
rupture in reaction times longer than 30min.
The condition “reaction time” included the interval of 60min.
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However, this interval was infeasible for the test, because the capsules
containing the immobilized enzyme ruptured during biotransformation.
Thus, the interval of 45min was select for the reaction.
As mentioned, the best conditions after the studies, which increased
the amount of bioactive isoflavones, were defined as: 10% (w/v) of
immobilized tannase concentration, pH 6.5, temperature of 50 °C, and
reaction time of 45min. The results of enzymatic optimization process
are presented in Table 1.
3.2. Characterization of extracts
The HPLC-DAD analysis clearly demonstrated the change in iso-
flavones profile in soymilk extracts. The analysis showed that all en-
zymatic biotransformation processes with tannase and β-glycosidase
enzymes, in free and immobilized forms, were able to promote sig-
nificant changes in isoflavones profiles in soymilk, bioconverting gly-
cosidic forms (daidzin and genistin) in their respective aglycone forms
(daidzein and genistein). Moreover, we were able to identify the equol
metabolite in “soymilk+ free tannase” sample. The chromatograms
obtained by HPLC-DAD are showed in Fig. 1.
The enzymatic biotransformation of phenolic compounds has been
presented as an alternative strategy to attenuate the variability in the
digestive efficiency of isoflavones (Chen et al., 2013; de Queirós et al.,
2016; Park et al., 2001). In work developed by Park et al. (2001) it was
studied the defatted soy flour, aiming to analyze the content of iso-
flavone aglycones after heating process and β-glycosidase reaction. The
application of heat treatment at 121 °C and the reaction by β-glycosi-
dase combined were able to hydrolyze the glycoside and malonyl gly-
coside forms into aglycone forms. From this finding, other studies have
demonstrated the action of β-glycosidase enzyme on isoflavones hy-
drolysis, in both free and immobilized forms (Chen et al., 2013; Ismail
& Hayes, 2005; Maitan-Alfenas et al., 2014).
Specific attention should be given to tannase due to the great po-
tential of the enzyme, attributed to its strong action on phenolics in
foods. A previous study of our research group evaluated the effect of
tannase extract of P. variotii to modify the profile of polyphenol com-
position of orange juice. The authors found that the enzyme does not
only exhibit the esterase and depsidic activities already described in
literature, but also deglycosylated action, acting in the bond between
aglycone and disaccharide molecules of flavonoids (Ferreira et al.,
2013).
As shown in Table 2, the glycosidic forms of isoflavones were pre-
dominant in the soymilk control. On the other hand, after soymilk
reaction with tannase and β-glycosidase enzymes, the concentration of
daidzein and genistein increased by 35–40 and 38–46 times, respec-
tively, compared to control of untreated soymilk. Comparing all sam-
ples with soymilk control, “soymilk+ free tannase” showed the highest
content of daidzein and genistein aglycones, corresponding to
115.75 ± 1.28 and 124.89 ± 3.79 µg/mL of sample, respectively. The
findings suggest that the glycosidic forms of isoflavones were converted
into aglycones forms, and other substrates were also transformed into
daidzein and genistein. Our results are in agreement with data observed
by De Queirós et al. (2016) when applying tannase to soymilk. They
suggest the ability of the enzyme to generate free aglycones from sub-
strates different than daidzin and genistin, possibly from polymerized
substrates.
The equol metabolite was quantified only in “soymilk+ free tan-
nase”, corresponding to 0.26 ± 0.03 µg/mL of sample. This finding is
probably due to the higher performance of the free form of tannase
when compared to immobilized form. To confirm the peak identified in
HPLC analysis, “soymilk+ free tannase” sample was analyzed by
GC–MS. As shown in Fig. 2, the equol metabolite was confirmed by
mass spectrum.
The total detectable phenolic content of the samples varied from
1432 ± 53 to 1543 ± 30 µg of GAE/mL of samples. There was no
statistical difference between samples biotransformed with im-
mobilized enzymes and soymilk control (P < 0.05). However, for
“soymilk+ free tannase”, a statistical difference was observed com-
pared to soymilk control, increasing from 1434 to 1543 µg/mL, an in-
crease of 7%.
These results suggest that the process with tannase in free form
improves the release of phenolic compounds from soymilk matrix.
Moreover, the activity of tannase in free form appeared to be more
extensive than the biotransformation performed by the immobilized
enzymes. The sample “soymilk+ free tannase” presented the highest
increase in the aglycone forms of isoflavones, which correlate with the
total phenolic content assay, evidencing that the tannase presented
broader action and did not only act as β-glycosidase, but was able to
produce the equol metabolite and generate aglycones from other sub-
strates.
According to literature, the gut microbiota are responsible for
converting the aglycone daidzein into equol, involving several in-
testinal bacteria in this process (Setchell et al., 2002; Yuan et al., 2007).
However, studies have also considered the equol production during
soymilk fermentation without intestinal bacteria, correlating the
synthesis of equol and the use of enzymes (Di Cagno et al., 2010; Rekha
& Vijayalakshmi, 2011).
Moreover, our study identified equol in soymilk biotransformed
with only tannase enzyme, without fermentative process. Our hypoth-
esis is that the presence of equol metabolite is probably due to the broad
catalytic performance of free form of tannase enzyme in other sub-
strates (other than daidzein) existing in the sample, since the extract
present a complex composition. Similar results were found by De
Queirós et al. (2016) using the same crude tannase enzyme extract from
P. variotii in soymilk biotransformation. The authors analyzed the
production of equol by bioprocess “in vitro”, changes in the profile of
isoflavones and antioxidant activity of soymilk. Biotransformation
processes based on soymilk fermentation by probiotic lactic bacteria
and enzymatic process with tannase were performed. The results
showed that both enzymatic and fermentation processes were able to
hydrolyze the glycosidic form into aglycone form and increased the
equol content. Although both biotransformation processes were effec-
tive in this study, the results indicated that the action of tannase was
better than fermentation process in increasing aglycones, in antioxidant
activity, and in the equol content in soymilk. So, further investigation
studies are necessary to find out the possible substrate for this equol
production by tannase catalyzes.
Table 1
Concentration of isoflavones (µg/mL) by HPLC-DAD from the different variable
conditions tested in the optimization process for immobilized tannase.
Isoflavones content (µg/mL)
Variables Glycosylated Aglycones
Daidzin Genistin Daidzein Genistein
Enzyme concentration 10% (w/v) 15.33 28.44 75.87 70.22
15% (w/v) 7.66 13.56 80.45 78.96
pH 5.0 29.05 48.96 50.10 43.15
6.0 41.17 65.44 46.99 38.66
6.5 15.33 28.44 75.87 70.22
7.0 52.04 78.21 35.33 28.12
Temperature 30 °C 34.72 57.52 41.32 33.62
40 °C 15.33 28.44 75.87 70.22
50 °C 6.17 6.85 82.53 84.09
60 °C 5.32 6.06 81.68 84.56
Reaction time 15min 15.54 28.85 53.89 48.88
30min 6.17 6.85 82.53 84.09
45min 6.16 7.52 97.45 102.40
The best conditions of each variable are in bold.
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3.3. Influence of biotransformation process on in vitro estrogenic activity
Natural isoflavones present structural similarity with 17β-estradiol
hormone demonstrating binding affinities for both estrogen receptors
subtypes (ERα and ERβ) (Wuttke et al., 2007). Estrogens play a fun-
damental role in many physiological processes in hormone dependent
tissues, such as cell proliferation, differentiation, or programmed cell
death. However, elevated levels of estrogens are associate with an in-
creased risk of developing hormone dependent diseases, including
breast, endometrial, and ovary cancers (Kumar et al., 2010; Schairer
et al., 2000; Uifălean et al., 2016).
Therefore, hormone replacement therapy for women in menopause
has some risks that cannot be neglected. Thus, the discovery of safer
ligands in estrogen receptors activation is promising and soy products
rich in isoflavones and metabolites appear as a healthy alternative to
relieve and improve the symptoms in menopausal women (Sunita &
Pattanayak, 2011).
The present study evaluated the soymilk samples in vitro to evidence
their ability to binding to estrogen receptors. First, MCF-7 BUS cells
were exposed to the samples to determine the higher non-cytotoxic
concentration; none of the extracts reduced cell viability after 24 or
144 h of exposure (Table 3). Thus, for the E-screen assay the con-
centrations selected were 0.1 and 1 µL/mL.
The E-screen assay was developed to elucidate estrogenic/anti-
estrogenic activity by changes in proliferation of MCF-7 BUS cell line, a
human breast carcinoma which overexpresses estradiol receptors. Thus,
all samples exhibited enhanced cell proliferation in comparison to un-
treated cells (Fig. 3).
At the lower concentration tested (0.1 µL/mL), immobilized tannase
or β-glycosidase treatment did not increase the ability of the soymilk to
enhance cell proliferation. Moreover, free tannase treatment resulted in
increase of 2.6 times, compared to untreated cells, which is as effective
as 17β-estradiol (10−9 M, Fig. 3A). When MCF-7 BUS cells were co-
treated with soymilk or biotransformed soymilk samples and E2
(Fig. 3B), E2 proliferative action significantly increased, which suggests
an additive effect.
For the higher concentration (1 µL/mL), both tannase treatments
(free and immobilized) increased the cell proliferation 3.2 and 3.3
Fig. 1. Chromatograms obtained by HPLC-DAD from samples (A) soymilk control, (B) soymilk+ immobilized tannase, (C) soymilk+ immobilized β-glycosidase,
and (D) soymilk+ free tannase.
Table 2
Concentration of isoflavones and equol (µg/mL) by HPLC-DAD of the biotransformed samples at the optimized conditions established.
Isoflavones and metabolite content (µg/mL)
Samples Glycosylated Aglycones Metabolite
Daidzin Genistin Daidzein Genistein Equol
Soymilk control 119.33a ± 1.03 145.77a ± 2.36 2.87c ± 0.24 2.73c ± 0.57 n/da
Soymilk+ immobilized tannase 8.05c ± 0.08 18.86c ± 2.93 102.53b ± 7.75 104.68b ± 8.23 n/d
Soymilk+ immobilized β-glycosidase 22.27b ± 1.21 49.38b ± 2.50 99.42b ± 1.87 104.29b ± 2.27 n/d
Soymilk+ free tannase 5.54c ± 1.46 13.88c ± 1.28 115.75a ± 1.28 124.89a ± 3.79 0.26 ± 0.03
Results are expressed as mean ± standard deviation (n=3). For each column, values with different lowercase letters are significant at P < 0.05 by Tukey’s test.
a n/d, not detected, under detection limit for this methodology and equipment.
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times, respectively, compared to untreated cells (Fig. 3C), which is
slightly more effective than E2 (19.4 and 20.4% higher, respectively). In
relation to co-treatment with E2, all samples were able to enhance the
cell proliferation, potentiating the 17β-estradiol action (Fig. 3D).
Equol, a daidzein metabolite, occurs in two different enantiomeric
forms (R)- and (S)-equol, and the (S)-equol is the only form produced by
human microbiota (Setchell et al., 2005). Both forms show distinct
performance in binding affinities with ERα and ERβ. The (S)-equol has
higher affinity for binding to ERβ and exhibits a binding preference
greater than its precursor, daidzein, whereas the (R)-equol shows pre-
ference for binding selectivity to ERα (Muthyala et al., 2004).
In our study, the equol metabolite was detected only in “soy-
milk+ free tannase” sample. It is noteworthy that this sample suffered
major modifications, although we haven't trace all of them yet. So, the
data allow us to infer the differentiated action of this sample in in vitro
assays, like the increased estrogenic potential observed in this work.
Even if the yield of equol generation is quite low, the results make it
seems to be enough to improve the bioactive potential of the biopro-
cessed soymilk, producing a functional ingredient of high health pro-
moting potential.
According to literature, the presence of soy isoflavones and their
metabolites in human blood were able to stimulate proliferation of
MCF-7 cells, and this effect is dependent of the estrogen concentration
in the media. Thus, at very low levels of estrogen (20 pM), soy iso-
flavones were able to inhibit cell proliferation; while at higher estrogen
levels, isoflavones can stimulate cell proliferation (Imhof, Molzer, &
Imhof, 2008). Moreover, for genistein, the ERα/ERβ ratio also influ-
ences the estrogenic effect. The induction of cell proliferation and
programmed cell death inhibition by genistein was observed in MCF-7
cells (with high ERα/ERβ ratio), but not in T47D cells (with low ERα/
ERβ ratio) and MDA-MB-231 (ER negative) (Pons et al., 2014). These
results are in agreement with our study, since the treatment with iso-
flavone aglycone-enriched extracts and E2 enhanced the proliferation of
MCF-7 BUS, that overexpresses estradiol receptors (ERα).
In breast cancer cells, the estrogen receptor β regulates the set of
genes evolved with control of cell cycle progression and generally
suppress the proliferation, whereas the estrogen receptor α activation
has an opposite effect (Chang, Frasor, Komm, & Katzenellenbogen,
2006). This statement also applies to our work, since the ERα probably
was activated by isoflavone aglycones and equol, resulting in increased
cell proliferation.
4. Conclusions
The enzymatic biotransformation is an efficient strategy to improve
bioactive potential of soymilk. The use of tannase proved that it is
possible to produce equol in soymilk using in vitro enzymatic bioprocess
without gut microbial intervention, which confirms the great potential
of this enzyme. Moreover, the soymilk biotransformed by tannase
presented higher estrogenic action, making it a promising nutraceutical
with possible effects to treat or improve menopausal symptoms.
Fig. 2. Mass spectra of equol peak identified in (A) soymilk+ free tannase sample and (B) standard equol.
Table 3
Relative cell viabilitya (%) of MCF-7 BUS cell line by Sulforhodamine B assay.
Incubation for 24 h Incubation for 144 h
Samples Samples concentration (µL/mL)
0.005 0.01 0.1 0.5 1 0.005 0.01 0.1 0.5 1
Soymilk control 94% 95% 97% 110% 117% 99% 99% 99% 101% 102%
Soymilk+ immobilized tannase 104% 105% 106% 118% 124% 99% 100% 99% 101% 101%
Soymilk+ immobilized β-glycosidase 99% 103% 114% 114% 126% 96% 97% 99% 102% 101%
Soymilk+ free tannase 95% 97% 105% 106% 113% 97% 96% 101% 103% 103%
a Results are expressed as percentages of cell viability compared to cell control (cell without any treatment)− 100% of cell viability.
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APPENDIX 3 – Resultados não incluídos nos artigos. 
 
Os resultados abaixo não foram incluídos nos artigos de pesquisa. No entanto, 
serão apresentados para complementar o corpo da tese e indicar a execução dos testes. 
Os grãos de soja, o extrato hidrossolúvel de soja (EHS), tanto líquido quanto 
liofilizado, assim como o resíduo da produção do EHS (okara), foram analisados quanto à 
composição centesimal. Análises de umidade (AOAC, 1997), cinzas (AOAC, 1997), lipídeos 
(BLIGH; DYER, 1959) e proteínas pelo método de Kjeldahl (AOAC, 1997) foram realizadas. 
A fração glicídica (carboidratos) foi obtida por diferença do somatório de umidade, proteínas, 
lipídeos e cinzas. Os dados são apresentados na Tabela 1.  
 
Tabela 1 Composição centesimal das amostras. 
Composição centesimal (%) 
  Umidade Cinzas Lipídeos Proteínas Carboidratos 
Soja 9,90 ± 0,08 4,18 ± 0,03 21,76 ± 0,32 41,59 ± 0,95 22,57 ± 0,75 
Okara 74,72 ± 0,27 0,80 ± 0,01 4,74 ± 0,10 12,85 ± 0,34 6,89 ± 0,15 
EHS líquido 96,08 ± 0,01 0,31 ± 0,03 1,04 ± 0,05 0,97 ± 0,04 1,60 ± 0,03 
EHS liofilizado 6,66 ± 0,07 7,58 ± 0,12 27,89 ± 0,48 23,25 ± 0,47 34,62 ± 0,86 
 
Os resultados apresentados são médias ± desvio padrão (n = 3). 
 
O extrato bruto de tanase, obtido a partir do fungo Paecilomyces variotii, é um 
extrato complexo e pode apresentar ampla atividade enzimática, uma vez que não foi 
purificado. Assim, o extrato foi avaliado quanto à atividade de tanase e de β-glicosidase. 
A atividade de tanase para o extrato bruto de tanase foi avaliada para as formas 
livre e imobilizada da enzima, conforme o método de SHARMA; BHAT; DAWRA (2000). 
Para a determinação da atividade específica, a quantificação de proteínas foi realizada pelo 
método de BRADFORD (1976). Os resultados são apresentados na Tabela 2. 
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Tabela 2 Atividade enzimática de tanase do extrato bruto de Paecilomyces variotii. 
Atividade de tanase 
 Atividade total Atividade específica 
(U mg-1 proteína)  U mg-1 de enzima U/cápsula 
Enzima livre 0,53 - 3,05 
Enzima imobilizada - 0,07 4,37 
 
O processo de imobilização da enzima normalmente resulta em perda de atividade 
enzimática por unidade de massa da mesma. Assim, torna-se importante padronizar a 
atividade enzimática das formas livre e imobilizada, para que sejam utilizadas atividades de 
catálise equivalentes nos testes.  
Em nosso estudo, foi definido trabalhar com a atividade de β-glicosidase 
equivalente para ambas as enzimas. Assim, tanto a tanase obtida a partir de P. variotii e a 
enzima β-glicosidase comercial (naringinase from Penicillium decumbens), nas formas livre e 
imobilizada, foram avaliadas quanto à atividade de β-glicosidase segundo o método de 
MATSUURA; SASAKI; MURAO (1995). Os dados são apresentados na Tabela 3.  
 
Tabela 3 Atividade enzimática de β-glicosidase avaliada no extrato bruto de tanase e na β-
glicosidase comercial. 
 Atividade de β-glicosidase  
 Tanase β-glicosidase 
 Atividade total Atividade Específica 
(U mg-1 
proteina) 
 
Atividade total 
Atividade 
Específica 
(U mg-1 
proteína) 
 U mg-1 de 
enzima 
U/ 
cápsula 
U mg-1 de 
enzima 
U/ 
cápsula 
Enzima livre 4,24 -  24,54 0,81 - 
 
4,26 
Enzima 
imobilizada - 0,68 
 
42,60 - 0,67 
 
4,48 
 
Através dos resultados, pode-se observar que o extrato bruto de tanase possui 
atividade específica de β-glicosidase, ou seja, apresenta ação deglicosilante, sendo maior que 
a atividade observada para a β-glicosidase comercial analisada. Esta alta atividade 
deglicosilante já era esperada, uma vez que foi observada uma alta taxa de conversão das 
isoflavonas glicosiladas em agliconas pela enzima tanase nos ensaios preliminares. 
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CHAPTER 2
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Bioconversions of Isoflavones in Bioactive 
Compounds
Danielle B. Lopes, Lívia D. de Queirós, Amanda R.A. de Ávila, 
Naice E.S. Monteiro, Gabriela A. Macedo
State University of Campinas, Campinas, São Paulo, Brazil
1 Introduction
Phenolic compounds are a huge class of plant secondary metabolites, with the primary 
responsibility of the protection against stress or pathogen attack, and belonging to an 
extensive and heterogeneous group of chemical components that have one or more aromatic 
benzene rings (C6) with a conjugated aromatic system and one or more hydroxyl groups 
(Bhattacharya et al., 2010; Cheynier, 2012). They present a diversity of functions and 
structures, from relatively simple ones—such as vanillin, ferulic acid, caffeic acid, and 
gallic acid—through polyphenols, including lignans, flavonoids (anthocianins, flavonols, 
flavanones, isoflavones, and so on), stilbenes, ellagic acids, and many other polymers 
derived from these groups with more complex structures (Cheynier, 2012; Liu, 2013; Marín 
et al., 2015). In general, the phenolics’ classification is based on the quantity of carbon atoms 
present in the molecule composition (Harborne and Simmonds, 1964); and they can be in 
the free form or conjugated with acids, sugars, and other biomolecules as compounds that 
are water-insoluble (condensed tannins) or water-soluble (flavonoids, phenolic acids, and 
quinones) (Skrovankova et al., 2015). Because they have the ability to donate a hydrogen 
atom or an electron to a free radical and transform it into an inoffensive molecule, phenolic 
compounds are regarded as important composites that exhibit significant in vitro and in vivo 
antioxidant activities (Alu’datt et al., 2016; Skrovankova et al., 2015).
Even though the term polyphenol is habitually applied as a synonym of phenolic compound, 
it should be restricted to molecules that contain at least two phenolic rings on its structure 
(Quideau et al., 2011). Therefore, according to their structural features, phenolic compounds 
are distributed in several subgroups, as shown in Fig. 2.1. However, those commonly found 
in plants can be categorized into three main subgroups: phenolic acids, flavonoids, and 
nonflavonoids (Tsao, 2010). The first one, phenolic acids, is hydroxyl derivatives of aromatic 
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carboxylic acids which have a single phenolic ring and can be further divided into two main 
types, the benzoic acids and cinnamic acids, based on the C1─C6 or C3─C6 skeleton. 
The second subgroup, flavonoids, possesses a benzo-γ-pyrone structure, with two phenolic 
rings connected by a three-carbon bond that is usually an oxygenated heterocycle, and has 
a usual C6─C3─C6 scaffold structure. Finally, the third subgroup, nonflavonoids, which 
are molecules that possess phenolic rings with different reactive groups (nitrosyl, hydroxyl, 
SH, etc.), comprising stilbenes, phenyl alcohols, lignans, and chalcones (Varela et al., 2016; 
Zhang and Tsao, 2016).
Phenolic compounds are habitually synthesized and stored in the subepidermal layers of 
plant tissues exposed to pathogen attack and stress, and their concentrations depends on 
the season and vary according to the different stages of growth and development of plants 
(Clé et al., 2008; Ozyigit et al., 2007; Schmitz-Hoerner and Weissenbock, 2003). Numerous 
external and internal factors also influence the production of these compounds, including 
wounding, trauma, drought, and light exposure (Bhattacharya et al., 2010; Kefeli et al., 2003).
All these phenolic compounds are valuable and exhibit properties and functions dependent 
on its chemical structure and are associated to specific roles in plants and foods, hence 
their specific distribution. Some of them are very distributed while others are present in 
specific families of plants or observed just in determined plant organs or at particular 
development stages (Cheynier, 2012). They play valuable roles in the plants’ development, 
Figure 2.1: Schematic Classification of Phenolic Compounds.
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and provide structural integrity and scaffolding support to plants (Bhattacharya et al., 2010). 
Anthocyanins, for instance, are the pigments for plant organs that are red and blue. They are 
fairly usual in young leaves, having a dissuasive effect against herbivore insects. They are 
also found in ripe fruits and in flowers, playing an important function involved in processes 
of attraction in dissemination of seeds and in pollination (Gould, 2010). Other examples 
are flavonols that protect plant tissues against UV irradiation (Winkel-Shirley, 2002) 
and proanthocyanidins (also entitled condensed tannins) and hydrolyzable tannins (i.e., 
ellagitannins and gallotannins) that might contribute in defense of plants against fungi, 
herbivores, and viruses, due to their properties of protein tanning, being found in almost 
every plant tissue from earlier development phases (Haslam, 2007). All phenolic compounds 
are also important for the sensory and nutritional quality of vegetables, fruits (which 
contain mainly flavonoids, phenolic acids, tannins, and anthocyanins), and other plants, 
being responsible for the color of juices, red fruits, and wines, besides acting as substrates 
for enzymatic browning, and are likewise involved in flavor properties (Cheynier, 2012; 
Haminiuk et al., 2012; Lapornik et al., 2005; Tomas-Barberan et al., 2000). They also play 
an important role as a protective mechanism against biotic and abiotic stresses (Zhang and 
Tsao, 2016). Phenolic compounds, comprising both components of plants and the products 
made up from them during processing, also contribute to properties as taste and flavor. 
Moreover, they might contribute to health benefits related to the dietary ingestion of fruits 
and vegetables (Cheynier, 2012).
The distribution of phenolic compounds in food is quite diversified. Some families are 
widespread in the diet while others are restricted to a specific food or abundant in another 
one. Differences in molecular sizes or conformation may induce different behaviors, and 
in particular different abilities to establish molecular associations, with potential impact 
on technological, organoleptic (e.g., taste, color, haze), and health properties. Addressing 
the molecular weight and conformation distribution together with characteristic structural 
features is thus essential to establish relationships between polyphenols composition and 
food quality (Cheynier, 2012). However, diets rich in polyphenols have been related to many 
health benefits (Tsao, 2010).
Dietary polyphenols or dietary phenolics compose one of the most abundant and 
extensively disseminated groups of natural products in the plant kingdom. More than 
8000 phenolic structures are currently known, and among them over 4000 flavonoids 
have been identified (Bravo, 1998; Cheynier, 2005; Harborne and Williams, 2000; 
Tsao, 2010). Therefore, dietary polyphenols have received tremendous attention 
among food scientists, consumers, and nutritionists, since they are regarded as strong 
antioxidants that fulfill the antioxidant function of enzymes and vitamins as a protection 
against oxidative stress produced by excess reactive oxygen species (ROS). Thus, they 
are related to the prevention of degenerative diseases, mainly cancers and cardiovascular 
and neurodegenerative diseases (Tsao, 2010).
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Among all phenolic compounds and their importance in human health, this chapter will 
discuss the class of flavonoids with greater emphasis, especially the group of isoflavones, 
which present a pronounced estrogenic effect as one of its most important health benefits.
1�1 Isoflavones
Isoflavones belong to a large group of phenolic compounds named flavonoids that are present 
naturally in plant foods, like vegetables, legumes, fruits, and plant leaves. Flavonoids are 
the most plentiful polyphenols in our diet, representing approximately 70% of all those ones 
ingested. They are responsible for flavor, color, as well as nutritional and health benefits, 
and the capacity to act as an antioxidant is considered their most significant biological 
effect (Bandele and Osheroff, 2007; Karakaya and El, 1999; Kumar and Pandey, 2013; 
Skrovankova et al., 2015; Zhang and Tsao, 2016), besides have antidepressant and 
antiinflammatory activities, as demonstrated in animal studies (Ahmed et al., 2015; Freitas 
et al., 2014; Mai et al., 2015). Another important ability displayed by these compounds 
is the estrogenic activity find mostly in flavanones, flavones, chalcones, and isoflavones 
(Baber, 2013; Lethaby et al., 2007). All the biological effects of flavonoids are widely 
endorsed to their specific chemical structures, since the aromatic property and highly 
conjugated system with multiple hydroxyl groups transform them in good electron or 
hydrogen atom donors, neutralizing free radicals and other ROS (Zhang and Tsao, 2016).
As phytoestrogens that have similarities to animal estrogen, isoflavones possess similar 
structures to 17 β-estradiol hormones (i.e., hydroxyl groups in the C4 and C7 positions, 
similar to the molecule of estradiol) by binding selectively, though weakly, to receptors of 
mammalian estrogen (ER), having preference for estrogen receptor β (ERβ) to the estrogen 
receptor α (ERα), and conferring numerous good effects on the organism (D’Archivio 
et al., 2007; Ignati et al., 2011; Klejdus et al., 2007). Thus, these compounds become 
interesting mainly in medicinal, nutritional and cosmetic fields (Baber, 2013; Mostrom and 
Evans, 2012; Nemitz et al., 2016; Vitale et al., 2013; Zhang et al., 2016).
Isoflavones have a limited distribution in nature; however, they are found in relatively high 
concentrations in leguminous plants, especially soybeans, which present mainly aglycones 
as daidzein, genistein, glycitein, and their respective malonyl, acetyl, and glucoside 
conjugated forms (Chen et al., 2012; Nemitz et al., 2015). Red clover is considered other 
important natural source of isoflavones, containing the aforementioned ones of soybeans, 
and the free and conjugated forms of biochanin A and formononetin (Nemitz et al., 2016; 
Vacek et al., 2008). In Korea, leaves of Maackia fauriei, a plant that has its bark used as 
a natural dye, is another important source of isoflavones, being particularly abundant in 
five types, as follows: pratensein, 2′-hydroxygenistein-7-O-β-d-glucopyranoside, genistin 
and its aglycone genistein, and 2,3-dehydrokievitone (Yoon et al., 2016). All isoflavones 
have clinically important properties, such as antioxidant activities (de Queirós et al., 2016; 
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Szymczak et al., 2015), antiangiogenic effects (Krenn and Paper, 2009; Varinska et al., 2015; 
Yu et al., 2012), protective effects on bone loss (Tousen et al., 2016; Zheng et al., 2016), and 
reduction of menopausal symptoms (Hirose et al., 2016; Malik et al., 2016).
Aglycones, as mentioned earlier, are isoflavone forms that have a great ability to be absorbed 
in skin and in the gastrointestinal tract, and due to this characteristic possess a significant 
therapeutic potential when compared to their conjugated forms (Izumi et al., 2000; Nemitz 
et al., 2015). In general, they can be obtained by extraction from plant supplies or acquired 
in the synthetic and isolated forms (Nemitz et al., 2015; Rostagno et al., 2009). These 
compounds are absorbed more rapidly and in higher concentrations than their glucosides and 
acetyl and malonyl-glucoside forms in human intestines due to their lower hydrophilicity and 
molecular weight (Barnes et al., 2011; Guadamuro et al., 2015; Liu and Hu, 2002).
In the human body, isoflavone glucosides ingested can be partially hydrolyzed in the small 
intestine, liberating their aglycone complements (Day et al., 1998; Pascual-Teresa et al., 2006; 
Zubik and Meydani, 2003). This conversion is performed, generally, by the gut microbiota 
enzymes, which are responsible for the conjugated isoflavones hydrolysis, but the knowledge 
about the pathways and enzymes that contribute to the metabolism of these compounds is 
quite limited (Clavel and Mapesa, 2013; Kemperman et al., 2010). However, it is proposed 
that the transformation of glucosides to its aglycones happens in sequential steps that 
involve numerous enzymes produced by many microorganisms (Clavel and Mapesa, 2013; 
Sánchez-Calvo et al., 2013). The first step in isoflavones degradation involves aglycones and 
oligomers release through the action of esterases, gastric acid pH, and microbial glucosyl 
hydrolases. All these three activities can implement the sugar moiety hydrolysis, favoring 
and improving their absorption, which occurs in the upper small intestine by passive 
diffusion (Cantarel et al., 2009; Clavel et al., 2006; Kemperman et al., 2010). Approximately 
one-third of the aglycones formed will be absorbed through the gut epithelium as free 
isoflavone. The remaining portion continues in a second step in which microbial sulfatases 
and glucuronidases achieve the corresponding conjugation with sulfate and glucuronic acid, 
respectively. These conjugated compounds can be then excreted by both renal and biliary 
pathways; the later suffering enterohepatic recirculation, which leads to deconjugation, 
reabsorption, and further metabolism (Yuan et al., 2007). Lastly, in the third step, some 
microbial transformations of the polyphenolic core, like ring fission by Eubacterium ramulus 
(Clavel et al., 2006), produce metabolites that may have changed bioactivities with respect to 
human health, originating from compounds either of greater biological activity, such as equol 
[7-hydroxy-3-(4-hydroxyphenyl)-chroman] and 5-hydroxy equol, or inactive molecules, 
such as O-demethylangolensin (O-DMA) and p-ethylphenol, which will be absorbed in the 
intestinal lumen (Clavel and Mapesa, 2013; Setchell et al., 2002a).
Equol (C15H14O3) and O-DMA (C15H14O4) are specific metabolites from daidzein 
(Fig. 2.2), which have the unabsorbed portion hydrogenated, leading to the formation of 
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Figure 2.2: Daidzein Metabolism into Equol.
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dihydrodaidzein (DHD), and this compound is then converted into O-DMA or equol 
(Bowey et al., 2003; Chang and Nair, 1995; Yuan et al., 2007). Equol is formed exclusively 
by gut bacteria (Bowey et al., 2003; Decroos et al., 2005), and probably, by the joint action 
of a variety of bacteria (Atikinson et al., 2008; Setchell et al., 2005). The interindividual 
diversity within the intestinal microbial communities is determinant for the nature of the 
metabolites formed (Atkinson et al., 2004; Matthies et al., 2012; NAMS, 2011; Redruello 
et al., 2015). Only approximately one-third of humans harbor an intestinal microbiota that is 
able to transform daidzein into equol, who are named equol producers; O-DMA production 
is spread more widely and is not directly related to equol (Atkinson et al., 2004; Pawlowski 
et al., 2015; Utian et al., 2015; Wada et al., 2016). Many studies confirmed that equol is 
the most important product of the soy isoflavone daidzein (Atkinson et al., 2005; Setchell 
and Clerici, 2010; Taghizadeh et al., 2015; Tousen et al., 2016), occurring in two distinct 
enantiomeric forms, (R)-(+)-equol and (S)-(−)-equol, with different biological activities, and 
can also be converted into six other metabolites, mainly 3′-hydroxy-equol, and 6-hydroxy-
equol (Rüfer et al., 2006). They have attracted great interest due to their high affinity for 
ER, greater absorption efficiency, antioxidant properties, and anticarcinogenic effects 
(Guadamuro et al., 2015; Lin et al., 2016; Rodríguez-Morató et al., 2015; Zheng et al., 2014). 
Both (R)-(+)-equol and (S)-(−)-equol show very different performance in terms of their 
binding affinities with ERα and ERβ. In humans, metabolism of daidzein only produces 
(S)-(−)-equol (Setchell et al., 2005). This form has a higher affinity for binding to ERβ, 
whereas the (R)-(+)-equol shows preference for binding to ERα. (S)-(−)-equol also binds 
ERβ better than daidzein (Muthyala et al., 2004).
In recent decades, due to the growing interest in isoflavones and their metabolites, the use of 
biotransformation is increasing to avoid the limitation of human microbiota. Several methods 
have been developed to promote the bioconversion of these compounds by biotransformation 
using specific microorganisms or using enzymatic processes, as will be described in this 
chapter.
2 Biotransformation of Isoflavones by Human Gut Microbiota
Recognized as a “metabolic organ,” the human intestinal microbiota is densely populated 
by microorganisms, about 1014 strains live symbiotically in the digestive tract, possessing 
100 times more genes than the human genome itself (Putignani et al., 2014). This highly 
diverse ecosystem consists of aerobic, anaerobic, and facultative microorganisms, 
which are divided in resident or endogenous microbiota, represented by those that live 
adhered to mucous membranes of the gastrointestinal tract for a prolonged period. 
The transient or exogenous microorganisms are able to cross the gastrointestinal 
barrier. These microorganisms live accommodated in different anatomical regions of 
the gastrointestinal tract that have different pH conditions, digestion stream, substrate 
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availability, and oxygen tension. Numerically a more significant population inhabits the 
large intestinal region, characterized by a slow digestive flow, neutral pH to slightly acidic, 
and therefore dominated by strict anaerobes. The small intestine has a considerably smaller 
amount of microorganisms, due to the environmental conditions that are not as favorable 
as the relatively short digestive tract (3–5 h), besides have high concentration of bile salts 
(Flint et al., 2012).
Even though there have been more than 50 phyla of gut bacteria labeled up to now, 
the human intestinal microbiota, in adulthood, is dominated by mainly two phyla, that 
are: Bacteroidetes and Firmicutes. The other ones like Actinobacteria, Proteobacteria, 
Cyanobacteria, Verrucomicrobia, and Fusobacteria occur in minor amounts. A thick and 
physicochemically complex mucus layer separates the intestinal epithelium from the lumen. 
The specific microbiota present in the intestinal lumen distinguishes significantly from the 
microbiota attached and embedded in this mucus layer as well as the microbiota present in the 
immediate proximity of the epithelium. Bacterial genera like Bifidobacterium, Enterococcus, 
Bacteroides, members of the Enterobacteriaceae, Streptococcus, Lactobacillus, 
Ruminococcus, and Clostridium are commonly found in intestinal contents and faeces; while 
Enterococcus, Clostridium, and Lactobacillus are detected in the mucus and epithelial crypts 
of the small intestine (Rodríguez et al., 2015; Serikov et al., 2010).
The microbial colonization of the intestinal human occurs instantaneously at birth, after 
the passage through the birth canal, when the child has the first contact with the bacterial 
inoculum from mother. Indications that the contact with microorganisms during birth 
impact the intestinal microbiota development, come from the statement that the mothers’ 
vaginal microbiota of their and the newborn intestinal microbiota demonstrate pronounced 
similarities (Mandar and Mikelsaar, 1996). Furthermore, newborns brought through 
cesarean section possess distinct microbial compositions when compared with vaginally 
brought newborns (Huurre et al., 2008). Afterward, his own microbiota becomes formed 
according to the environment, diet, and lifestyle that the infant is exposed to, but an initial 
fetal colonization may also occur. Neu and Rushing (2011) reported the existence of a 
similar microbial community residing in the meconium of some premature babies and the 
amniotic fluid of their mothers. The human microbiota tends to be stable throughout life, but 
can change abruptly in some diseases, such as cancer and obesity, or even nonpathological 
conditions, such as pregnancy, menopause, and aging itself (DiBaise et al., 2012; Gagnière 
et al., 2016; Nakatsu et al., 2014).
Understanding the composition and functional capacity of the intestinal microbiota is 
very important once it is known that the gut microbiome plays an important role in human 
health and prevention of some diseases (Guinane and Cotter, 2013). The manipulation of 
these microorganisms by the use of antibiotics, supplementation with probiotics, prebiotics, 
and symbiotics or reconstitution of bacterial populations by fecal transplantation can be 
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considered as good strategies to improve the host health (Gareau et al., 2010; Marchesi 
et al., 2016; Preidis and Versalovic, 2009). Severals factors, including diet, inflammatory 
state of the host, aging, host genetics, and environmental factors can influence the intestinal 
microbiota composition (Buddington and Sangild, 2011; Musso et al., 2010; Walsh 
et al., 2014).
Considering the influence of diet on microbiota composition, some studies have showed 
the association between the dietary intake and distinct microbial communities (Claesson 
et al., 2012; David et al., 2013; Turnbaugh et al., 2008; Wu et al., 2011). So, understanding 
how diet influences microbial profiles becomes very important, because ingestion of foods 
can alter the gut microbiota. Macronutrients have a great impact on the formation of gut 
microbiome, mostly due to the formation of short-chain fatty acids as final products of 
carbohydrates and proteins, which provide energy to the enterocytes by oxidation (Walsh 
et al., 2014).
Minor dietary constituents, such as polyphenols, found in many foods including soybean, 
tea, grapes, and berries, may have a significant influence on microbial populations (Martin 
et al., 2012; Tzounis et al., 2011). Moreover, individual differences in microbiota compositon 
may result in different capacities for polyphenol bioconversion with potential consequences 
for health (Gross et al., 2010). There is an extensive literature about the health benefits 
attributed to a group of these phenolics compounds, classified as isoflavones, such as 
hypolipidemic (Cavallini et al., 2016; Potter et al., 1998) and antitumor effects (Fournier 
et al., 1998), cardiovascular protection (Erdman, 2000), estrogen mimetics capacity in 
menopause woman (Han et al., 2002; NAMS, 2015) and in prevention of osteoporosis 
(Messina et al., 2001; Pawlowski et al., 2015). However, it is known that, besides the regular 
inclusion of these compounds in the diet, it is also necessary that its chemical form presents 
a biological activity and bioavailability to be able to modulate the intestinal microbiota 
(Queipo-Ortuño et al., 2012).
The glycosylated isoflavones ingested in the diet can be absorbed, even in small amounts 
(5%–10%) by the small intestine after deconjugation and deglycosylation reactions. After 
initial absorption, phenolic compounds undergo biotransformation through oxidation, 
reduction, and hydrolysis reactions and, after that, the conjugation reaction occurs primarily 
in the enterocytes and extends into hepatocytes, generating water-soluble compounds that are 
distributed throughout the body, the systemic circulation, and are also excreted through urine. 
However, most (90%–95%) of dietary isoflavones are not absorbed in the small intestine, 
going to the large intestine where they will serve as a substrate for the intestinal microbiota, 
which through enzymatic reactions of deglycosylation, dehydroxylation, and demethylation 
with main action of the β-glucosidase enzyme will produce different metabolites in 
physiological amounts (Cardona et al., 2013). The production of some metabolites as equol 
and O-DMA, produced from the conversion of the aglycone daidzein to DHD, may vary 
64 Chapter 2
between individuals due to differences in gut microbiota and influence of other components 
of the diet (Gaya et al., 2016).
The consumption of isoflavones can modulate the microbiota, and the intestinal microbiota 
may also be modulated by consuming probiotics to use the isoflavones more efficiently. This 
modulation of the intestinal microbiota may also be performed by commercial probiotics, 
such as members of the Lactobacillus and Bifidobacterium that are generally used in 
association for the sake of obtaining synergistic effect (Walsh et al., 2014).
Some microorganisms present in the human microbiota have been reported to be responsible 
for the metabolism of isoflavones. Table 2.1 shows some of them cited by Clavel and 
Mapesa (2013), Setchell and Clerici (2010), and Selma et al. (2009), as capable of converting 
daidzein to equol (in isoform (S)-(−)-equol, which have estrogenic activity), and O-DMA or 
DHD, molecules with minor activity. The equol molecule had its first citation in the research 
of Xu et al. (1995), and his discovery in urine did arouse clinical and nutritional interest in 
Table 2.1: Intestinal bacteria capable of converting the isoflavone daidzein in metabolites.
Metabolitesa Bacterial Strains References
DHD Lactococcus sp. 20-92 Shimada et al. (2010)
Strain HGH6 Hur et al. (2002)
Strain TM-40 Tamura et al. (2007)
Equol Adlercreutzia equolifaciens FJC-B9T Maruo et al. (2008)
Bacteroide ovatus spp. Ueno and Uchiyama (2002)
Bifidobacterium spp. Raimondi et al. (2009)
Bifidobacterium spp. Tsangalis et al. (2002)
Eggerthella sp. YY7918 Yokoyama and Suzuki (2008)
Enterococcus faecium EPI1 Decroos et al. (2005)
Finegoldia magna EPI3 Wang et al. (2005)
Lactobacillus mucosae EPI2 Minamida et al. (2006)
Lactobacillus sp. Niu-O16 Wang et al. (2007)
Ruminococcus productus Blair et al. (2003)
Slackia equolifaciens DEZ Jin et al. (2008)
Slackia isoflavoniconvertens HE8 Matthies et al. (2009)
Slackia sp. NATTS Tsuji et al. (2010)
Strain Julong 732 Wang et al. (2005)
Streptococcus intermedius spp. Setchell et al. (2002a)
Veillonella spp. EP Hur et al. (2002)
Veillonella spp. EP Schoefer et al. (2002)
O-DMA Clostridium spp. HGHA136 Hur et al. (2002)
Eubacterium ramulus Schoefer et al. (2002)
Eubacterium ramulus wK1 Schoefer et al. (2002)
Strain HGH136 Hur et al. (2002)
Strain SY8519 Yokoyama and Suzuki (2008)
aFor the final metabolite equol the definitive structure was not determined in most papers, but it can be assumed that in all 
cases the product is the (S)-(−)-equol enantiomer by its activity.
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phytoestrogens, but the first bacteria associated with the production of this metabolite (Julong 
732) was only isolated years later by Wang et al. (2005) and since then other strains began to 
be related equol production by human microbiota.
The ability to produce equol from intake of isoflavone has a big interindividual variability 
due to the different types of the gut microbiome that are responsible for metabolizing 
and increase the bioavailability of phenolic compounds, such as the isoflavones (Timan 
et al., 2014). It is known that the profile of the intestinal microbiota is critical to metabolism 
and increased bioavailability of isoflavones; some studies have shown that isoflavones 
administration in association with probiotics are able to optimize the performance of these 
phytoestrogens (Benvenuti and Setnikar, 2011; McCabe et al., 2015; Palacios et al., 2008; 
Piazza et al., 2007).
Probiotics are defined by FAO (Food and Agriculture Organization) as “live microorganisms 
which when administered in adequate amounts confer health benefits on the host” 
(FAO, 2001). In general, these probiotics behave with a shared mechanism of creating 
a more favorable gut environment, and support a healthy digestive tract and a healthy 
immune system. However, each bacterial strain are genetically different and possess distinct 
functionalities, which highlights the requirement to not use the general term probiotics, when 
describing mechanisms of action, but try to specify the strains to the desired function in the 
organism (Reid, 2016).
Among the bacterial strains used as probiotics, there are members of lactic acid bacteria, as 
the Lactobacillus spp., Enterococcus spp., and Bifidobacterium spp. genera, that stand out 
for being a group of bacteria usually used in treatment of several gastrointestinal disorders, 
with antiinflammatory properties, that modulate the production and release of cytokines and 
antimicrobial compounds as organic acids, lactic and acetic acid, bacteriocins, acetaldehyde, 
hydrogen peroxide, and other low-molecular-mass compounds with antimicrobial activity 
(Suskovic et al., 2010).
Others probiotic strains, such as Escherichia spp., represented by the nonpathogenic 
E. coli Nissle 1917 (Nzakizwanayo et al., 2015), and Bacillus spp., which together 
with Saccharomyces yeast has been widely used for its probiotic effects, have been 
recommended for their health effects, and although no official recommendation about a 
standard dose of a probiotic strain or combination of probiotic strains has been established, 
these microorganisms often can be used in clinical practice in doses that are similar to 
gastrointestinal indigenous bacterial population (FDA, 2004).
Beyond the isolated use of probiotics, a widely used approach is the association of probiotics 
strains with prebiotic components, such as inulin and fructooligosaccharides, which are 
substrate promoters of selection and growth of certain microorganisms, and which can cause 
further significant changes in the gastrointestinal environment due to the resultant symbiosis 
(McCabe et al., 2015).
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The preexisting knowledge about the role of gut microbes on the metabolism of isoflavones 
allows that the administration of probiotic and prebiotics, associated or isolated, may be able 
to supply better utilization of the useful plant compounds and to produce more beneficial 
byproducts. Probiotics can play their role, either directly acting on the phytonutrients or 
changing the activity of the gut microbiota and their enzymes to enhance their metabolizing 
capacity, and therefore the selection of strains with high activity of β-glucosidase enzyme is 
important (Selma et al., 2009).
Aware that the isolated use of probiotics or association between probiotics and prebiotics can 
optimize the polyphenols metabolism, Piazza et al. (2007) investigated the influence of fibers, 
like inulin, in concentrations of isoflavones on plasma of healtful postmenopausal women, by 
the consumption of isoflavones with and without addition of inulin. The study continued for 
21 days and showed that plasma concentrations of the aglycones genistein and daidzein were 
higher (91 and 38%, respectively) in subjects consuming the isoflavone administered with 
inulin when compared to those in which the formulation was not increased inulin, suggesting 
facilitated absorption by the presence of the fiber.
The bioavailability of orally ingested isoflavone also can be increased by intake associated 
with probiotic microorganisms, such as Lactobacillus spp. and Bifidobacterium spp., as 
demonstrated by Benvenuti and Setnikar (2011) in a study that evaluated the bioavailability 
of isoflavonas, genistein associated with probiotics was higher than isoflavone administered 
alone, showing that the probiotic potential from the bacterial association between 
Bifidobacterium and Lactobacillus has been utilized to the maximum extent.
The probiotic intervention can be used in situations where phenolic compounds are already 
suggested in the treatment of climacteric symptoms, as proposed by a study accomplished 
by Palacios et al. (2008). They assessed the perceived efficacy of the combination of a soy 
extract probiotic in menopausal women, demonstrating that after 6 months of treatment was 
73% reduction in menopausal symptoms. This result was attributed to compounds derived 
from the isoflavone probiotic combination, which when metabolized produce substances such 
as lactic acid, which to acidify the intestinal medium promotes absorption of minerals, such 
as calcium, iron, and phosphorus, important for bone mineralization. In addition, the enzymes 
produced as lipases and proteases helped the digestive process and glucosidases, which 
permit the breakage of the glucosidic bonds of isoflavones, rendering them bioavailable.
Similarly, Cohen et al. (2007) evaluated the administration of 1012 UFC Lactobacillus 
GG in combination with isoflavones, yielding 40% reduction in the urinary excretion of 
isoflavones, which suggests that the probiotic prevented deconjugation/degradation of the 
phenolic compound, increasing its residence blood. In contrast, Bonorden et al. (2004) used 
for 2 months the association of probiotics Lactobacillus acidophilus and Bifidobacterium 
longum (109 UFC) to the consumption of soy (soy protein isolate) for 4 days in women in 
premenopause, found no significant increase of excretion of equol; perhaps the low level 
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of probiotic bacteria and rapid dietary intervention has undermined the study and caused 
underestimated results.
The symbiotic association of prebiotics to microorganisms was studied by Timan et al. 
(2014), which compared the effect of isolated consumption of a simple soy beverage to 
the use associated with a soymilk that was fermented by Lactobacillus paracasei with the 
presence of inulin on the pharmacokinetics and oral bioavailability of isoflavones in healthful 
women during the postmenopausal period. Results of this study showed that the consumption 
of soy beverage then symbiotic oral administration of a conventional soy beverage 
isoflavones promoted greater bioavailability than that obtained with a nonisolated ingestion of 
fermented soymilk (conventional).
One of the purposes of combining probiotic to isoflavone is to optimize production of equol; 
this conversion may be particularly important, because equol has significantly enhanced 
antioxidant activity compared with daidzein or other isolated isoflavone, and may increase 
potential health benefits (Atkinson et al., 2005). The production of equol has usually been 
associated with Coriobactericeae family, although there are reports of production of this 
metabolite by strains of Bifidobacterium—B. breve 15700, B. longum B536, B. animalis, and 
B. pseudolongum (Elghali et al., 2012; Tsangalis et al., 2002)—and even though the genus is 
known as a producer of β-glucosidase, it is also known that some species metabolize daidzin 
to daidzein without subsequent production of equol, demonstrating the importance of the 
selection of strains for the purpose of producing metabolite.
The production of equol is of special interest because not all individuals have the intestinal 
microbiota required to produce it, so the identification of bacteria producing equol can 
enable a dietary supplementation of these probiotics to people so that they become equol 
producers or even using these strains in food products to directly offer (S)-(−)-equol, as 
proposed by Ishiwata et al. (2009), which offered a supplement (S)-(−)-equol base for 
Japanese women aged 40–59 years with regular intake of isoflavones limited to 20 mg/day, 
grouped in producing and nonproducing equol, the test was 12 weeks, the (S)-(−)-equol 
supplement was supplied at a dosage of 10 and 30 mg/day compared with placebo, and a 
survey of menopausal symptoms and profile of mood at the beginning and end of the study 
was conducted. The results showed that compared to the placebo, dosage of 30 mg of equol 
per day gave lower levels of anxiety, depression, and fatigue, and increased feelings of vigor, 
suggesting that supplementation of (S)-(−)-equol can be an interesting alternative therapy for 
menopausal women, including producing no equol.
Essential for the metabolism of isoflavones, β-glucosidase activity has also been associated to 
the genus Lactobacillus spp., as demonstrated in the study of Hati et al. (2015) that used six 
strains of Lactobacillus, as follows: L. rhamnosus (C6 and C2), L. rhamnosus (NCDC19 and 
NCDC24), and L. casei (NCDC17 and NCDC297) in a soymilk fermentation. They observed 
an increase in the β-glucosidase activity and a significant decrease in glucosides toward the 
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formation of aglycones after 12 h of fermentation with the selected cultures, demonstrating 
that among the strains analyzed, L. rhamnosus C6 demonstrated the best response for 
enzyme activity and bioconversion of isoflavones. The other strains also had good responses, 
indicating that the Lactobacillus genus has great potential fermentation to produce food with 
functional purpose, making Lactobacillus and Bifidobacterium relevant for a modulatory role 
in a healthy intestinal microbiota.
Thus, consumption of isoflavones with the addition of probiotics can optimize the action of 
these phytoestrogens to improve phenolic profile and antioxidant activity, as described by 
Cavallini et al. (2016). To investigate the association of a soy product fermented by probiotic 
Enterococcus faecium CRL 183 and Lactobacillus helveticus 416 on cardiovascular risk 
markers in men with moderate hypercholesterolemia, Cavallini et al. observed decrease in 
total cholesterol and LDL-C inversely correlated with equol production, suggesting a logical 
association between isoflavones and probiotics, few tested yet as an alternative route in the 
use of phytoestrogens in maintaining health, not only as a hormone replacement, but also in 
other metabolic conditions.
3 Microbial Bioconversion of Isoflavones
In the past decade several studies have shown that the interest in soybeans and soy-based 
products has grown significantly due to their reported nutritional and health-promoting 
effects. The main bioactive compound of soybean, isoflavones, has been a focus of special 
attention due to their weak estrogenic capacity and antioxidant activity (Chen et al., 2012).
In general, in nonfermented soy foods and unprocessed foods, isoflavones are present 
mainly as glucoside form and rarely as aglycone forms, whereas in fermented and processed 
foods the aglycones are predominant (Tsangalis et al., 2003; Wang et al., 2006b; Wang and 
Murphy, 1994). The glucoside isoflavones are very poorly absorbed in the small intestine of 
healthy adults because of their higher hydrophilicity and molecular weight (Brown, 1988; 
Hur et al., 2000). Thus, their bioavailability requires the hydrolysis of glucosides into 
aglycones forms and subsequent metabolism (Setchell et al., 2002a,b). Therefore, to enhance 
the biological activity and antioxidant capacity of soy products, the concentration of bioactive 
isoflavone aglycones has to be increased (Landete et al., 2014; Selma et al., 2009).
Since soybeans predominantly present the conjugated forms of isoflavones, the hydrolysis of 
glucoside isoflavones via the action of β-glucosidase from bacteria has been the method most 
often described to increase the concentration of bioactive isoflavones in soybeans or soy-
based-foods (Izumi et al., 2000).
β-Glucosidases (b-d-glucoside glucohydrolases; EC 3.2.1.21) are enzymes that catalyze the 
hydrolysis of terminal nonreducing residues in β-glucosides (Cairns and Esen, 2010; Kaya 
et al., 2008; Xue et al., 2009). This enzyme have attracted considerable attention due to their 
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several biotechnological applications including food detoxification, flavor enhancement of 
beverages, biomass conversion, the production of fuel ethanol from agricultural residues, 
and also, the conversion of glycosylated isoflavones in their aglycone forms during soybean 
process (Cairns and Esen, 2010; Coughlan, 1985; Gueguen et al., 1996; Matsuura and 
Obata, 1993; Pal et al., 2010; Song et al., 2011; Yeom et al., 2012).
Many researchers has proved that the transformation of glucoside to aglycones isoflavones 
using β-glucosidases produced by microorganisms can increase the concentration of 
bioactive isoflavones in soy foods, such as soy-based fermented food (Horri et al., 2009; 
Yang et al., 2009; Xue et al., 2009). Therefore, β-glucosidases produced by gut bacteria 
that colonize the small and the large intestine show a highly commercial value since they 
are considered to be the key enzyme for the bioconversion of glucosides to bioactive 
aglycones in soy products (Setchell et al., 2002a,b). However, the individual differences 
in the composition of the gut microbiota can lead to a high variability in the bioconversion 
of isoflavones (Setchell and Cassidy, 1999). There are some differences in the capacity of 
individual bacterial strains or mixed cultures to produce endogenous β-glucosidase (Cho 
et al., 2012; Landete et al., 2014; Otieno et al., 2006; Raimondi et al., 2009; Wei et al., 2007).
The different degrees of β-glucosidase activity during soymilk fermentation can be due to 
type of microorganism, bacterial characteristics, the substrate type, the growth medium, 
and the presence of isozymes (Chien et al., 2006; Matsuura and Obata, 1993; Tsangalis 
et al., 2002). There are significant differences between the actions of bacterial strains. 
Some studies was carried out to select cultures, individually or in combination, based on 
comparison of their β-glucosidase activities during the soymilk fermentation (Donkor 
and Shah, 2008; Hati et al., 2015; Lee et al., 2015). In general, the higher β-glucosidase 
activity of some culture shows more bioconversion of the glucoside to aglycone isoflavones 
(Lee et al., 2015). Probiotics, as already mentioned, have several beneficial effects on 
human health. Recent studies have associated probiotics with several health-beneficial 
effects, such as improvement of gastrointestinal disorders, stress alleviation of immune 
system, antihypertensive properties, anticarcinogenic effects, and antimutagenic properties 
(Liong, 2007; Lye et al., 2009). It has been shown that the probiotic microorganisms possess 
β-glucosidase activity and play important roles in the bioconversion of glucoside isoflavones 
during soymilk fermentation (Jeon et al., 2002; Marazza et al., 2009; Matsuda et al., 1994; 
Otieno et al., 2005).
Probiotic strains including members of the genera Lactobacillus and Bifidobacterium are 
known as the most common type of bacteria exhibiting probiotic properties and commonly 
inhabit the healthy gut (Liong, 2007; Saxelin et al., 2005). These microorganisms, which 
are generally recognized as safe and are traditionally used to ferment raw materials, play 
essential roles in the intestinal hydrolysis of numerous β-glucoside compounds (Aguirre 
et al., 2008).
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The fermentation processes using lactic acid bacteria and bifidobacterium are widely used 
to improve the nutritional and functional value of soy-based foods (Yeo and Liong, 2010). 
During the fermentation process using a soy matrix, the lactic acid bacteria are able 
to improve the bioavailability and conversion rate of isoflavones by the action of the 
β-glucosidase (Rekha and Vijayalakshmi, 2010; Rodríguez-Roque et al., 2013). Moreover, 
these bacteria also are able to eliminate antinutritional and flatus-producing factors in 
soybeans (Wang et al., 2003; Wang et al., 2006b). Therefore, the use of lactic acid bacteria 
to ferment soybeans has been a good alternative to improve the quality, nutritive value, and 
some sensory properties of soy-based-foods (Wang et al., 2003; Wang et al., 2006b; Yeo and 
Liong, 2010).
It has been reported that some probiotic organisms, including L. acidophilus, Lactobacillus 
casei subsp. rhamnosus, Bifidobacterium breve, and Bifidobacterium bifidum strains have 
great potential to enrich bioactive isoflavones aglycones in soymilk fermentation for the 
development of functional fermented soy-based products (Bordignon et al., 2004; Chien 
et al., 2006; Hati et al., 2015).
In a study performed by Lee et al. (2015), black soymilk was fermented at 37°C for 24 h, 
with single and mixed cultures to identify the best starter culture to bioconvert the isoflavone 
glucosides to aglycone in this matrix. L. acidophilus ATCC 4356, Lactobacillus plantarum 
P8, and Streptococcus thermophilus S10 were used in this study. The assay of β-glucosidase 
activity was used to compare the performance of the different cultures. The results showed 
that the S. thermophilus S10 single culture had higher β-glucosidase activity than mixed 
cultures, resulting in the highest aglycone content and best antioxidant effect, compared 
with controls. Similar results was found in a study where a single culture of S. thermophilus 
BCRC 14085 showed higher β-glucosidase activity and a rapid increase in aglycone activity 
compared to a mixed S. thermophilus and bifidobacteria (Bifidobacterium infantis BCRC 
14633, B. longum B6) after 12 h of fermentation of soymilk (Chien et al., 2006).
Another study described the relation between the effectiveness of β-glucosidase-producing 
by the probiotic Lactobacillus cultures and the increase in the biotransformation of 
isoflavones in fermented soymilk medium (Hati et al., 2015). The six strains of lactobacilli 
studied (L. rhamnosus C2 and C6, L. rhamnosus NCDC24 and NCDC19, and L. casei 
NCDC297 and NCDC17) used to ferment the soymilk at 37°C for 12 h, showed variable 
β-glucosidase activity. All six β-glucosidase-producing strains were able to biotransform 
the glycones isoflavones to aglycones forms during the fermentation period. However, each 
culture produced significantly different rates of bioconversion of isoflavones and the highest 
β-glucosidase activity as well as isoflavone bioconversion during the fermentation period 
was attributed to Lactobacillus rhamnosus C6 strain (Hati et al., 2015). A study described 
by Rodríguez de Olmos et al. (2015) demonstrated the ability of Bifidobacterium longum 
and Lactobacillus paracasei subsp. paracasei to improve soybean substrate in a solid-state  
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fermentation as a possible strategy for the elaboration of new soy food with enhanced 
functional and nutritional properties.
The conversion of isoflavone glucosides to aglycones using β-glucosidases from the 
microorganisms has been described by many researchers; however, in some cases, the 
hydrolysis ability of these β-glucosidases is not sufficient once the conversion efficiency 
of this enzyme can be reduced due to their sensitive to glucose inhibition (Bordignon 
et al., 2004; Chien et al., 2006; Hati et al., 2015; Lee et al., 2015; Rodríguez de Olmos 
et al., 2015). So, in a study performed by Li et al. (2012), the use of novel β-glucosidase with 
high hydrolyzing ability obtained by molecular cloning using unculturable microorganisms 
of environment was investigated. The authors identified a novel β-glucosidase (Bgl1269) 
that showed high hydrolyzing ability for soybean isoflavone glucosides and also exhibited a 
very high tolerance to glucose. This new enzyme, obtained from a metagenomic library of 
mangrove soil by activity-based functional screening, was overexpressed in Escherichia coli 
and purified. The excellent enzymatic properties make this new enzyme a good candidate of 
β-glucosidases in the production of soybean with bioactive isoflavone aglycones.
Soybeans have higher polyphenols content that are known for high antioxidant capacities 
(McCue et al., 2004; Pratt and Birac, 1979). However, when the polyphenols compounds 
have a large molecular weight the antioxidant capacity can be lower, as is the case of 
glucosides isoflavones in soybeans. The intestinal bacteria are able metabolizes the complex 
polyphenols into smaller molecules which are generally better absorbed in the intestine and, 
consequently, show higher antioxidant capacity (Manach et al., 2005; Selma et al., 2009). 
Once the isoflavones are the majority phenolic compounds in soybean (Pratt and Birac, 1979), 
some studies indicates the use of β-glucosidase-producing cultures to biotransform the 
isoflavone glucoside to aglycone, resulting in the improvement of the antioxidant activity of 
fermented food products (Chun et al., 2007; Pyo et al., 2005).
A study described by Cheng et al. (2013) demonstrated that solid-state fermentation with 
three filamentous fungi including Rhizopus oligosporus (BCRC 31996), R. oligosporus 
(NTU-5), and Rhizopus oryzae (BCRC 30894) can significantly increase the total phenolic 
and isoflavone aglycones content as well as antioxidant activity of black soybean samples. 
The results obtained from this study showed that the activity of β-glucosidase produced by 
the cultures increased with fermentation time and resulted in accumulation of isoflavone 
aglycones. Marazza et al. (2009) also reported that the fermentation process by Lactobacillus 
rhamnosus CRL981 as a β-glucosidase producer had a great potential to enrich bioactive 
isoflavones and, consequently, enhanced the antioxidant capacity in fermented soymilk.
The use of lactic acid bacteria and Bifidobacteria as functional starter culture to increase the 
antioxidant properties during soybean fermentation was also demonstrated in a study by Pyo 
et al. (2005). In this study the fermentation of soybean with four bacterial strains producing 
β-glucosidase (Bifidobacteria thermophilum KFRI 00748, Lactobacillus delbrueckii subsp. 
72 Chapter 2
latis KFRI 01181, Lactobacillus plantarum KFRI 00144, and Bifidobacteria breve K-10) 
resulted in a significant improvement of the antioxidant capacity of a fermented soybean 
product due to the increased concentration of bioconverted isoflavone aglycones.
de Queirós et al. (2016) evaluated the capacity of three new biotechnological process to 
increase the bioactive properties of soymilk, and showed that one of the biotransformation 
processes, based on soymilk fermentation by probiotic lactic bacteria, caused an increase in 
the antioxidant capacity of soymilk and bioactive isoflavone aglycones. The fermentation 
process of soymilk using, simultaneously, Streptococcus ssp. thermophilus (YF-L811), 
Lactobacillus delbrueckii ssp. bulgaricus (LB-340), Bifidobacterium animalis ssp. lactis 
(Bb-12), and Lactobacillus acidophillus (LA-05) was performed at 37°C for 12 h in 
anaerobic conditions. The results showed that after the fermentation process the total phenolic 
content improved around 2.5 times, subsequently the fermentation process, compared with 
the standard, suggesting that the fermentation process improved the release of phenolic 
compounds of soymilk. Moreover, the antioxidant capacity of fermented soymilk increased 
significantly by around 2.2 and 2.1 times by the ORAC and DPPH assays, respectively. The 
β-glucosidase activity inherent in the microorganisms used in this study was proved by the 
reduction of the concentrations of glucosides daidzin and genistin and increase of aglycones 
daidzein and genistein after the fermentation process.
Based on these facts, the microbial bioconversion of isoflavones have great potential 
to develop functional fermented soy-based products enriched with aglycone forms of 
isoflavones, with enhanced health-promoting properties.
4 Enzymatic Bioconversion of Isoflavones
Biotransformation of phenolic compounds has been presented as a good alternative to 
reduce the variability in digestive efficiency of isoflavones. The term biotransformation can 
be defined as a specific modification of chemical structures performed by cells or isolated 
enzymes in a process comprising one or two reaction steps. In fermentation, unlike noted in 
biotransformation, the substrate is converted to a product through a complex cell metabolic 
pathway and the product obtained has not often structural resemblance with the substrate 
(Castro and Anderson, 1995; Lilly, 1994).
Natural polyphenols frequently occur in chemical forms as glucosides, esters, and polymers, 
which could affect their absorption and metabolism. Thereby, biotransformation in the 
gastrointestinal tract plays a crucial role in the bioavailability of these compounds (Scalbert 
and Williamson, 2000). As technological alternatives, bioprocesses such as fermentation and 
enzymatic hydrolysis of plant sources and their derivatives products appears to be an attractive 
mode to improve the functional activity of phenolic compounds by enhance the concentration 
of free phenolics from their glucosides or other conjugates (Georgetti et al., 2009).
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In foods, isoflavones are found mainly in the glucoside form and in minor concentrations as 
aglycones (Izumi et al., 2000). The glucoside form is poorly absorbed in the small intestine 
and less bioactive than aglycone form due to the high molecular weight and hydrophilicity 
(Piskula et al., 1999). According to Setchell et al. (2002b) isoflavone β-glucosides do not 
cross the intestinal barrier of healthy humans, and their bioavailability requires preliminary 
hydrolysis of the sugar moiety by intestinal β-glucosidase for uptake by peripheral 
circulation. Notwithstanding, the variation in metabolism of isoflavones is an important factor 
to be considered, because it seems to differentiate considerably between individuals, since 
there is a variability in digestive efficiency of these phytoestrogens by gut microbiota, and 
also by the influence of many dietary components, such as food matrix, diet, fermentation, 
and intestinal transit time (Larkin et al., 2008). For this reason, the bioconversion 
of isoflavone glucosides to aglycones forms in soy-based products can increase the 
bioavailability and bioactivity of these compounds and consequently improve the isoflavone-
associated health benefits (Ghafoor et al., 2013).
The composition and content of isoflavones in soy-based products depend on the techniques 
used in processing, such as cooking, heat treatment, fermentation, and enzymatic hydrolysis 
(Wang and Murphy, 1994). Processing soybean into different food products results in 
changes in the chemistry and biochemistry of their constituents. Fermented soy foods, such 
as tempeh and miso, contain the aglycone forms, whereas nonfermented soy foods, such as 
soymilk, soy flour, tofu, isolated soy protein, and soy-protein concentrate contain the β-
glucoside conjugates (Ghafoor et al., 2013).
Researchers suggest that different processing methods promote chemical modifications 
on soy isoflavones and may change their respective rates of absorption and metabolism 
independently of each individual’s microbiota. Therefore, the enzymatic biotransformation is 
an interesting option that have been explored in studies aiming the deglycosylation of these 
compounds for better absorption (Chen et al., 2013; Park et al., 2001; Yang et al., 2009).
The bioconversion reaction of isoflavone-glucoside into isoflavone-aglycone can be 
enhanced by the use of enzymes in isolated form, free or immobilized, such as β-glucosidase. 
β-glucosidase is an enzyme that hydrolyzes β-1,4 glucosidic linkages of cellobiose and alkyl 
glucosides. It can be produced by microorganisms, such as filamentous fungi, yeasts, and 
bacteria, or may be extracted from fruits and plants. The interest in β-glucosidase enzyme 
has increased due to their participation in various biotechnological processes, with potential 
applications in food industry (González-Pombo et al., 2011; Palmeri and Spagna, 2007). 
In fermentation substrates, for example, it has been observed an association of fungal 
β-glucosidase activity with increasing total phenolic content, suggesting that this enzyme 
releases the aglycone forms and even increases the antioxidant activity (Randhir et al., 2004).
In a study conducted by Park et al. (2001), isoflavones extracted from defatted soy flour were 
evaluated for aglycones content after a heating process, at different temperatures, and reaction 
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with β-glucosidase enzyme obtained from Aspergillus oryzae. The results demonstrated that 
applying heat treatment at 121°C and the reaction combined with β-glucosidase converted 
the majority of isoflavones, initially in the form of glucosides and malonyl glucosides, 
to aglycone form. Furthermore, soy flour samples showed higher antioxidant activity 
after reaction with β-glucosidase by cooxidation of β-carotene/linoleic acid assay. From 
this finding, other studies have demonstrated the action of β-glucosidase enzyme in the 
hydrolysis of isoflavones, either in free form (Ismail and Hayes, 2005; Ryu et al., 2010; Yang 
et al., 2009) as in immobilized form (Chang et al.; 2013; Chen et al., 2013; Maitan-Alfenas 
et al., 2014).
Ismail and Hayes (2005) studied the β-glucosidase enzyme activities in isoflavone standards 
of β-glucosides and their conjugated forms. Isoflavone standards of β-glucosides (daidzin, 
glycitin, and genistin) and their conjugated forms (malonyl and acetyl glucosides) were 
treated with β-glucosidase from E. coli and β-glucosidase extracted from almonds. The 
results indicated that both β-glucosidase from E. coli as β-glucosidase from almonds were 
able to hydrolyze unconjugated β-glucosides into aglycones forms. Nevertheless, when 
the enzyme amount and/or activity was restricted, variances in enzyme activity toward 
β-glucosides were detected. In contrast, when sthe levels of enzyme were increased and 
incubation was prolonged, β-glucosidase was not effective in hydrolyzing the conjugated 
glucosides to aglycones forms. Based on the results found, the authors confirmed that for the 
glucosides to be bioavailable they must be in nonconjugated forms.
Yang et al. (2009) analyzed the thermostable β-glucosidase from Paecilomyces thermophila 
and the commercial enzyme extracted from almonds in hydrolysis of isoflavone glucosides. 
The authors applied the enzymatic extract of β-glucosidase in samples of isoflavones obtained 
by grinding soybeans, soy flour suspension and soy-based drink. The authors found that the 
thermostable β-glucosidase was able to convert more than 95% of isoflavone glucosides 
existing in soy flour in their aglycone forms after 4 h of incubation, except malonyl 
glucosides, that were hardly hydrolyzed. The β-glucosidase thermostable was also capable 
to hydrolyze the isoflavones present in soy flour suspension and soy-based drink, increasing 
up to 35 times the isoflavone aglycones content in these samples, whereas the commercial 
β-glucosidase enzyme increased only 10 times the original content. The authors concluded 
that thermostable β-glucosidase from P. thermophila was more effectual in isoflavones 
hydrolysis from soy products than the commercial enzyme extracted from almonds.
Other research led by Ryu et al. (2010) examined the β-glucosidase enzyme derived from 
Aspergillus fumigatus in hydrolysis of soft tofu. The reaction at 55°C for 30 min using β-
glucosidase (0.02%, w/v) resulted in a conversion rate of 84.5% from isoflavone glucoside 
into isoflavone aglycone. Moreover, the β-glucosidase had a higher affinity toward daidzein 
and genistein than glycitein. This work also reported that the bioconversion reaction in part 
depended on the enzyme concentration. Based on the results, the authors concluded that the 
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use of β-glucosidase in tofu processing is advantageous for the conversion of glucoside forms 
to promptly bioavailable aglycone forms of isoflavones.
Wu and Muir (2010) studied the behavior of different proteases on the isoflavones throughout 
enzymatic hydrolysis of soybean flour. Proteases itself did not influence isoflavones’ 
hydrolysis; on the other hand, the applied conditions and contaminated β-glucosidase in 
the enzyme could significantly affect the composition and content of isoflavones. Soybean 
flour hydrolysis by Enzeco Alkaline Protease L-FG resulted in complete deprivation of 
malonylglucosidic and acetylglucosidic conjugates in the hydrolyzate and residue. The 
residue prepared by Protease M contained more than 10 times higher concentration of 
aglycones than that of soy flour. The results indicated that β-glucosidase contaminated in 
Protease M has a unique specificity compared to that of the purified almond β-glucosidase 
and showed that hydrolysis of soybean flour may supply another alternative approach to 
improve aglycone isoflavones in soy-based products.
Research by Chang et al. (2013) studied the isoflavone-glucoside hydrolysis by immobilizing 
β-glucosidase on chitosan-carbon beads in an aqueous-organic two-phase system. The 
chitosan-carbon beads were cross-linked with glutaraldehyde to immobilize β-glucosidase 
from Exiguobacterium sp. DAU5. The immobilized enzyme was able to hydrolyze isoflavone 
glucoside in an aqueous-organic two-phase system, and the hydrolyzed products were 
improved in the organic phase, making it easy to recover the products. These results indicated 
that immobilized β-glucosidase may be applicable for the industrial-scale isoflavone-
glucoside hydrolysis.
In a study by Chen et al. (2013), spent coffee grounds were utilized as enzyme 
immobilization solid carriers instead of commercialized solid supports. β-Glucosidase from 
Aspergillus niger was covalently immobilized onto spent coffee grounds for the conversion of 
isoflavone glucosides into their aglycones in black soymilk. The kinetic parameters like rate 
constant (k), time (τ50) in which 50% of isoflavone deglycosylation was reached, and time 
(τcomplete) required to achieve complete isoflavone deglycosylation, were 0.16 ± 0.02 min−1, 
4.54 ± 0.32 min−1, 60 min−1 for daidzin, and 0.16 ± 0.02 min−1, 2.28 ± 0.11 min−1, 60 min−1 
for genistin, respectively. The total aglycone content in black soymilk was enriched by 
67.14 ± 0.60% in the enzymatic treatment of 60 min duration. The authors concluded that 
β-glucosidase immobilized on spent coffee grounds is capable of catalyzing the hydrolysis of 
isoflavone glycosides in black soymilk in a highly efficient mode.
An intracellular β-glucosidase from Debaryomyces hansenii UFV-1 was produced, purified, 
and characterized. Yeast cells containing the intracellular β-glucosidase were immobilized 
in calcium alginate. Soy molasses was treated for 2 h at 40°C with the free enzyme and the 
immobilized cells containing β-glucosidase. The treatment resulted in effective hydrolysis 
of isoflavone glucosides to their aglycones forms. The results showed that this enzyme, in 
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the free or immobilized forms, could be used in the food industry for a process to hydrolyze 
isoflavone glucosides in soy molasses (Maitan-Alfenas et al., 2014).
Another enzyme with demonstrated potential and also involved in bioconversion of 
isoflavones is tannase (EC 3.1.1.20) or tannin acyl hydrolase. It is an esterase enzyme that 
acts on phenolic complex being capable of performing hydrolysis reactions on ester linkages 
and depsides connections of hydrolyzable tannins, besides presenting deglycosylation 
activity (Fernandez-Lorente et al., 2011; Ferreira et al., 2013; Kumar et al., 2007; Treviño-
Cueto et al., 2007). The extracellular enzyme is produced by filamentous fungi, bacteria, or 
yeasts and may be also obtained from plants and animals (Aguilar et al., 1999; Lekha and 
Lonsane, 1997; Ramírez-Coronel et al., 2003; Selwal et al., 2010).
Work conducted by de Queirós et al. (2016) evaluated the production of equol by 
bioprocess in vitro, changes in the profile of isoflavones and antioxidant activity of soymilk. 
Biotransformation processes based on soymilk fermentation by probiotic lactic bacteria 
and enzymatic process with tannase obtained from Paecilomyces variotii were performed 
in this study. The results showed that both enzymatic and fermentation processes were able 
to promote significant changes in isoflavones profiles present in soymilk, bringing on the 
bioconversion of the glycosidic forms (daidzin and genistin) in their respective aglycone 
forms (daidzein and genistein), and increased significantly the equol content. Furthermore, 
a relevant increase in the bioactivity of soymilk was observed and confirmed by DPPH and 
ORAC assays. Although both biotransformation processes were effective in this study, the 
results indicated that the action of tannase was better than fermentation process in increasing 
aglycones, antioxidant activity, and the equol content in soymilk. Based on these findings, 
the invention was considered unprecedented because the isoflavone glucoside hydrolysis 
by the method mentioned earlier like the generation of equol by biotechnological process in 
vitro, using enzymatic biotransformation only, is novel in the scientific literature (Macedo 
et al., 2015).
5 Clinical Implications
Researches in the clinical and epidemiological area have been evaluated the health 
benefits associated with soy isoflavones and their progression in human diseases (Acharjee 
et al., 2015; Cano et al., 2010; Crawford et al., 2013; Leclercq and Jacquot, 2014; 
Mahmoud et al., 2014; Mourouti and Panagiotakos, 2013; Park and Weaver, 2012; Scalbert 
et al., 2005; Shor et al., 2012; Yu et al., 2015). Many studies have already demonstrated 
that phytochemicals as isoflavones can be used in chemoprevention strategies to decrease 
cancer risk, for example (Dong et al., 2012; Imhof et al., 2008; Miyanaga et al., 2012; Pabona 
et al., 2013; Travis et al., 2009; Xu et al., 2010). In breast cancer cells, for instance, Uifalean 
et al. (2016) compared the metabolome of two types of breast cancer cells (MDA-MB-231 
and MCF-7), in response to soy seed extract, daidzein, and genistein, and they demonstrated 
that using the correct dose, isoflavones can act as a powerful weapon in the chemoprevention 
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of breast cancer. Liu et al. (2010) also demonstrated the relationship between the 
production of equol and the reduction of breast cancer risk. Research led by Goodman 
et al. (2009) conducted a nested case-control study within the Multiethnic Cohort Study 
with postmenopausal women. The investigation analyzed the relationship between urinary 
phytoestrogens with the risk of postmenopausal breast cancer. In conclusion, the authors 
sustain the hypothesis that the consumption of foods rich in isoflavones may decreases the 
risk of postmenopausal breast cancer, especially in populations with elevated excretion of 
phytoestrogens. In addition, Verheus et al. (2007) investigated the association of plasma 
phytoestrogen levels and breast cancer risk in a prospective study. The researchers observed 
that elevated levels of plasma genistein also were associated with reduced breast cancer risk 
in the Dutch population.
The relationship between a diet rich in soy isoflavones and decreased risk of prostate cancer 
has been evidenced in Asian populations (Mahmoud et al., 2014). Some articles show 
significant association between isoflavones intake and a reduced risk of prostate cancer 
(Miyanaga et al., 2012; Park et al., 2009; Travis et al., 2009). Furthermore, some of articles 
show consistently that equol producers carry a significantly reduced risk of prostate cancer 
than that in equol nonproducers (Jackson et al., 2010; Kurahashi et al., 2008). According to 
this statement, Akaza et al. (2004) studied Japanese, American, and Korean subjects, and they 
reported that the rate of equol producers is significantly higher in the Asian population and 
lower in patients who present prostate cancer. Another example of reducing prostate cancer 
can be shown by genistein-mediated transcriptional p21 upregulation, induce cell cycle arrest 
and apoptosis in prostate cancer cell lines LNCaP (androgen-dependent/p53 wild type) and 
PC-3 (androgen-independent/p53 mutant type) (Seo et al., 2011). In DU145 cells, androgen-
independent prostate cancer cell line, genistein treatment resulted in a significative induction 
of p21 and p27, reduction of CDK4, and a mild inhibition of CDK2, cyclin D1, and cyclin 
E (Agarwal, 2000). Moreover, it has been reported that higher plasma concentrations of 
circulating genistein are associated with a low risk for prostate cancer (Travis et al., 2009). In 
in vitro cell culture assays, researchers observe that low isoflavone concentrations enhanced 
the cell proliferation of human prostate cancer cells via inositol trisphosphate-kinase and 
estrogen-dependent pathways, and of nontumorigenic epithelial human prostate cells (El 
Touny and Banerjee, 2009; Wang et al., 2006a).
Some studies have shown, through in vitro and in vivo essays, that the isoflavones can exert 
antioxidant activity (Huang et al., 2008; Ma et al., 2013; Rodríguez-Roque et al., 2013). In a 
study described by Widyarini et al. (2001), some isoflavones and their metabolites, isolated 
from red clover (Trifolium pratense), were tested for their potential to offer protection from 
UV irradiation in hairless mice. The results demonstrated that lotions containing genistein, 
equol, isoequol, and dehydroequol showed a strong potential to decrease the inflammatory 
edema reaction. In addition, this study also showed that the lotions containing equol was 
able to protect the system immune from photosuppression. Moreover, a comparative in 
vitro study of phenolic compounds demonstrated that equol is a potent antioxidant that 
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exhibits higher antioxidant activity when compared to vitamins C and E (Rüfer et al., 2006). 
Foti et al. (2005) compared the protective effect of daidzein and genistein opposed to 
oxidative damage in Jurkat T-cell line and in peripheral blood lymphocytes of healthy 
subjects. Supplementation of Jurkat cells and primary lymphocytes with genistein and 
daidzein notably enhanced DNA protection from oxidative damage. Shin et al. (2007) 
related enhanced nitric oxide (NO) plasma concentration by genistein, which was occurring 
with high expression of cyclooxygenase-2 and prostaglandin E2 production. Expression of 
endothelial NO synthase (eNOS) and inducible NOS (iNOS) was unaltered. These suggest 
that genistein increased NOS activity directly and/or it enhanced NO bioavailability by 
reducing oxidative stress.
Isoflavones have also been employed to minimize menopause symptoms, as an alternative 
to the hormonal replacement therapy, due to their similarity with 17β-estradiol hormone. 
Although therapy with pharmaceutical hormone replacement is efficient in the majority 
of cases, this option has not been widely used, since some studies showed that it can 
increase the risk of breast cancer development (Beral, 2003; Cavallini and Rossi, 2009; 
Schairer et al., 2000). According to Ruiz and Hernández (2016), the consumption of soy 
isoflavones has led to a reduction not only in breast cancer, but also in lung, colon, and 
prostate cancers. Howes et al. (2006) also relate that the ingestion of phytoestrogens 
has shown moderate estrogenic effects in postmenopausal women, inducing symptom 
improvement. Many factors affect the bioavailability and activity of isoflavones, such 
as dosage, administration, metabolism, and the ingestion of other substances. Research 
performed by Jou et al. (2008) studied the effect of a daily ingestion of isoflavones 
(135 mg) on menopausal symptoms in equol producers and nonproducers. Results 
demonstrated that isoflavones supplementation was effective in the reduction of 
menopausal symptoms only in female equol producers. In another study, Taku et al. 
(2012) related that soy isoflavones taken for 6 weeks to 12 months by perimenopausal and 
postmenopausal women significantly decreased hot flash frequency by around 21% and 
hot flash gravity by about 26% compared to placebo. Moreover, isoflavone supplements 
that supplied more than 18.8 mg of genistein were twice as effective at reducing hot 
flash frequency. Furthermore, according to Villa et al. (2009), postmenopausal women 
supplemented with genistein improvement in glycemic and vascular reactivity indexes 
compared to placebo group.
Osteoporosis is a disease caused, in part, by the decrease of estrogen hormone levels. It is 
characterized by the enhancement of bone resorption, accelerated bone loss, and amplified 
fractures risk as well as reduced healing of the bone fractured (Hao et al., 2007). To improve 
this clinical condition, estrogen replacement therapy has been used to reduce the osteoporosis 
risk. The estrogenic effects caused by phytoestrogens have been proposed to prevent bone 
resorption and stimulate an increment in bone density (Patisaul and Jefferson, 2010; Tousen 
et al., 2011). A study described by Yamori et al. (2002) demonstrated that the ingestion of soy 
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isoflavones, in postmenopausal women, was associated with bone resorption. The isoflavone-
administered group showed better femoral and/or lumbar spine density when compared to 
placebo group. However, the effect of soy isoflavones on bone health can depend on the 
capacity to produce equol (Yamori et al., 2002). The production of equol could, in part, 
elucidate the reason why the isoflavones’ beneficial effects observed in laboratory rodents 
have not been easily reproduced in humans. It occurs because rodents generate high equol 
levels, more than 3 times, when compared to human population (Lampe et al., 1998; Setchell 
et al., 2003).
The effect of soy isoflavone extracts in enhancing bone mineral density (BMD) in 
menopausal women observed in Taku et al. (2010) was consistent with the increase found 
by Ma et al. (2008). These results showed that soy isoflavones consumed either alone in 
extracted form or as constituent parts of isolated soy protein increased lumbar spine BMD in 
menopausal women. In another study conducted by Turhan et al. (2008), 6-month genistein 
supplementation administration to postmenopausal women led to enhance in bone density 
and simultaneous decrease in the concentration of biochemical markers of bone resorption. 
According to Polkowski and Mazurek (2000), the positive effect of isoflavones on bone 
metabolism may be mediated by the impact on osteoclasts via activation of apoptosis and/or 
by the inhibition of tyrosine-kinase activity via modulation of membrane ERs with successive 
modifications in the activity of alkaline phosphatase.
The risk of ischemic heart disease among postmenopausal women increases according to 
deficiency in the production of gonadal steroid. For this reason, therapy using estrogen 
replacement has been employed to improve HDL cholesterol and decrease LDL cholesterol, 
avoiding heart diseases. Studies propose that phytoestrogens could act as estrogen agonists, 
effecting lipoproteins similar to those induced by estrogen (Kurzer and Xu, 1997). Significant 
diminution in LDL cholesterol levels are usually small and only seen in individuals 
with high cholesterol who replace a considerable part of their animal protein intake with 
soy, consuming between 40 and 318 mg of isoflavones per day (Sacks et al., 2006). In a 
small study conducted by Hall et al. (2008), healthy postmenopausal women consumed 
an isoflavone-enriched low-fat meal. The results showed that the regular intake of soy 
isoflavones may protect against endothelial dysfunction.
Nevertheless, the lack of clear evidence for the cardiovascular benefits of isoflavones 
in larger scale clinical trials may reflect that 30%–50% of individuals lack intestinal 
bacteria necessary to metabolize daidzein to equol, suggesting that effects of dietary soy 
may be distinct in equol producers and nonproducers (Setchell et al., 2002a; Setchell and 
Clerici, 2010). Furthermore, the importance of the ability to produce equol becomes very 
important once this metabolite also has vasodilator activity, induces nitric oxide synthase-
dependent endothelial relaxation, and can prevent chronic vascular diseases (Cheng 
et al., 2010; Jackman et al., 2007).
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6 Conclusions
Phenolic compounds are the largest group of natural antioxidants of human diets that have 
direct and indirect activities that help the maintenance of human health and welfare. The 
microbial bioconversion of isoflavones, by the action of β-glucosidase enzyme, is widely 
used to improve the biological functionality of soy-based foods. So the application of some 
lactic acid bacteria to ferment soybeans has great potential to produce functional fermented 
soy products with enhanced antioxidant capacities, which can contribute to the health and 
nutritional status improvement of consumers. As well as microbial biotransformation, 
bioconversion of isoflavones by enzymes has been an attractive technological alternative to 
biotransformation of glucoside in aglycone forms, increasing the bioactivity of soy-based 
products and consequently improving the isoflavone-associated health benefits. Based on the 
discussed studies, the isoflavones, in particular the aglycone form and the metabolite equol, 
present a great potential in prevention and control of the progression of human diseases.
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